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Abstract
The lipid composition of chylomicrons is directly affected by diet and the 
remnants of these particles may contribute to atherogenesis. Apolipoprotein 
B-48 is uniquely associated with chylomicrons of dietary origin, whereas 
apolipoprotein B-100 is associated with lipoproteins of hepatic origin. 
Apolipoprotein B-48 is identical to the N-terminal of apolipoprotein B-100 and 
this has previously prevented production of specific antibodies to 
apolipoprotein B-48. Antibodies were directed to the charged carboxyl 
C-terminus of apolipoprotein B-48 because it had been identified as a 
potential discriminatory region between the two apolipoproteins. This was 
achieved by conjugating heptapeptides, which corresponded to the C-terminal 
of apolipoprotein B-48, to carrier proteins to enhance their immunogenicity. A 
screening enzyme-linked immunosorbent assay was developed to monitor the 
antibody response to; immunisation. The specificity of the resultant antisera 
was tested by immunostaining of chylomicron-enriched serum and lymph 
samples following separation of the proteins by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis. Subsequently, measurement of 
apolipoprotein B-48 by three different enzyme-linkedj immunosorbent assay 
formats and a slot blot was investigated. These were unsuccessful and so a 
semi-quantitative assay based on sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis followed by immunoblotting and detection by 
enhanced-chemiluminescence and densitometric scanning was developed. 
Levels of apolipoprotein B-48 detected by this method correlated (r=0.68) with 
those measured on a gel which was stained with Coomassie Blue for protein.
This assay was tested using chylomicron-enriched plasma samples obtained 
at regular intervals from eleven healthy subjects following two test meals
which differed in their fatty acid composition. Apolipoprotein B-48 levels 
showed similar patterns to triacylglycerol in response to the two test meals. 
Differences in the pattern and nature of response were found in comparison 
of these two parameters with retinyl palmitate. Retinyl palmitate loading is 
currently the most widely used method of monitoring chylomicron metabolism 
and hence the production of an antibody and development of an assay for 
apolipoprotein B-48 are major contributions to the study of postprandial lipid 
metabolism.
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CHAPTER ONE
GENERAL
INTRODUCTION
1.1 Plasma lipoproteins
The biological problem of how to transport water-immiscible lipids from their 
sites of formation to their sites of utilisation in the predominantly aqueous 
environment of the blood, has been solved by stabilising the lipid particles 
with a coat of amphipathic phospholipids and proteins to form lipoproteins. 
These are spherical particles with a surface layer of apolipoproteins and 
polar lipids (phospholipids and cholesterol) surrounding an apolar core of 
cholesteryl ester (CE) and triacylglycerol (TAG) (Fig. 1.1) (Lewis, 1990).
1.2 Historical perspective
The historical references cited in this section can be found in Alaupovic 
(1991). The discovery that fat was present in fasting serum was made by 
Christison in 1830. It was at the beginning of this century that Nerking 
postulated that plasma lipids were chemically bound to proteins and almost 
thirty years later that Macheboeuf, working at the Pasteur Institute, isolated 
and identified a plasma lipoprotein. Macheboeuf removed globulins in 
horse plasma by precipitation with ammonium sulphate. Acidification of the 
supernatant resulted in precipitation of a fraction containing 59 % protein, 
23 % phospholipid and 18 % CEs.
Using electrophoresis, Blix et al. (1941) demonstrated the existence of two 
distinct lipid-protein complexes in plasma with the mobilities of a1- and 
p-globulins. This was supported a few years later by development of the first 
preparative procedure for isolation of human plasma lipoproteins which was 
based on fractionation of human plasma in ethanol/water mixtures (Cohn et 
al., 1946). The advent of zonal electrophoresis extended the classification of
1
Fig. 1.1 Model of a lipoprotein
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plasma lipoproteins to four classes: those which remained at the origin and 
those which migrated to the cc1-, p- and pre-p-positions. One of the first
major symposia on lipoproteins was held at the University of Birmingham in 
August of 1949, at which time there were fewer than 100 published reports 
on lipoproteins.
Due to the presence of lipid, plasma lipoproteins have relatively low 
hydrated densities in comparison with other proteins. Gofman and co­
workers (1949) and Havel et al. (1955) exploited this phenomenon to 
separate plasma lipoproteins on the basis of their density by fractional 
ultracentrifugal flotation in salt solutions of successive increasing densities. 
Five major classes of lipoproteins were identified: chylomicrons (CM) 
(d < 0.94 g/mL), very low density lipoproteins (VLDL) (d = 0.94 - 1.006 g/mL), 
low density lipoproteins (LDL) (d = 1.006 - 1.063 g/mL), high density 
lipoproteins (HDL) (d = 1.063 - 1.21 g/mL) and very high density lipoproteins 
(VHDL) (d > 1.21 g/mL). The popularity of this classification system was 
enhanced by clinical studies which related certain disorders of lipid transport 
to a particular lipoprotein density class or electrophoretic pattern. However, 
the emphasis on the lipid component ignored the marked protein 
heterogeneity within the different density classes and obscured the 
functional significance of the protein moieties.
In the 1960s, the apolipoproteins became the focus of interest as methods 
for their isolation and chemical and physical characterisation were reported. 
Gustafson et al. (1966) suggested that there were three distinct 
apolipoprotein (apo) patterns: apo A described the patterns of HDL, apo B 
of LDL and apo C of VLDL. Within the next five years identification of 
related, but non-identical, peptides resulted in subclasses of apo A-l, apo
3
A-ll, apo C-l, apo C-l I and apo C-lll. The picture was further complicated by 
the availability of specific antibodies to apolipoproteins A, B and C which 
showed that all three were detectable in VLDL, LDL and HDL. Later in the 
1970s apo E and apo A-IV were described. A more detailed description of 
lipoprotein classification using apolipoproteins appears in Alaupovic (1991).
Heterogeneity of apo B was first described by Kane and co-workers in 1980 
(Kane et al., 1980). Unlike the other apo subclasses, apo B-48 is identical to 
part of apo B-100. Naming of the apo B subtypes was based on the 
observation that the size of apo B-48 was estimated to be 48 % that of apo 
B-100 when measured by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE).
The availability of molecular biology techniques in the 1980s allowed the 
genes for apo A-l, A-ll, A-IV, B-48, B-100, C-l, C-ll, C-lll, and E to be isolated, 
sequenced and localised in the human genome (Angelin & Rudling, 1992). 
Generally, development of more sophisticated analytical techniques has 
allowed a greater understanding of apolipoprotein metabolism, which has 
been shown to be increasingly complicated in its own right.
1.3 Structure and function of the apolipoproteins
The protein moieties are the apolipoproteins which, in addition to providing 
a stabilising role, regulate lipoprotein metabolism by interacting with certain 
enzymes and specific receptors on cell surfaces. An apolipoprotein has 
been defined as a lipid-binding protein (single polypeptide or multiple 
polypeptides) with the capacity to form a system of soluble, polydisperse 
lipoprotein particles (Alaupovic, 1991). There are several types of
4
apolipoproteins with differing chemical compositions, physical properties 
and metabolic functions, but their common role is to transport lipids from one 
tissue to another to supply the lipid needs of different cells (Table 1.1). It has 
now become accepted to use a series of letters, A to E, to identify 
apolipoproteins and these can be divided further into several sub-classes. 
These are usually referred to in abbreviated form, thus apo A-l, apo C-lll etc. 
(Gurr & Harwood, 1991). A good review of structure and function of 
apolipoproteins has been written by Mahley etal. (1984) and unless stated 
otherwise information on the individual apolipoproteins was taken from this 
reference.
1.3.1 Apolipoprotein A-l
Human apo A-l is synthesised by both liver and intestine and is found mainly 
on CM and HDL. In the circulation, lipase hydrolysis of CM results in rapid 
transfer of the intestinal form onto HDL particles. Apo A-l has a plasma 
concentration of 100-150 mg/dL and a half life of about 4 days.
It is a single polypeptide of 243 amino acids with a calculated molecular 
mass of 28.1 kDa. Both newly secreted intestinal and hepatic apo A-l 
appear in plasma as a 249 amino acid proprotein which is processed slowly 
to the major plasma form. It is not known to undergo intracellular post- 
translational modifications such as glycosylation or phosphorylation. A large 
portion of the protein structure is a series of tandemly repeated 22 amino 
acid segments, punctuated almost exclusively by proline residues, that are 
predicted to be helical and amphiphilic in nature. The amphiphilic helix has 
been implicated as a crucial structural element for lipid binding. Apo A-l is a
5
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cofactor of lecithinrcholesterol acyltransferase (LCAT) and this may explain 
how apo A-l stimulates cholesterol efflux from cells.
1.3.2 Apolipoprotein A-ll
The major site of synthesis of apo A-ll is the liver and it is associated 
primarily with HDL. It has an approximate plasma concentration of 
30-40 mg/dL and an average half-life of about 4 days.
It has two identical subunits of 77 amino acids, covalently linked by a 
disulphide bridge, to give a dimer with a molecular mass of 17.4 kDa. It is 
not known whether apo A-ll is glycosylated. Three potential roles for apo A-ll 
have been identified. It has been shown to inhibit apo A-l-mediated 
cholesterol efflux from cells, to increase in vitro hepatic lipase (HL) activity 
and to decrease lipoprotein lipase (LPL) activity on VLDL particles (Brewer 
& Rader, 1991).
1.3.3 Apolipoprotein A-IV
Apo A-IV is synthesised by both the intestine and liver and is a prominent 
component of newly synthesised CM. It is only a minor component of HDL, 
to which it seems to be weakly bound and it can therefore also be found in 
the lipoprotein-free fraction of plasma (Lagrost etal., 1990). It is present at a 
serum concentration of 15 mg/dL and its half-life is not known.
Apo A-IV is a single polypeptide of about 46 kDa which does not appear to 
be post-translationally modified. Studies on rat apo A-IV show that it has 
repeated amphiphilic helical structures, similar to those of apo A-l. Apo A-IV
7
enhances the activity of LCAT, may interact with cholesteryl ester transfer 
protein (CETP) and could therefore play an important role in reverse 
cholesterol transport (Lagrost etal., 1990).
1.3.4 Apolipoprotein B-48
Two recent reviews have been published on apo B-48 and apo B-100 Apo 
B-48 (Young, 1990; Chan, 1992).
Structurally apo B-48 is identical to the N-terminal 48 % of apo B-100 and 
has a predicted molecular mass of 241 kDa (Powell etal., 1987) and an 
apparent molecular mass from SDS-PAGE of 264 kDa (Kane etal., 1980). 
In 1986 four groups reported the complete nucleotide sequence for the apo 
B cDNA, along with the deduced amino acid sequence (Chen et al., 1986; 
Cladaras et al., 1986; Knott etal., 1986; Law et al., 1986). In 1987 three 
groups simultaneously demonstrated that apo B-48 is produced from the 
apo B-100 gene by a novel form of processing (Chen eta l., 1987; 
Hospattankar etal., 1987; Powell etal., 1987). They found that apo B cDNA 
isolated from intestinal cDNA libraries contained a T at nucleotide 6666, in 
contrast to the C found at the position in the liver apo B cDNA clones. This 
substitution converts codon 2153 from glutamine (CAA) in apo B-100 mRNA 
to a stop codon (UAA) in apo B-48 mRNA. Protein sequencing by Chen et 
al. (1987) largely confirmed the apo B-48 structure predicted from cDNA. 
However, there was a discrepancy over the precise location of the apo B-48 
C-terminus. Chen etal. (1987) analysed amino acid content of peptides 
produced by digestion of apo B-48 with trypsin. They found that apo B-48 
terminated with methionine at residue 2151. Hardman eta l. (1987a) 
investigated the C-terminal of apo B-48 using cyanogen bromide which
8
specifically cleaves proteins at the carboxyl-side of methionine residues. 
Amino acid analysis of cyanogen bromide digests indicated the apo B-48 
.terminated at residue 2152 in the sequence Met-lle. Chan (personal 
communication, 1990) believed that "the evidence taken together suggested 
that newly secreted human apo B-48 has isoleucine as its C-terminus and 
that inside the vascular compartment isoleucine is partially removed leaving 
methionine as the new C-terminal residue". This cleavage could be 
achieved by carboxypeptidase-A, an enzyme which removes non-polar 
residues from the C-terminal of proteins and would therefore leave 
methionine as the C-terminal residue (Chen etal., 1987).
The post-transcriptional editing mechanism is a unique example in 
mammalian biology and is currently under investigation by several groups. 
The exact nature of the C to U conversion is unknown, but the most plausible 
mechanism is a sequence-specific cytidine deaminase or transaminase 
reaction. Current evidence suggests that the editing enzyme has a 
recognition domain and a catalytic domain, with a relatively lax specificity 
(Chan, 1992). Mature apo B-48 has six potential N-glycosylation sites of 
which there is estimated to be one high-mannose type and four complex- 
type chains. The role of the carbohydrate moiety in apo B-48 is unknown 
(Sasak ef a/., 1991).
Apo B-48 seems to be uniquely associated with CM and CM remnants and it 
is assumed there is only one apo B-48 molecule on each newly secreted 
CM particle (Elovson etal., 1988). The plasma concentration of apo B-48 is 
estimated to be 0.05-0.20 mg/dL (calculated from Karpe etal., 1993a ) and 
its half-life, measured as removal of CM remnants, between 10-53 mins 
(Berr, 1992). Apo B-48 is necessary for the secretion of CM (Section 1.5.1)
and its role is primarily structural since it has not been shown to specifically 
interact with any receptors or enzymes.
It is widely accepted that in humans apo B-48 is exclusively synthesised by 
the small intestine, but in rodents the liver also produces large amounts of 
apo B-48 (Tennyson etal., 1989; Wu etal., 1990). Despite the presence of 
edited apo B mRNA in the kidney and stomach, synthesis and secretion of 
apo B-48 appears to be confined to the small intestine (Teng et al., 1990). 
The apo B editing process seems to be developmental^ regulated. 
Intestinal organ cultures from foetuses produced mainly apo B-100 at 
11 weeks, both apo B-100 and B-48 at 16 weeks and mainly apo B-48 in 
the adult intestine (Glickman etal., 1986).
1.3.5 Apolipoprotein B-100
Apo B-100 cDNA is 14121 nucleotides in length. This codes for a mature 
protein of 4536 amino acids following cleavage of a 27 amino acid signal 
peptide. Apo B-100 has a predicted molecular mass of 513 kDa (Chen et 
al., 1986; Cladaras etal., 1986; Knott etal., 1986; Law etal., 1986) and an 
apparent molecular mass on SDS-PAGE of 549 kDa (Kane etal., 1980). 
There are 19 potential N-glycosylation sites of which only 16 are actually 
glycosylated.
The predicted secondary structure contains 43 % a-helix, 21 % proline-rich 
p-sheet structure, 16 % p-turns and 20 % random coil structure. Using 
electron microscopy to visualise pairs of antibodies Chatterton etal. (1991) 
showed that apo B-100 extended over at least a hemisphere of LDL. The 
a-helix and proline-rich p-sheet regions confer lipid binding properties on
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apo B-100. In addition, the proline-rich hydrophobic sequences, which are 
unique to apo B may be important in rendering apo B-100 non-transferable 
from its lipoprotein particles.
There are two regions in apo B-100 which show similarity to the apo E LDL 
receptor binding domain. They span amino acid residues 3147-3157 and 
3359-3367. This region is absent in apo B-48 which is not capable of 
binding to the LDL receptor. Heparin binding sequences have been 
identified throughout the length of apo B-100. These may serve to promote 
the binding of triacylglycerol-rich lipoproteins (TRL) (i.e. CM and VLDL) to 
the capillary endothelium, where the TAG is hydrolysed by LPL.
The normal plasma concentration of apo B-100 is 60-120 mg/dL. More than 
90 % of apo B-100 in the plasma of normolipidaemic subjects is associated 
with LDL and it is widely accepted that most apo B-100 is secreted from the 
liver on VLDL (Edge et al., 1985). However, two groups have suggested that 
apo B-100 may also be synthesised by the intestine: Hoeg etal. (1990) 
found 16 % of intestinal apo B mRNA encoded for apo B-100 in intestinal 
biopsy organ cultures. Levy eta l. (1990) identified apo B-100 in the 
intestinal mucosa by immunostaining. However, they discussed the 
possibility that their results could be interpreted as uptake of apo B-100 by 
epithelial cells.
1.3.6 Apolipoprotein C-l
Apo C-l is mainly synthesised in the liver and to a lesser extent in the 
intestine. Apo C-l has 57 amino acids with a calculated molecular mass of
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6.6 kDa and does not contain a propeptide. It has a plasma concentration of 
about 6 mg/dL.
During absorption of dietary fat by the intestine or during active synthesis of 
VLDL by the liver, apo C-l preferentially redistributes to the surface of CM 
and VLDL. In the reverse manner, when CM and VLDL are hydrolysed apo 
C-l transfers to HDL. It is predicted to have a high helical content for lipid 
binding and is also capable of activating LCAT.
1.3.7 Apolipoprotein C-ll
Apo C-ll is also synthesised mainly by the liver and is associated with CM, 
VLDL and HDL in a similar fashion to apo C-l. It is present in plasma at a 
concentration of about 4 mg/dL. It has 79 amino acids with a calculated 
molecular mass of 8.9 kDa.
Apo C-ll has no prosegment and does not appear to be post-translationally 
modified. It has three helical regions for lipid binding and four p-turns. 
Although it may be capable of activating LCAT, its prime metabolic function 
is as a co-factor for LPL. The presence of apo C-ll in CM and VLDL is 
possibly to provide the additional anchoring point for LPL thus providing a 
high local concentration of TAG near the active centre of the enzyme. This 
would allow continued hydrolysis of TAG molecules without necessitating 
dissociation of LPL from the lipoprotein particle (Wang, 1991). Apo C-ll does 
not represent the rate limiting factor in the lipolysis of CM and VLDL because 
apo C-ll binds with high affinity to LPL and is available at saturating 
concentrations (Wang etal., 1985).
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1.3.8 Apolipoprotein C-lll
Synthesis and distribution among lipoproteins of apo C-lll is similar to apo 
C-l and apo C-ll. It consists of a single polypeptide chain of 79 amino acid 
residues with a calculated molecular mass of 8.8 kDa and has a plasma 
concentration of 12 mg/dL. Apo C-lll enriched particles delay the 
apo E-mediated removal by the liver. Other functions of apo C-lll include 
inhibition of LPL activity and stimulation of LCAT (Nestel, 1987).
1.3.9 Apolipoprotein D
Apo D is a glycoprotein with a molecular mass of 19.3 kDa. Apo D mRNA is 
found at significant levels in many organs including: spleen, adrenal gland, 
lung, brain, testis, kidney, heart, intestine and liver. Apo D is found mainly in 
dense HDL, LDL and VLDL. There is no free apo D in the plasma and it has 
a normal concentration of about 12 mg/dL. The exact role of apo D has yet 
to be defined, but it forms a complex with LCAT. It has been shown to bind 
some steroids and bilirubin and may therefore play an important role in 
tissue cholesterol homeostasis (Weech etal. , 1991).
1.3.10 Apolipoprotein E
A review of apo E can be found in Mahley (1988). Apo E is synthesised 
mainly by the liver, but up to 20 % may be synthesised by peripheral tissues 
such as brain, adrenal gland, kidney, lung, spleen, ovary and muscle. 
Intestinal epithelium does not appear to participate in apo E synthesis. It is 
associated with CM, CM remnants, VLDL and HDL. The plasma 
concentration in normolipidaemic subjects is 3-7 mg/dL.
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The primary translation product of apo E is composed of 317 amino acids, 
with the 18 amino terminal amino acids serving as a signal peptide. The 
mature apo E is secreted as a 299 amino acid polypeptide with a molecular 
mass of 34.2 kDa. Apo E undergoes post-translational modification by 
sialylation, but only 20 % of circulating plasma apo E is sialylated.
Six different phenotypes exist (E4/4, E3/3, E2/2, E4/3, E4/2 and E3/2) due to 
a genetically determined allele at a single locus. The most common 
phenotype in the human population is E3/3 which is present in 
approximately 60 % of the population. Apo E2 and E4 differ from apo E3 by 
a single amino acid substitution. Apo E2 is the most common form of apo E 
associated with type III hyperlipoproteinaemia (Section 1.8) and is defective 
in receptor binding.
The predicted secondary structure of apo E is 62 % a-helix, 9 % p-sheet, 
11 % p-turn and 18 % random structure. There are two distinct structural 
domains which have distinct functions. The carboxyl terminal has a high 
frequency of amphipathic a-helices and is likely to represent a lipid binding 
region, whereas the amino terminal contains the LDL receptor binding 
domain.
Apo E plays an important role in the cellular uptake of HDL, VLDL remnants, 
IDL and CM remnants. It binds to the apo B/E (LDL) receptor on the liver 
with a much greater affinity than apo B-100 and also has a high affinity for 
hepatic apo E receptors. It also binds to heparin and thus may have a role in 
orientating TRL to endothelial surfaces in the lipolytic process. Apo E may
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also participate in intra-organ redistribution of cholesterol from cells with 
excess cholesterol to others requiring cholesterol.
1.3.11 Apolipoprotein (a)
Apo (a) is highly glycosylated and has a very similar structure to 
plasminogen. It contains a serine protease domain connected to five ring 
structures known as kringles. There is a genetically determined variability in 
the number of repeats of kringle 4 which directly affects the molecular size of 
apo (a) (Anonymous, 1991).
Since apo (a) belongs structurally to a superfamily of proteins including 
proteases of fibrinolytic and coagulation systems and does not appear to 
form its own family of lipoprotein particles, dr to possess a specific function in 
lipid transport, it was considered by Alaupovic (1991) not to fulfil the criteria 
of an apolipoprotein.
1.3.12 Other apolipoproteins
Apo H is a 326 amino acid serum glycoprotein of approximately 50 kDa. 
Apo H mimics the distribution of apo A-IV and around 70 % occurs in the 
lipid-free form, with 8 % in CM, 1 % in LDL and 17 % in HDL (Alaupovic, 
1991). It has a poorly defined physiological function, but seems to enhance 
the apo C-ll activation of LPL. It may be involved with inhibition of the blood 
coagulation pathway via binding to phospholipids on the surface of 
damaged cells and ADP-mediated platelet aggregation (Cellar etal., 1993).
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Apo J is a glycoprotein present in plasma at a concentration of 10 mg/dL. It 
is associated with HDLg, HDL3 and VHDL classes. Although apo J mRNA is 
present in many tissues, it is not found in the adult intestine and the liver is 
thought to be the main site of synthesis. Evidence has suggested that apo J 
is secreted by the liver in a TRL which may interact with apo A-l. Apo J has 
three predicted amphipathic lipid binding domains, which implies a role in 
lipoprotein metabolism and it is associated with the complement system of 
the immune response (Burkey etal., 1992).
Apo F, apo G and apo I were also included by Alaupovic (1991) in his 
treatise of apolipoprotein nomenclature. However, there is very little 
information available regarding these three apolipoproteins and it remains 
to be seen whether they are truly distinct apolipoproteins and whether they 
have an important role in lipoprotein metabolism.
1.4 Other components of lipoprotein metabolism
A number of other proteins and enzymes play important roles in the 
metabolism of lipoprotein particles.
1.4.1 Choiesteryl ester transfer protein
Human CETP is a hydrophobic protein with a molecular mass of 74 kDa. 
CETP mRNA has been detected in many tissues, but the main sites of 
production appear to be adipose tissue and liver. CETP promotes a net 
mass transfer of CEs from HDL to CM and VLDL in exchange for a reciprocal 
transfer of TAG in the reverse direction (Swenson, 1991).
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CETP can transfer a wide range of lipids. The rate of CETP-mediated 
transfer increases with acyl chain length and decreases with increasing 
number of double bonds. Numerous factors concerning the acceptor and 
donor lipoprotein structures appear to affect transfer activity. Increasing free 
cholesterol content of either LDL or VLDL appears to inhibit CE transfer 
without affecting TAG transfer, while free cholesterol on HDL has no effect 
on CE transfer and stimulates TAG transfer (Swenson, 1991). Mann etal.
(1991) found that in normolipidaemic subjects (where CETP was in excess) 
VLDL concentration limited the rate of CE transfer, whereas in 
hypertriacylglycerolaemic patients (where VLDL concentration was 
elevated) net CE transfer was dependent on CETP activity.
1.4.2 Lipoprotein lipase
A review of LPL can be found in Eckel (1989). LPL is found in many tissues 
including: adipose tissue , heart, lactating mammary gland, skeletal muscle, 
adrenal gland, ovary, spleen, small intestine, testes, lung, kidney, brain 
(hippocampus) and neonatal liver. LPL directs the flux of fatty acids and its 
activity and role depend on a given tissue.
The mature protein contains 448 amino acids with a molecular mass of
50.4 kDa and seems to be active in a dimeric form. Several functional sites 
have been identified within the LPL monomer. These include a lipid binding 
region, a catalytic site, a site for interaction with apo C-ll co-factor and a 
heparan sulphate proteoglycan binding site.
After transcription of the LPL gene in the nucleus of a parenchymal cell in a 
tissue, LPL is translated and N-glycosylated in the rough endoplasmic
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reticulum. Catalytic activity is acquired by trimming of terminal glucose 
residues and probable dimérisation in the endoplasmic reticulum. The fully 
processed LPL is sorted in the frans-Golgi network for delivery either to the 
lysosomes for degradation or to the parenchymal cell surface where the 
enzyme is bound to heparan sulphate proteoglycans. Finally, the enzyme is 
translocated across the interstitial space by unknown mechanisms to 
functional heparan sulphate proteoglycan binding sites on the luminal 
surface of capillary endothelium where the hydrolysis of CM and VLDL takes 
place (Braun & Severson, 1992). LPL is found near the luminal end of the 
proteoglycan complex, which stabilises the enzyme and orientates it so that 
it can best bind and hydrolyse the circulating TAG (Eckel, 1989).
LPL hydrolyses CM and VLDL to produce monoacylglycerols and free fatty 
acids with the concomitant formation of CM remnants, IDL and LDL. 
Increases in the activity of LPL occur in adipose tissue after feeding and the 
fatty acids generated are used for TAG synthesis. In muscle, fatty acids are 
oxidised to provide energy and in the lactating breast they are used for milk 
TAG synthesis (Eckel, 1989).
The preferential substrate for LPL is primary ester bonds in triacylglycerol 
molecules. In the absence of a fatty acid acceptor, such as albumin, free 
fatty acids and monoacylglycerols accumulate at the site of TAG hydrolysis. 
This inhibits the reaction by interfering with the binding of LPL to TAG and 
decreases the activation of the enzyme by apo C-ll. LPL is also inhibited in 
a non-competitive manner by apo C-lll (Wang etal., 1985). A deficiency in 
LPL activity, or its apo C-ll activator, results in severe 
hypertriacylglycerolaemia as seen in Type I hyperlipoproteinaemic patients 
(Section 1.8) (Eckel, 1989).
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1.4.3 Hepatic lipase
HL is synthesised and secreted by hepatocytes and transported to the 
sinusoidal surface of the liver. The protein consists of 476 amino acids with 
a predicted molecular mass of 53.5 kDa (Ameis et al., 1992) and following 
glycosylation it has a molecular mass of 67.5 kDa (Durrington, 1989). 
Glycosylation is necessary for secretion but not lipolytic activity. The 
secreted protein is bound to the endothelium of the hepatic microcirculation 
by glycosaminoglycan components. Less is known about the mode of action 
of HL than LPL, but it seems to be most active against smaller, denser 
cholesteryl-ester rich lipoproteins. Thus, HL catalyses the conversion of IDL 
to LDL (Durrington, 1989), HDLg to HDLg (Ameis etal., 1992) and may play 
a role in the final stages of CM remnant hydrolysis (Brasaemle et al., 1993).
1.4.4 Lecithinxholesterol acyltransferase
LCAT catalyses the transfer of a fatty acid from the 2-position of lecithin 
(phosphatidyl choline) to the 3-p-hydroxyl group of cholesterol to form CE. 
LCAT is glycosylated and has a molecular mass of about 68 kDa. It is 
mainly synthesised by the liver and is localised to HDL in the circulation. 
Apo A-l is an essential co-factor for its activity. Apo A-IV, apo C-l and apo E 
can act as activators whilst apo A-l I, apo C-ll, apo C-lll and apo D have an 
inhibitory effect, but these actions may not be physiologically significant. 
The main function of LCAT is to re-esterify free cholesterol which has been 
transferred to HDL from both VLDL and peripheral tissues (Durrington, 
1989).
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1.5 Structure and function of lipoproteins
Lipoproteins differ according to the ratio of lipid to protein within the particle 
as well as having different proportions of lipids: TAGs, esterified and 
non-esterified cholesterol and phospholipids (Fig. 1.2). These 
compositional differences influence the density of the particles and this 
forms the basis of their classification (Section 1.2). The density increases as 
particle size decreases and the ratios of lipidiprotein, TAGiphospholipid and 
TAGicholesterol decrease. It is worth bearing in mind that the classes 
overlap with respect to density, since there is wide variety of particle sizes 
and chemical compositions within each class (Table 1.2).
1.5.1 Chylomicrons
The usual dietary fat intake in Western civilisations ranges from 50-100 g per 
day (Patsch, 1987). Most of it is in the form of triacylglycerols and less than 
1 % consists of CEs and phospholipids. Mechanical émulsification and 
lipolysis of lipid begins in the stomach and continues in the duodenum. 
Triacylglycerols are hydrolysed mainly to 2-n-monoacylglycerols and some 
completely to glycerol and free fatty acids. CEs are hydrolysed to 
unesterified cholesterol and fatty acids. The end products are poorly soluble 
in water and are made available for absorption through micellar formation 
brought about by bile acids. The micelles move down a concentration 
gradient and enter mucosal cells by passive diffusion. Absorption of dietary 
TAG is more than 95 % whilst that of cholesterol is only 20-50 % (Patsch, 
1987).
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Fig. 1.2 Composition of lipoproteins
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Once within the enterocyte fatty acids with less than 10-12 carbon atoms 
pass from the mucosal cells into the portal circulation and are transported as 
free fatty acids to the liver and other tissues bound to albumin. The longer 
chain fatty acids are bound to fatty acid binding protein which transports 
them from the mucosal cell brush border to the smooth endoplasmic 
reticulum where they are re-esterified. Eighty to ninety percent of TAG is 
formed from 2-monoacylglycerol which is acylated to diacylglycerol and then 
TAG. A smaller fraction is formed by estérification of glycerol-3-phosphate, 
though this pathway becomes more important when the concentration of 
2-monoacylglycerol falls in the intestinal lumen. Cholesterol is re-esterified 
by either acyl-CoA:cholesterol acyltransferase or cholesterol esterase 
(Patsch, 1987).
The enzymes involved in the monoacylglycerol pathway are located on the 
surface of the smooth endoplasmic reticulum. The end result of TAG 
synthesis is a lipid droplet in the cisternae of the endoplasmic reticulum. 
Apolipoproteins A-l, A-l I, A-IV and B-48 are synthesised in the rough 
endoplasmic reticulum. Incorporation of the apolipoproteins and TAG may 
occur in the smooth endoplasmic reticulum following transfer of the 
apolipoproteins, though this stage is not well understood. Following 
assembly into pre-CM some glycosylation takes place. Transport of pre-CM 
from the endoplasmic reticulum to the Golgi apparatus may take place along 
tubules, or following budding of the smooth endoplasmic reticulum. 
Considerable modification of pre-CM takes place in the Golgi apparatus; 
terminal glycosylation occurs, along with a decrease in protein and increase 
in phospholipid content of the particle. The Golgi-derived vesicles 
containing CM migrate toward the lateral membrane of the enterocytes and
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the CM are discharged into the intercellular space through exocytosis (Tso & 
Fujimoto, 1991).
Following a meal, Redgrave (1983) proposed that CM production could 
proceed by three possible mechanisms:
1. An increase in CM number with no change in size
2. An increase in CM size with no change in number
3. An increase in both number and size of CM.
Which of the three mechanisms is correct has still not been resolved. It is 
widely believed that feeding a fatty meal results in an increase in the number 
of CM. However, an increase in CM size but not number was found by 
Hayashi etal. (1990) in rats infused intra-duodenally with lipid emulsion.
Secreted CM pass into the lymph and enter the general circulation via the 
thoracic duct. Newly secreted CM range in diameter between 80-500 nm 
(Kane & Malloy, 1991). The CM are rapidly modified by removal of apo A-l, 
A-l I and A-IV onto HDL and acquisition of apo C-l, C-ll, C-lll and apo E from 
VLDL and HDL (Fig. 1.3). Apo C-ll enhances the binding of CM to LPL 
which hydrolyses the TAG. As the core shrinks, apo C-l, C-ll, C-lll, 
phospholipids and free cholesterol are transferred to HDL. The resulting CM 
remnant is only 5 % of its original size and mainly comprises CE, apo B-48 
and apo E (Patsch, 1987). Recent work has shown that HL can hydrolyse 
CM remnant lipids thereby causing increased exposure of apo E (Brasaemle 
etal., 1993).
Hepatic uptake of CM remnants is mediated by apo E binding to cell surface 
remnant receptors (Fig. 1.4). Identification of a distinct apo E or remnant 
receptor from the apo B/E (LDL) receptor has been the source of intense
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Fig. 1.3 Summary of CM metabolism
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investigation over the past few years. In metabolic studies using Watanabe 
Heritable Hyperlipidaemic rabbits, which lack LDL receptors, Kita et al. 
(1982) concluded remnant removal was normal, thus supporting the notion 
of an independent remnant receptor. Later, Bowler etal. (1991) found that 
there was slower clearance of CM remnants in Watanabe Heritable 
Hyperlipidaemic rabbits, suggesting a lack of evidence for an independent 
receptor. Using mice Hussain etal. (1991) showed that CM remnants could 
inhibit binding of cca-macroglobulin to its receptor. They concluded that the 
ag-macroglobulin receptor (also known as LDL receptor-related protein) 
could function as an independent CM remnant receptor. Windier et al.
(1991) reported that CM remnants were taken up by both the LDL receptor 
and an asialoglycoprotein receptor in Hep G2 cells.
A recent review on CM remnant uptake has been published by Cooper
(1992) . He concluded that there are multiple pathways for remnant 
removal. Under normal circumstances the LDL receptor plays a major role, 
but the ag-macroglobulin receptor may play a significant role, particularly 
when the LDL receptor is down-regulated. He speculated there may be a 
third, poorly characterised site in the liver that allows remnant trapping, but 
does not lead to endocytosis. This could explain why remnant removal is 
rapid, even when the LDL receptor and ag-macroglobulin have been
inactivated.
The effect of CM remnant composition on hepatic uptake has also been 
investigated. Borensztajn & Kotlar (1990) separated the phospholipid 
fraction from CM, CM remnants and HL-treated CM and re-emulsified the 
phospholipids with the different phospholipid-free CM fractions. Only the 
particles emulsified with phospholipids derived from remnants and
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HL-treated CM were taken up efficiently by the liver in rats. The lipid surface 
of TRL was investigated by Small etal. (1990). Hepatic uptake of CM 
remnants by rats was found to be inversely proportional to particle fluidity in 
artificial lipoprotein-like emulsions. This supports the work of Redgrave et al.
(1988) who found that CM containing TAG rich in certain saturated fatty 
acids (SFA) at the 2-position were metabolised more slowly than CM with 
unsaturated fatty acids at this position.
There are a number of factors which could potentially contribute to the rate of 
clearance of CM remnants including: acquisition of apo C-ll, the ratio of apo 
C-ll to apo C-lll, TAG-fatty acid composition, activity of LPL, isoform and 
exposure of apo E and receptor-mediated uptake of the CM remnant. 
Reported half-lives of plasma CM range from 10-53 minutes. Berr (1992) 
investigated whether clearance was saturable by a physiological load of CM 
remnants in eleven subjects. Autologous plasma containing 
retinyl-palmitate-labelled CM and their remnants was injected intravenously 
and their disappearance was measured in serial blood samples. The 
disappearance of the label was best described by mono- or bi-exponential 
first order kinetics, with a half-life of 19 minutes. The process of removal was 
saturable, but LPL activity, hepatic blood flow and availability of apo E were 
discounted as the rate-limiting step. It was concluded that hepatocellular 
uptake was the rate-limiting step and estimated that a 70 g fat load would 
lead to CM remnant concentrations which exceed the putative saturation 
concentration for more than 7 hours in an healthy individual.
After a mixed meal, although CM remnants are enriched in CE, they are still 
relatively rich in TAG compared to LDL. Interestingly, using isolated 
perfused liver from rats, Cooper (1992) found that the uptake of TAG-rich CM
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remnants actually stimulated intracellular cholesterol synthesis and 
suppressed cholesterol estérification, whereas cholesterol-rich particles had 
the opposite effect.
Clearly, identification of an independent CM remnant receptor and the 
importance of diet on CM composition and subsequent metabolism awaits 
further work.
1.5.2 Very low density lipoprotein
VLDL is the main transport system for endogenous TAG. Nascent VLDL is 
synthesised in the hepatocytes and contains apo B-100, apo C-l, apo C-ll, 
apo C-lll, apo E, unesterified cholesterol and TAG. The apo C and apo E 
content are increased by transfer from HDL (Fig. 1.5). VLDL particles are 
30-100 nm in diameter and initial catabolism resembles that of CM, i. e. 
lipolysis by LPL removes about 90 % of the TAG, followed by transfer of 
unesterified cholesterol and phospholipid to HDL. Apo B-100 is conserved 
and the half-life of VLDL apo B-100 is 1-3 hours (Kane & Malloy, 1991).
There appear to be two types of primary VLDL particles. The largest are 
catabolised very quickly to IDL and appear to have a relatively high apo E 
content. This favours binding to hepatic apo B/E receptors. Smaller VLDL 
are relatively poor in apo E and are catabolised more slowly. Further 
hydrolysis, possibly by HL, produces LDL (Lewis, 1990).
29
Fig .1.5 Summary of VLDL and LDL metabolism
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1.5.3 Low density lipoprotein
LDL metabolism has been reviewed by Nestel (1987) and Durrington
(1989). Low density lipoproteins are the result of lipolysis of VLDL (Fig. 1.5). 
They are small particles (19-25 nm) which are relatively rich in cholesterol 
and have only apo B-100 remaining. The major role of LDL is to deliver 
cholesterol to the tissues where it is used for membrane repair, growth and 
steroid hormone and vitamin D synthesis. LDL particles have a half-life of 
about two-and-a-half days (Kane & Malloy, 1991).
The liver accounts for around half of LDL degradation and although most 
tissues have the capacity to recognise and remove LDL, only a few organs 
contribute significantly to LDL catabolism. LDL can be taken up by a 
specific, regulated apo B/E (LDL) receptor (Fig. 1.4), or by a 
non-receptor-mediated pathway. Apo B-100 is the ligand for the apo B/E 
receptor and around two-thirds of LDL is removed via this route.
After binding, the LDL-receptor complex is internalised within the cell where 
it undergoes lysosomal degradation. Cholesterol is produced by the 
hydrolysis of CE and has three main regulatory actions:
1. 3-hydroxy, 3-methylglutaryl CoA reductase, the rate-limiting enzyme for 
cholesterol biosynthesis, is repressed,
2. Synthesis of apo B/E receptor is suppressed
3. Acyl CoA: cholesterol acyltransferase is activated. This converts any free 
cholesterol to CE which is hydrophobic in nature and can be stored in 
droplets in the cytoplasm. Thus uptake of LDL by the apo B/E receptor is an 
important mechanism for regulating intracellular cholesterol concentrations.
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The liver is also the major site for non-receptor-mediated uptake of LDL. 
This route is non-saturable, appears not to be regulated and can therefore 
predominate at high plasma LDL levels.
1.5.4 High density lipoprotein
HDL plays a central role in the reverse transport of cholesterol from the 
tissues back to the liver. In humans, cholesterol is transported out of the gut 
and liver in quantities which greatly exceed its conversion to steroid 
hormones and its loss through skin as sebum. Therefore, except when 
membrane synthesis is high, for example during growth or active tissue 
repair, the greater part of cholesterol transported to tissues must be returned 
to the liver for elimination as bile or re-assembled into lipoproteins 
(Durrington, 1989). The half-life of HDL is 5-6 days (Patsch, 1992).
HDL consists of several types of particles with roles which have not yet been 
fully defined. There are also four classes of HDL which differ in apo content: 
HDL containing apo A-l; apo A-l & apo A-l I, apo A-l & apo A-IV and apo A-l & 
apo E (Brewer & Rader, 1991). Small quantities of apo Cs and apo D may 
also be present (Fruchart & Ailhaud, 1991). The sole source of HDL-apo A-l 
appears to be the intestine, but the other three HDL-apolipoprotein species 
are synthesised by the liver. The metabolic interrelationship between the 
apo-subpopulations has not been established. HDL can also be divided 
into two classes according to density: CE-enriched HDLg which is less 
dense and CE-depleted HDLg which has a higher density.
32
HDL is a small particle (4.5-12.0 nm), compared to the other lipoproteins, 
which allows it to easily cross the vascular endothelium to cells in peripheral 
tissues. It has been proposed that apo A-l and apo A-IV are agonists and 
apo A-l I is an antagonist in the recognition of HDL binding sites on the 
surface of cells (Fruchart & Ailhaud, 1991). Unesterified cholesterol is 
transported out of the cells onto HDL3 , thus converting it to HDL2 (Fig. 1.6). 
LCAT esterifies the cholesterol to form CE which is transported back to the 
liver via two possible routes (Durrington, 1989):
1. HDL2 transports CE back to the liver. Residual TAG is selectively 
removed by HL, thus regenerating HDL3.
2 . CETP transfers CE from HDL2 to the TRLs. The CE is then transported 
back to the liver by IDL, LDL or CM-remnants.
1.5.5 Lipoprotein (a)
Lipoprotein (a) denotes a spectrum of mainly cholesterol-rich particles which 
have a general chemical composition similar to LDL, but with the addition of 
apo (a). The apo (a) is linked to apo B, probably by a single disulphide 
bond. The plasma concentration of lipoprotein (a) is inversely correlated 
with genetically determined apo (a) isoform size. There is wide 
concentration range (1-200 mg/dL) and a low geometric mean (10 mg/dL) 
(Anonymous, 1991).
The physiological function of lipoprotein (a) is Unknown since there is no 
description of a disease associated with a deficiency. It has been 
speculated that lipoprotein (a) may bind to fibrin, thus delivering cholesterol
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Fig. 1.6 Summary of HDL metabolism
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For explanation of symbols see legend to Fig. 1.3 
For explanation of metabolism see Section 1.5.4
to sites of recent injury and wound healing. Lipoprotein (a) may also 
prolong fibrinolysis by competing with plasminogen for the plasminogen 
receptor and inhibiting the conversion of plasminogen to plasmin (Uterman,
1989).
1.6 Postprandial changes in lipoproteins and apolipoproteins
Relatively little work has been published on the changes in lipoprotein and 
apolipoprotein levels following consumption of a meal which is 
representative of a typical diet. In normotriacylglycerolaemic subjects fed a 
liquid formula diet for ten days consisting of 40 g fat (50 % carbohydrate, 
35 % fat, 15 % protein) Olefsky et a i (1976) took two samples at 1 and 
5-6 hours postprandially. They found increases in CM-TAG and VLDL-TAG, 
a decrease in LDL-TAG and no change in HDL-TAG. The plasma 
cholesterol levels were unchanged. These observations have been 
supported by Schneeman et a i (1993) who found increased levels of CM 
and, VLDL between 3 to 6 hours after a test meal containing 46 % 
carbohydrate, 38 % fat, 16 % protein and 1015 kCal total energy.
Seishima et al. (1988) fed 8 healthy male subjects 55 g of butter. They 
found that serum concentrations of apo A-l, A-ll, B, C-ll, C-lll and E did not 
change significantly in the 6 hour postprandial period, but serum apo A-IV 
was significantly elevated 4 hours after the meal. Both apo A-IV and apo 
B-48 were significantly elevated in the TRL fraction for 2-6 hours following 
the meal. These observations were largely confirmed by Karpe et al. 
(1993a) who fed 10 normal subjects a mixed meal (26.5 % carbohydrate,
60.2 % fat and 13.3 % protein) which comprised mainly of a soybean oil 
emulsion providing 50 g oil/m2 body surface area. The total plasma
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concentrations of apo C-l, C-ll, C-lll and E did not significantly alter in the 
twelve hour postprandial period. However apo B-48, B-100, C-l, C-ll, C-lll 
and apo E were all significantly elevated in TRL fractions.
1.7 Lipoproteins and coronary heart disease
Coronary heart disease (CHD) can be considered to occur in two phases. 
An irregular thickening of the inner wall of the artery reduces the size of the 
arterial lumen, followed by formation of a clot at the site of this lesion which 
leads to a cessation of blood flow. The first phase, atherosclerosis, is a 
multi-factorial event which is still not completely understood. In outline, it is 
speculated that events begin with a subtle injury to the endothelial wall 
which could alter its function and lead to increased adhesiveness of 
monocytes and other leucocytes. The monocytes migrate subendothelially, 
probably because of chemotactic signals from cells in the artery wall, 
leading to the formation of a single layer of lipid laden macrophages known 
as foam cells. Smooth muscle cells then migrate from the arterial intima to 
the media and contribute to expansion of fatty streaks. These events lead to 
endothelial retraction, allowing platelets to attach to subendothelial 
macrophages and development of a fibrous plaque. The lipid which 
accumulates in the foam cells probably arises from lipoproteins that have 
entered the subendothelial space (Woolf & Chait, 1990).
Epidemiological evidence relates disease patterns in a population to 
endogenous and environmental patterns in those populations. 
Considerable epidemiological data show a direct relationship between 
increased concentration of total plasma cholesterol and the development of 
atherosclerosis. However, the relationship is strongest for LDL cholesterol
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and there is an inverse relationship between HDL levels and CHD (Gurr & 
Harwood, 1991). Although Lp (a) has been considered an independent risk 
factor it is unclear whether increased Lp (a) concentrations are a significant 
risk factor in normolipidaemic subjects (Uterman, 1989). The influence of 
VLDL and CM on atherogenesis is difficult to assess since most large 
epidemiological studies have not included fractionation of TRL 
(Nordestgaard & Tybjaerg-Hansen, 1992).
The epidemiological evidence for TAG levels and CHD has been reviewed 
by Gotto (1992). Nearly all case-control studies have shown a significant 
positive correlation between fasting TAG levels and coronary artery disease 
(CAD) incidence. The relationship is confirmed in most prospective studies 
on univariate analysis, but on multivariate analysis the relationship weakens 
or disappears, particularly when HDL cholesterol is taken into account. 
Triacylglycerol level does not enter into the primary algorithm of the National 
Cholesterol Education Program (1988) adult diagnosis and treatment 
guidelines. However, the European Atherosclerosis Society (1988) 
guidelines consider TAG level in addition to total cholesterol in stratifying 
risk. The report of the International Committee for the Evaluation of 
Hypertriacylglycerolaemia as a Vascular Risk Factor (1991) concluded the 
major focus should be on LDL cholesterol. However, later evidence from the 
Prospective Cardiovascular Munster study and from the Helsinki Heart 
Study, showed that subjects with elevations of both LDL cholesterol and 
TAG and low levels of HDL cholesterol are at a higher risk for CAD than 
persons with elevation of LDL alone (Gotto, 1992).
The simplest explanation of the cardioprotective effects of HDL is that it 
removes cholesterol from cells (Section 1.5.4) and therefore high levels of
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HDL retard lesion development. However, the mechanism may be more 
complex and involve interaction with CM and VLDL (Section 1.9).
The mechanism for involvement of LDL is more widely documented. 
Macrophages and arterial smooth muscle cells have two types of LDL 
receptors. The first recognises native LDL and delivery of cholesterol via 
this pathway is tightly regulated. The second type is a scavenger receptor 
which recognises oxidatively-modified LDL and is not regulated by cell 
cholesterol content (Fig. 1.4). This potentially allows massive accumulation 
of cholesterol which converts macrophages and smooth muscle cells to 
foam cells. Oxidative modification of LDL probably occurs by a metal ion 
catalysed free-radical process which may lead to expression of an epitope 
on apo B-100 that is recognised by the scavenger receptor. The source of 
the free-radicals could be superoxide which is generated by monocytes, 
neutrophils and macrophages following activation. There is less evidence 
that macrophages take up CE after exposure to VLDL, but it is conceivable 
that modified VLDL could be recognised by the scavenger receptor (Woolf & 
Chait, 1990).
1.8 Disorders affecting metabolism of chylomicrons
Specific knowledge of defects in human lipoprotein metabolism has shed 
light on how elevation of specific types of plasma lipoproteins can cause 
atherosclerosis. A recent review has appeared on the genetic defects of 
lipoprotein metabolism (Mahley etal., 1991) and the clinical implications are 
covered by Kane & Malloy (1991).
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Abetalipoproteinaemia is a rare genetic autosomal recessive disorder 
characterised by the absence of both apo B-48 and apo B-100 in the 
plasma. It results from an inability to secrete apo B-containing lipoproteins 
from the liver and intestine and is associated with lipid retention in these 
tissues. It is manifested clinically by malabsorption of lipid and fat-soluble 
vitamins with resultant neurological disease. The molecular basis of the 
disease is unknown since apo B-48 synthesis appears to be normal. Levy et 
al. (1990) failed to show synthesis of apo B in cultured jejunal explants from 
two patients. However, using intestinal mucosal biopsies, Bouma et al.
(1990) demonstrated synthesis of normal sized apo B-48 in one subject and 
detected apo B-48 by immunoenzymatic techniques in another subject. 
Glickman eta l. (1991) characterised apo B-48 synthesis by in vitro 
^H-leucine incorporation in small intestinal biopsy specimens. In 
comparison to a normal subject, three out of four patients demonstrated apo 
B-48 protein synthesis and markedly higher mRNA levels. They speculated 
that enhanced degradation of apo B-48 may contribute to decreased 
secretion of CM in these patients. In a variation of this disease, known as 
normotriacylglycerolaemic abetalipoproteinaemia, CM synthesis appears to 
be normal but there is a deficiency of apo B-100 (Herbert etal., 1985).
Patients suffering from a variation of hypobetalipoproteinaemia, known as 
chylomicron retention disease (or Anderson's disease), develop symptoms 
of diarrhoea, steatorrhoea and a failure to thrive in the first decade of life. 
This disease is characterised by an absence of plasma CM and half-normal 
levels of LDL. The precise aetiology of the disease is unknown, but apo 
B-48 is present in enterocytes and therefore the defect seems to lie in CM 
assembly or secretion (Bouma et al., 1986). CM retention disease should 
not be confused with familial hypobetalipoproteinaemia which is
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characterised by low plasma levels of LDL and where patients are not at an 
increased risk of CHD. This latter condition is caused by mutations of apo B 
mRNA which result in truncated species of apo B-100, but synthesis of apo 
B-48 and CM secretion is normal in these subjects (Kane & Malloy, 1991).
Type I hyperlipoproteinaemia (also known as familial lipoprotein lipase 
deficiency) is a rare autosomal recessive disorder that results in severe 
hyperchylomicronaemia and increases in plasma VLDL. It may be caused 
by a failure of synthesis or structural abnormality in LPL, by failure to 
produce apo C-ll, or by abnormal sialylation of apo C-lll (Durrington, 1989).
Type III hyperlipoproteinaemia (also called familial dysbetalipoproteinaemia 
and broad beta-disease) is associated with hypertriacylglycerolaemia and 
hypercholesterolaemia and is caused by accumulation in the plasma of 
cholesterol-rich remnants of CM and VLDL (collectively known as (3-VLDL). 
It may affect up to 1 in 100 people and patients have the potential to become 
hyperlipidaemic in the presence of additional environmental or genetic 
factors, such as obesity or diabetes. The underlying defect is synthesis of an 
abnormal form of apo E which does not bind normally to 
apo B/E LDL-receptors. The cholesterol-rich remnants which accumulate 
may be cleared from the plasma by scavenger receptors on macrophages 
and thus promote foam-cell formation (Mahley etal., 1991).
1.9 Postprandial lipaemia as a risk factor for coronary heart 
disease
Postprandial triacylglycerolaemia following oral lipid loads has been 
monitored in several studies. Simpson etal. (1990) reported that patients
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with CHD have a pronounced postprandial hypertriacylglycerolaemia and 
enhanced postprandial triacylglycerolaemia has been shown to be 
positively correlated with age in males Cohn etal. (1988a).
Prospective studies have established HDL-cholesterol as an independent 
negative risk factor for CHD (Section 1.7). There is also a strong inverse 
relationship between HDL-cholesterol and the plasma levels of TRL. This 
relationship is valid in the fasting state but becomes much stronger in the 
postprandial state (Miesenbock & Patsch, 1991).
Miesenbock & Patsch (1991) considered whether low HDL-cholesterol 
levels are a result of low reverse transport of cholesterol, or whether they are 
a marker for inefficient TAG clearance. When TAG transport operates 
efficiently there are two distinct lipoprotein families: triacylglycerol-rich 
lipoproteins (CM and VLDL) and CE-rich particles (LDL and HDL). 
Alimentary lipaemia can be considered as an aggravated or transient form of 
hypertriacylglycerolaemia. If TAG clearance is impaired, accumulation of 
TAG in the plasma results in CETP-mediated exchanges between the 
distinct lipoprotein families. This produces CM and VLDL which are 
enriched in CE and LDL and HDL which are enriched in TAG. Replacement 
of lipase-susceptible TAG by lipase-resistant CEs in CM and VLDL causes 
an accumulation of CM remnants and IDL. In contrast, TAG-enriched LDL 
and HDL are more susceptible to hydrolysis by LPL and HL, resulting in 
smaller LDL and a preponderance of smaller HDL (i.e. increased proportion 
of HDLg and lower concentrations of HDLa).
A preponderance of small LDL has been linked to increased risk of 
myocardial infarction (Austin et al., 1988). These authors showed that small
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LDL is closely associated with the other lipoprotein and apolipoprotein 
profiles that are known to influence risk of atherosclerosis (Austin et al.,
1990). This group have proposed a genetic locus which is responsible for 
small LDL and have shown that small LDL is inherited as a single-gene trait 
with a dominant mode of inheritance. In studies on 32 men with 
angiographically ascertained premature atherosclerosis, Karpe et al. 
(1993b) found around 50 % of the distribution of LDL into smaller particles 
was accounted for by LPL activity and postprandial levels of TRL. They have 
also noted a strong relationship between plasma concentrations of small CM 
remnants after intake of an oral fat load and the rate of progression of 
coronary atherosclerosis. Miesenbock etal. (1993) have recently described 
an example of "impaired TAG tolerance" in two Austrian families. The 
patients had heterozygous LPL deficiency, caused by a missense mutation, 
which resulted in pronounced postprandial lipaemia.
The hypothesis that HDL levels are merely a marker of postprandial TAG 
metabolism is attractive because it can explain many of the alterations in 
lipoproteins which are associated with increased risk of CHD. It is 
particularly useful since it links the involvement of HDL, for which there is 
strong epidemiological evidence, with postprandial TAG which has not been 
thoroughly investigated by epidemiological studies. LPL deficiency may be 
the first clearly defined defect of impaired postprandial TAG metabolism 
though it is likely that other defects will be described in future.
One of the consequences of impaired TAG tolerance is enrichment of CM 
with CE. These particles were first considered to be a potential cause of 
atherogenesis by Zilversmit (1979) . He pointed out that CM are the 
principal carriers of dietary cholesterol in the bloodstream and the first stage
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of their degradation takes place in contact with the vascular endothelium. 
Subsequently, in vitro experiments have been conducted to explain the 
mechanism by which CM remnants could contribute to atherosclerosis. 
Using macrophage cultures from the Watanabe Heritable Hyperlipidaemic 
rabbit (which lack the LDL receptor) Van Lenton etal. (1985) showed that 
CM remnants were taken up by a low affinity, high capacity process for 
which apo È was the preferential ligand. Chung etal. (1989) found that 
circulating TRL isolated from certain hypertriacylglycerolaemic patients were 
cytotoxic to macrophages even in the absence of prior in vitro lipolysis. 
Furthermore, the cytotoxicity was increased by in vitro lipolysis. Ellsworth et 
al. (1990) compared processing of rat dietary-derived CM remnants and 
cholesterol-rich [3-VLDL by mouse peritoneal macrophages. They found that 
internalisation of the CM remnants, after binding to the LDL receptor, was 
much slower than that of [3-VLDL. They also observed that rates of CM
remnant apolipoprotein degradation and CE hydrolysis by lysosomal 
enzymes was less than that of [3-VLDL. They concluded that accumulation
of undegraded CM remnants within macrophages could lead to the
formation of foam cells.
Evidence implicating CM remnants and atherogenesis has also come from 
clinical studies. In patients with type III hyperlipoproteinaemia it has been 
demonstrated that clearance of CM remnants from the plasma is seriously 
hampered (Hazzard & Bierman, 1976). G root etal. (1991) demonstrated 
that the clearance of postprandial lipoproteins was delayed in 
normolipidaemic CAD patients compared to that of controls. In a separate 
study Simons etal. (1987) reported that the prevalence of CAD increased 
progressively with the apo B-48:apo B-100 ratio. In a group of 
non-insulin-dependent diabetic patients, who are at risk from developing
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CHD, Nakai eta l. (1991) found the apo B-48:apo B-100 ratio was 
significantly higher in patients compared to controls.
A number of clinical studies and in vitro experiments have provided 
evidence that CM could play an important role in the development of CHD. 
CM and large VLDL from hypertriacylglycerolaemic patients are the only 
native human lipoproteins that can cause in vitro conversion of 
macrophages to foam cells (Gianturco & Bradley, 1992).
Epidemiological evidence for elevated fasting TAG levels and increased 
incidence of CHD has been lacking. However, there is strong evidence for a 
negative correlation between HDL and CHD. A possible mechanism by 
which postprandial TAG may influence HDL levels has been described 
(Section 1.9). Postprandial metabolism of CM has an important potential 
role to play in the development of CHD. Each CM particle carries 500,000 
molecules of TAG compared to only 300 in each LDL. In addition each CM 
carries approximately 60,000 molecules of cholesterol and CE compared to 
only 2,000 in each LDL (Gianturco & Bradley, 1992).
Both postprandial lipaemia and CM remnants may prove to be crucial factors 
in the development of CHD. CM are the primary transport particles of 
intestinally-derived lipid and therefore diet can play a major role in their 
metabolism. Most previous work has concentrated on the effects of fat on 
LDL metabolism and now there is a need for more studies of dietary fat 
content and composition on the metabolism of CM and CM remnants. This 
could be particularly important in groups at a higher risk from CHD.
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A major limitation in understanding postprandial lipaemia has been the 
ability to quantify the relative contributions of the intestine and liver to the 
increase in triacylglycerol concentrations. Since the density range of CM 
and VLDL overlap, lipoproteins of dietary origin cannot be separated from 
those of hepatic origin simply by ultracentrifugation. Apo B-48 is uniquely 
associated with CM and CM remnants and is therefore an ideal marker for 
lipoproteins of dietary origin. The homology of apo B-48 with apo B-100 
precludes raising antibodies to the whole apo B-48 molecule and 
presumably explains why there has been no previously published 
immunoassay for apo B-48.
1.10 Methods of measuring apolipoprotein B-48
There is no currently available assay for apo B-48 which is capable of 
accurately measuring large numbers of samples in a reasonable time. In 
order to measure apo B-48 in patients or subjects on dietary trials there is 
clearly a need for a routine assay for apo B-48. An immunoassay, such as 
an enzyme linked immunosorbent assay (ELISA), for plasma apo B-48 
would be ideal because it would be sensitive, be capable of measuring over 
100 samples in one day and would not require the use of expensive 
specialised equipment.
The most common way of measuring apo B-48 has been by densitometric 
scanning of Coomassie Blue stained SDS-polyacrylamide gels. This 
technique is outline in Section 2.4 and is further discussed in Section 5.1. 
The main drawback of this technique is that the samples require 
ultracentrifugation for 16 hours prior to loading on the gels. In addition, only 
15 samples can be loaded onto a single gel.
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A more recently described technique has involved labelling of apo B-48 by 
oral infusion of a stable isotope of leucine (Lichtenstein etal., 1992). 
Following ultracentrifugation to prepare TRL, the apo B-48 band was 
excised from the gel and analysed by gas chromatography-mass 
spectrometry. Therefore this method suffers the drawbacks of SDS-PAGE 
described above as well as requiring expensive and specialist equipment 
for detection of the stable isotope.
1.11 Aims of the study
The main objective of the present study was to develop an immuno-based 
assay to measure apo B-48. The first aim was to use a novel approach to 
raise antisera specific for apo B-48. The next step was to employ the 
antisera in an assay for apo B-48 by firstly developing an enzyme-linked 
immunosorbent assay and secondly to use gel electrophoresis and 
immunoblotting. The final aim was to validate the apo B-48 assay by 
measuring CM-enriched samples in subjects fed acute test-meals of differing 
fatty acid composition.
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CHAPTER TWO
MATERIALS
AND
METHODS
2.1 Treatment of blood and lymph samples
2.1.1 Materials
Human thoracic duct lymph from a patient undergoing thoracic surgery and 
serum from a patient with Type V hyperlipidaemia were kindly supplied by 
Dr. J. Wright at the Royal Surrey County Hospital, U.K. Other blood samples 
were obtained from healthy volunteers. Aprotinin (kallikrein inactivator), 
benzamidine, gentamicin sulphate and chloramphenicol were obtained from 
Sigma Chemical Co. Ltd., Poole, Dorset. Sodium azide, sodium chloride, 
sodium hydroxide and ethylenediaminetetraacetic acid (disodium salt) 
(EDTA) ("Analar" grade) were from BDH Laboratory Supplies, Merck Ltd., 
Lutterworth, Leics.
2.1.2 Procedure
Preservative was prepared for plasma, lymph and CM-enriched fractions 
following the method of Edelstein & Scanu (1986). First, 1.2 g of EDTA was 
added to 40 mL of water and the pH adjusted to pH 7.4 with sodium 
hydroxide to aid solubilisation. Then 0.1 g of sodium azide, 10000 units of 
aprotinin, 8.8 g of sodium chloride, 0.16 g of benzamidine, 80 mg of 
chloramphenicol and 80 mg of gentamicin sulphate were added and the 
total volume made up to 50 mL.
Blood was collected into tubes containing no anti-coagulant (for serum) or 
heparinised tubes (for plasma) and centrifuged at 3000 g.min. Serum or 
plasma was removed and preservative added to give a concentration of 
5 % (v/v). Plasma, serum and lymph were stored at -20 °C.
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2.2 Preparative ultracentrifugation of CM-enriched fractions
2.2.1 Principle
Since this technique is central to investigating lipoprotein metabolism it is 
worth considering the three main variations of this method. All of these 
techniques are discussed in much greater detail in Mills etal. (1984).
1. Serial ultracentrifugation is where the solvent density of plasma (or other 
solution of lipoproteins) is adjusted to the lower limit of the fraction that is to 
be isolated and then centrifuged at about 100 000 g for several hours. The 
lipoproteins of density less than that to which the solution was adjusted float 
to the top of the tube, while other substances sediment towards the bottom. 
The floating lipoproteins are removed. However, no matter how carefully the 
experiment is performed, fractions always overlap because particles with a 
density close to that of the solvent migrate very slowly into (or out of the 
upper part of the tube). This technique has the drawback that it, cannot be 
used to sub-fractionate CM or VLDL, which are less dense than 
physiological salt solution.
2. Density gradient ultracentrifugation depends on floating the lipoprotein 
particles through a gradient formed by layering salt solutions of decreasing 
density above a layer of plasma adjusted to a density greater than the 
solution above it. Centrifugation in a swinging bucket rotor causes the 
lipoprotein particles to float through the gradient. The gradient can either be 
continuous or discontinuous and the fractions can be removed from either
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the top or the bottom of the tube. Again, CM and VLDL cannot be separated 
by this method.
3. Sequential flotation ultracentrifugation is used to sub-fractionate CM and 
VLDL where it is necessary to resolve them according to their different 
flotation rates i.e. by using a combination of mass and hydrated density as 
the discriminant. The plasma (or lipoprotein solution) is overlayered with 
0.196 M NaCI (d = 1.006 g/mL at 20 °C) and centrifuged for a precise time at 
consistent temperature. After removal of the supernatant, the infranatant is 
overlayered with 0.196 M NaCI and re-centrifuged, for longer duration at 
higher speed. The resolution of this process is low because slow-moving 
particles that start from the top of the sample layer will reach the top of the 
tube at the same time as faster particles that travel from the bottom of the 
tube.
Therefore, it is important to follow published methods exactly and to bear in 
mind that any CM preparation will produce a heterogeneous population with 
a significant VLDL content.
2.2.2 Materials
The ultracentrifuge was a Beckman L7-65 model. The ultracentrifuge tubes 
and 50.2 Ti rotor were also supplied by Beckman RIIC Ltd., High Wycombe, 
Bucks. Sodium chloride ("Analar" grade) was from BDH Laboratory 
Supplies, Merck Ltd., Lutterworth, Leics.
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2.2.3 Procedure
The CM-enriched fraction was prepared as described by Grundy & Mok 
(1976) with modifications from Mills etal. (1984). Sodium chloride solution 
of density 1.006 g/ml was prepared by dissolving 10.49 g of NaCI in 1 L of 
water. The density was accurately adjusted with the aid of a hydrometer. 
3.5 g of plasma was weighed into a 32 mL thick-walled ultracentrifuge tube 
and overlayered with 3.5 g of the sodium chloride solution. The tubes were 
centrifuged at 45000 rpm in a 50.2 Ti rotor at 12 °C for either 30 min 
(including acceleration and deceleration) (2.1 x 106 g.min) or 16 hours 
(1.4 x 108 g.min). Using a fine bore pipette, the upper layer, which will be 
termed "CM-enriched fraction", was carefully removed and stored at -20 °C.
2.3 Measurement of protein in CM-enriched fraction
2.3.1 Materials
Butanol ("Analar") grade was obtained from BDH Laboratory Supplies, 
Merck Ltd., Lutterworth, Leics. Diisopropyl ether (99 %) was from Aldrich 
Chemical Co. Ltd., Gillingham, Dorset.
2.3.2 Procedure
To prevent interference by lipid, the CM-enriched samples were delipidated 
according to the procedure of Cham & Knowles (1976). Briefly, this involved 
mixing 400 p i  of CM-enriched fraction with 800 pL of butanol/diisopropyl 
ether (25:75) by end-over-end rotation in an Eppendorf tube. The mixture
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was centrifuged at 13000 rpm for 2 mins (2.1 x 104 g.min) after which the 
upper organic phase was removed with a glass pipette.
The protein content was measured following the method of Lowry et al. 
(1951) with modifications by Bollag & Edelstein (1991) using bovine serum 
albumin (BSA) (0-100 pg/ml) as a standard.
2.4 SDS-polyacrylamide gel electrophoresis and 
immunoblotting
2.4.1 Principle
An excellent source of information on electrophoresis techniques can be 
found in Names (1990). Any charged ion or group migrates when placed in 
an electric field. Since proteins carry a net charge at any pH other than their 
isoelectric point, the application of an electric field to a protein mixture in 
solution results in different proteins migrating at different rates towards one 
of the electrodes. A gel can be considered as a porous medium in which the 
pore size is similar to the size of the protein molecules so that a molecular 
sieving effect occurs and the separation is dependent on both charge 
density and size. In gradient polyacrylamide gels the concentration of 
polyacrylamide increases (and hence pore size decreases) as the protein 
migrates further from the origin. This results in separation of a wide range of 
molecular masses (e.g. 14-300 kDa). Most proteins bind sodium dodecyl 
sulphate (SDS) in a constant weight ratio (1.4 g of SDS per gram of 
polypeptide). If excess SDS is added to the protein sample the intrinsic 
charges of the polypeptide become insignificant and SDS-polypeptide 
complexes migrate in the polyacrylamide gels strictly according to
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polypeptide size. In addition to SDS, denaturing buffer systems contain a 
thiol reagent (to cleave disulphide bonds) and urea (to disrupt hydrogen 
bonds) with the net result that proteins dissociate into their individual 
polypeptide units.
Proteins can be visualised directly on the polyacrylamide gel by staining 
with Coomassie Blue. Alternatively they can be transferred by 
electroblotting to a support matrix such as a nitrocellulose membrane. The 
mechanism of protein binding is not fully understood, but it is certainly 
non-covalent and probably involves hydrophobic interactions. Following 
electrotransfer the membrane can be incubated with antibody solutions 
allowing detection of particular proteins. Non-specific binding of antibody to 
the filter matrix is prevented by blocking vacant sites with a protein such as 
that contained in dried milk.
2.4.2 Materials
Chloramphenicol, Ponceau Red, Tween 20, molecular weight marker 
pro te ins,  SDS, di th io thre i to l ,  ammonium persu lphate ,  
tetramethylethylenediamine, Tris (7-9), 2-mercaptoethanol, Coomassie Blue 
R-250, biotinylated goat anti-rabbit immunoglobulin G (IgG) and extravidin- 
peroxidase conjugate were all from Sigma Chemical Co. Ltd., Poole, Dorset. 
Sodium chloride, EDTA, disodium hydrogen phosphate (anhydrous), 
potassium dihydrogen phosphate, urea, glycine, sucrose, trichloroacetic 
acid, glycerol, methanol (all "Analar" grade) and bromophenol blue were 
supplied by BDH Laboratory Supplies, Merck Ltd., Lutterworth, Leics.
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Butanol and potassium chloride (both analytical reagent grade) were from 
Fisons Scientific Equipment, Loughborough, Leics.. Sodium hydroxide and 
hydrochloric acid were obtained from May and Baker Ltd., Dagenham, 
England. Protogel was supplied by National Diagnostics, Aylesbury, Bucks., 
and Marvel milk powder was from Tesco Stores Ltd., Ware, Herts. The 
nitrocellulose membrane (BA 85) was manufactured by Schleicher and 
Schuell and supplied by Anderman and Company Ltd., Kingston-upon- 
Thames, Surrey. The Saranwrap was manufactured by the Dow Chemical 
Company and supplied by Gene Research Instrumentation Ltd., Dunmow, 
Essex.
Hoefer Scientific Instruments, Newcastle-under-Lyme, Staffs., supplied the 
electrophoresis equipment. The densitometric scanner was a dual 
wavelength flying spot CS-9001PC model manufactured by Shimadzu and 
supplied by V.A. Howe, Banbury, Oxon. Enhanced chemiluminescence 
(ECL) reagents and ECL film were supplied by Amersham International Pic., 
Little Chalfont, Bucks..
2.4.3 Stock solutions
Sample buffer (two-fold concentrated)
1.51 g of Tris was dissolved in 35 mL of water, 20 mL glycerol was added 
and the pH adjusted to pH 6.75 with 12 M HCI. Then 4 g of SDS, 10 mL of 
2-mercaptoethanol and 2 mg of bromophenol blue were added and diluted 
with water to a final volume of 100 mL.
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3 M Tris buffer (pH 8.8)
36.3 g of Tris was weighed and dissolved in approximately 90 ml of water. 
The pH was adjusted to 8.8 with 12M HCI and water was added to a final 
volume of 100 m l. This solution was stable for several weeks when stored 
at 4 °C.
0.5 M Tris buffer, (pH 6.8)
6.02 g of Tris was dissolved in approximately 80 ml of water. The pH was 
adjusted to pH to 6.8 with 12M HCI and water was added to a final volume of 
100 m l. This solution was stable for several weeks when stored at 4 °C.
PBS buffer (10-fold concentrated, pH 7.4)
80 g of sodium chloride, 11.5 g of disodium hydrogen phosphate, 2 g of 
potassium chloride and 2 g of potassium dihydrogen phosphate were 
dissolved in 1 L of distilled water. This solution was stable for two weeks 
when stored at room temperature (RT).
Urea/SDS/dithiothreitol solution
38.4 g of urea, 24.6 mg of dithiothreitol and 0.16 g of SDS were dissolved in 
50 mL of water and the final volume was made up to 80 mL.
1.5 % ammonium persulphate solution
0.15 g of ammonium persulphate were dissolved in 10 mL of water.
Electrode buffer (pH 8.3)
71 g of glycine, 15.3 g of Tris and 5 g of SDS were dissolved in 5 L of water.
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Transfer buffer (pH 8.3)
86.4 g of glycine, and 18.15 g of Tris were dissolved in 6 L of water. 
PBS-Marvel Tween (PBSMT) buffer (pH 7.4)
25 g of Marvel milk powder, was dissolved in 500 m l of water and 0.25 mL 
of Tween 20 was added.
2.4.4 Procedure
Preparation of SDS-polyacrylamide gel
Linear gradient (5-20 %) polyacrylamide gels were prepared following the 
method of Names (1990) according to the original method of Laemmli 
(1970): a 5 % acrylamide resolving gel (16.36 mL) and a 20 % acrylamide 
resolving gel (15.01 mL) were prepared as shown in Table 2.1.
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Table 2.1 Gel mixtures for 5 - 20 % gradient gel
Resolving gels Stacking gel
5% 2 0 %
Sucrose 2.25 g
Tris buffer 1.85 mL 1.85 mL 3.75 mL
Protogel 2.5 mL 10 mL 1.85 mL
U rea/S DS/ 1.5 mL 150 pL 0.3 mL
dithiothreitol
1.5 % ammonium 0.35 mL 0.35 mL 1.15 mL
persulphate
water 10.1 mL 1.35 mL 7.5 mL
3 M Tris buffer, pH 8.8 was used for the resolving gels and 0.5 M Tris buffer, pH 6.8, was used 
for the stacking gel. Neat protogel is a mixture of 30 % (w/v) acrylamide and 0.8 % (w/v)
N, N'-bis-methylene acrylamide.
The final concentrations in the 5 % gel were as follows: 0.340 M Tris-HCI 
(pH 8.8), 0.015 % (w/v) SDS, 0.0023 % (w/v) dithiothreitol, 3.53 % (w/v) urea 
and 0.032 % (w/v) ammonium persulphate. In the 20 % gel concentrations 
were: 0.370 M Tris-HCI (pH 8.8), 0.0016 % (w/v) SDS, 0.00025 % (w/v) 
dithiothreitol, 0.38 % (w/v) urea, 0.15 % (w/v) sucrose and 0.035 % (w/v) 
ammonium persulphate. To both the 5 % and 20 % gels 11.5 pL of 
tetramethylethylenediamine was added to initiate polymerisation just before 
pouring the gel.
The gel was poured with the aid of gradient forming apparatus following the 
manufacturer's (Hoefer Scientific Instruments, Newcastle-under-Lyme,
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Staffs.) instructions. Basically, the procedure was as follows: the 20 % 
solution was placed in the mixing chamber and the 5 % solution in the 
reservoir chamber and the free end of the tubing from the mixing chamber 
was placed between the glass plates of a gel mould. Stirring was started 
and the valve to the outlet port was opened. Simultaneously, the peristaltic 
pump was started and the valve between the two chambers was opened, 
thus forming a concentration gradient of acrylamide from 5-20 %. The gel 
was then overlayered with water saturated butanol. Following 
polymerisation, the top of the gel was rinsed several times with distilled 
water.
A stacking gel (14.55 m l) was prepared as shown in Table 2.1. The final 
concentrations in the stacking gel were: 0.123 M Tris-HCI (pH 6.6), 0.1 % 
SDS (w/v), 1 mM dithiothreitol, 4 M urea, 0.1 % (w/v) ammonium 
persulphate. 11.25 pL of tetramethylethylenediamine was added to the 
stacking gel which was then poured on top of the resolving gel using a 
syringe barrel as a funnel. A fifteen-well sample comb was quickly inserted 
and the gel was allowed to polymerise. Following polymerisation the 
sample comb was carefully removed.
Electrophoresis sample preparation
Usually, 100 p i of CM-enriched samples were mixed with 300 pL of sample 
buffer (two-fold concentrated) in an Eppendorf tube and heated at 95 °C for 
2 mins to denature the proteins. The tubes were then centrifuged at 
13000 rpm for 2 mins (2.1 x 104 g.min) to separate insoluble material. 
Molecular weight markers were dissolved in sample buffer according to the 
supplier's (Sigma Chemical Co. Ltd.) instructions, aliquoted and stored at
-20 °C. Before use molecular weight markers were defrosted and treated as 
for samples described above. After allowing samples to cool to RT, 20 \iL of 
molecular weight markers were loaded into each lane with the aid of gel 
loading tips. The amounts of other samples loaded are given in the 
appropriate Chapters.
Electrophoresis
The upper electrode chamber was attached to the gel cassette and the lower 
chamber was filled with 3.5 L of electrode buffer. The plate assembly was 
placed in the lower chamber and the upper chamber was filled with 
electrode buffer. The lid of the upper chamber was fitted and the water 
cooling system switched on. Electrophoresis was carried out at 30 mA until 
the bromophenol blue marker reached the resolving gel after which the 
current was raised to 60 mA. When the dye reached the bottom of the 
resolving gel (after about 3 hours) the power was switched off. The gel was 
then removed from the apparatus and either stained for protein or 
electrotransferred for immunodetection.
Protein staining of acrylamide gel
The gel was immersed in stain containing 10 % (w/v) trichloroacetic acid, 
40 % (v/v) methanol and 0.1 % (w/v) Coomassie Blue R-250 and shaken 
gently for 30 mins. It was then diffusion-destained with several changes of 
10 % (w/v) trichloroacetic acid over 16 hours.
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Electrotransfer
This is based on the method first described by Towbin et al. (1979). The gel 
was equilibrated in transfer buffer for 30 mins. Some transfer buffer was 
poured into the bottom of a tray and into it was placed one half of the 
cassette, two pieces of sponge and two pieces of filter paper. The gel was 
carefully placed onto the filter paper and any air bubbles were smoothed 
out. A piece of nitrocellulose membrance was cut to size and carefully 
placed onto the gel, smoothing out air bubbles and adding more buffer if 
necessary. Two further pieces of filter paper and two pieces of sponge were 
placed on top and the other half of the cassette was used to clamp the whole 
sandwich together. The tank was filled with transfer buffer and the cassette 
placed at the back of the tank with the gel towards the cathode. The tank 
was topped up with transfer buffer and the water cooling system was 
switched on. The lid was attached and electrotransfer carried out for 
17 hours at a constant voltage of 50 V.
Immunostaining of the nitrocellulose
The transfer cassette was dismantled and the nitrocellulose membrane was 
placed in a plastic tray with the protein side uppermost. The membrane was 
immersed in Ponceau Red stain for 1 min and then the excess stain was 
washed off with distilled water. The appearance of protein bands was noted 
before the membrane was placed inside a hybridisation tube. Incubation 
steps were carried out by adding solutions to the tube and rotating on a 
roller mixer. The Ponceau stain was removed and unoccupied sites on the 
membrane were blocked simultaneously by incubation with 2 x 20 mL of 
PBSMT for 1 hour with one change after 30 min. The membrane was then
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incubated sequentially with 15 mL of primary, secondary and tertiary 
antibodies diluted in PBS (Fig. 2.1):
1. 15 m l of rabbit anti-apo B-48 (1:1000)
2. 15 mL of biotinylated goat anti-rabbit immunoglobulin G (1:1000)
3. 15 mL of extravidin-peroxidase conjugate (1:1000)
Each incubation with an antibody was for 1 hour and separated by 6 x 5 min 
washes with PBSMT. Following addition of the tertiary antibody the 
membrane was washed four times with PBSMT and twice with PBS. The 
membrane was then removed from the tube and immersed in PBS in a tray.
Enhanced chemiluminescence detection
This was carried out according to the manufacturer's (Amersham 
International Pic.) instructions. 5 mL of both of the enhanced 
chemiluminescence (ECL) reagents were mixed. The PBS poured off and 
the ECL reagent was pipetted evenly over the surface of the membrane. 
After precisely 60 seconds excess reagent was poured off and the 
membrane was placed on a piece of Saranwrap film. The Saranwrap film 
was folded around the membrane to form a watertight seal and placed in a 
photographic film cassette. A piece of pre-flashed ECL film was exposed to 
the membrane and then developed using an automatic developing machine.
Densitometric scanning
This was performed using a dual wavelength flying spot scanner with the 
parameters shown in Appendix I. The wavelength used for both the ECL
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Fig. 2.1 Immunoblotting method
A A A A A
1 1
See Section
1. Nitrocellulose 
strip with bound 
proteins
2. Blocked
3. Rabbit anti-apo B-48
4. Biotinylated anti­
rabbit IgG
5. Streptavidin-HRP 
complex
6. ECL substrate 
showing the 
apo B-48 band
.4.4 for details
61
blots and Coomassie Blue protein stain gels was 550 nm. The lanes were 
scanned in zig-zag mode and integrated manually.
2.5 Enzyme-linked immunosorbent assay
2.5.1 Principle
ELISA uses antibodies or antigens conjugated to enzymes which can be 
measured by spectrophotometry. The two main ELISA formats used in the 
present study are described below.
In the antigen-coated plate ELISA a specific antigen is attached to a 
solid-phase. Serum containing antibodies is added, incubated and washed. 
Any specific antibody molecules bind to the antigen and all other material is 
washed away. Exposure of the complex to enzyme-labelled 
anti-immunoglobulin results in binding to any specific antibody molecules 
adsorbed from the original serum. The complex is washed and the substrate 
for the enzyme added, resulting in activity proportional to the amount of 
specific antibody in the original serum.
In the two-site format, or sandwich ELISA, the solid-phase is coated with a 
capture antibody to the test antigen. The test antigen is added and allowed 
to bind to the antibody on the plate. Bound antigen is subsequently detected 
by addition of an enzyme-labelled antibody which binds to a different part of 
the test antigen.
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The sensitivity of an ELISA may be greatly enhanced by amplification. An 
example of this is where a biotinylated-second antibody is detected using 
enzyme-labelled avidin.
2.5.2 Materials
Casein and gelatin (biochemical grade) and sodium azide, glacial acetic 
acid and thiomersal (general purpose grade) were supplied by BDH. 
Sodium carbonate, sodium hydrogen carbonate, citric acid, disodium 
hydrogen phosphate (anhydrous), sodium dihydrogen phosphate, 
potassium dihydrogen phosphate, glycine, sulphuric acid, diethanolamine 
and hydrogen peroxide were all "Analar" grade from BDH Laboratory 
Supplies, Merck Ltd., Lutterworth, Leics.
Dimethylsulphoxide (standard laboratory reagent), potassium chloride and 
sodium chloride (both analytical reagent grade) were obtained from Fisons 
Scientific Equipment, Loughborough, Leics. Tween 20, BSA, BSA (fatty 
acid-free), 3, 3', 5, S'-tetramethylbenzidine (TMB), biotinylated anti-rabbit IgG 
and SDS were from Sigma Chemical Co. Ltd., Poole, Dorset.
Horse-radish peroxidase (HRP) was obtained from Biozyme, Blaenavon, 
Wales. Anti-total apo B antiserum was from Boehringer Corporation Ltd., 
London and streptavidin-biotin horseradish peroxidase complex came from 
Amersham International Pic., Little Chalfont, Bucks. Microtitre, Immulon 1 
and Immulon 2 ELISA plates were from Dynatech and Polysorp and 
Maxisorp plates were from Nunc. The ZetaPrep diethylaminoethyl cellulose 
ion-exchange disc was from LKB Bromma (Sweden) and the manual plate 
washer from Titertek, ICN Biomedicals Ltd., High Wycombe, Bucks. The slot
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blot manifold and nitrocellulose membrane were both manufactured by 
Schleicher and Schuell and supplied by Anderman and Company Ltd., 
Kingston-upon-Thames, Surrey.
Postprandial plasma samples were obtained from healthy volunteers 
specifically for the purposes of this investigation and were used to prepared 
CM-enriched fractions (see Chapter 4 for details). Human thoracic duct 
lymph, obtained from a patient undergoing thoracic surgery, was kindly 
supplied by Dr. J. Wright at the Royal Surrey County Hospital, U.K.
2.5.3 Stock solutions
0.5 M Carbonate buffer (pH 9.6)
1.59 g of sodium carbonate and 2.93 g of sodium hydrogen carbonate were 
dissolved in 1 L of water.
0.1 M carbonate buffer (pH 9.6)
This was prepared by a 1:5 dilution of 0.5 M carbonate buffer (pH 9.6)
0.07 M Citrate-phosphate buffer (pH 5.3)
1.17 g citric acid and 1.82 g disodium hydrogen phosphate (anhydrous) 
were dissolved in 250 mL of water.
TMB substrate solution
20 mg of TMB was dissolved in 1 mL of dimethylsulphoxide. 100 pL of this 
solution and 20 pL of hydrogen peroxide were added to 20 mL of 0.07 M 
citrate-phosphate buffer (pH 5.3).
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PBS buffer (10-fold concentrated, pH 7.4)
80 g of sodium chloride, 11.5 g of disodium hydrogen phosphate, 2 g of 
potassium chloride and 2 g of potassium dihydrogen phosphate were 
dissolved in 1 L of distilled water. This solution was stable for two weeks 
when stored at RT.
0.01 M sodium phosphate buffer (pH 7.4)
0.38 g of disodium hydrogen phosphate and 1.15 g of sodium dihydrogen 
phosphate were dissolved in 1 L of water.
0.1 M sodium periodate
42.8 mg of sodium periodate were dissolved in 5 mL of water.
1 mM sodium acetate (pH 4.4)
0.68 g of sodium acetate were dissolved in 500 mL of water. Glacial acetic 
acid was used to adjust the pH to 4.4 and water added to 5 L.
Ethanolamine/glycine buffer (pH 9.6)
37.5 mg of glycine and 0.5 mL of diethanolamine were added to 9.5 mL of 
water.
Blocking buffer solutions
Casein buffer: 9 g of sodium chloride, 1.2 g of Tris base and 5 g of casein 
were dissolved in 1 L of water and the pH was adjusted to 7.6 with 3 M 
hydrochloric acid.
Casein/Thiomersal: this was casein buffer with 0.02 % (w/v) thiomersal 
added.
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The following buffers were based on PBS (pH 7.4) to which different 
additions were made:
PBST (0.05 %) contained 0.05 % (v/v) Tween 20.
PBST (1 %) contained 1 % (v/v) Tween 20.
PBSBT contained 1 % (w/v) BSA and 0.05 % (v/v) Tween 20.
PBSFFBT contained 1 % (w/v) fatty acid-free BSA and 0.05 % (v/v) 
Tween 20.
PBSCT contained 0.5 % (w/v) casein and 0.05 % (v/v) Tween 20.
PBSGT contained 0.1 % (w/v) gelatin and 0.05 % (v/v) Tween 20.
PBSBCT contained 1 % (w/v) BSA, 0.5 % (w/v) casein and 0.05 % (v/v) 
Tween 20.
PBSBCT (Gly) contained 1 % (w/v) BSA, 0.5 % (w/v) casein, 50 mM glycine 
and 0.05 % (v/v) Tween 20.
2.5.4 Preparation of IgG and HRP conjugates
Anti-Met IgG, anti-lie IgG (from antisera collected 8 days after the first boost 
from rabbits 2006 and 2008, Chapter 3) and anti-apo B IgG were prepared. 
This was accomplished using a diethylaminoethyl cellulose ion-exchange 
ZetaPrep Disc, according to the manufacturer's (LKB Bromma) instructions. 
Briefly, 1 mL of antiserum was diluted 1:10 with 0.01 M sodium phosphate 
buffer (pH 7.4). This was passed through a pre-equilibrated ZetaPrep Disc 
and eluted with the same buffer. 1 mL fractions were collected and 
monitored at 280 nm by spectrophotometry.
HRP conjugates of the above IgG fractions were prepared by the method of 
Beyzavi etal. (1987) with modifications by Overton (1992). Briefly, HRP was
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activated with 0.1 M sodium periodate and dialysed against 1 mM sodium 
acetate (pH 4.4). IgG was desalted by dialysis against 0.1 M carbonate 
buffer (pH 9.6). Dialysed HRP was added to the stirred solution of IgG and 
mixed for 2 hours. The reaction was terminated by addition of 
ethanolamine/glycine buffer (pH 8.0). The product was dialysed against 
PBS (pH 7.4) containing 0.02 % (w/v) thiomersal and stored at 4 °C.
Materials and specific details of ELISA methods appear in the appropriate 
Chapters.
2.6 Analysis of triacylglycerol
This assay was performed by another investigator using an automated 
Cobas Bio centrifugal analyser. The reagents were supplied in kit form from 
Roche Diagnostics Ltd., Welwyn Garden City, Herts.
The analysis is an enzymatic colorimetric method based on the following 
reactions:
1. Triacylglycerol--------> glycerol + fatty acids
2. Glycerol + ATP-------->glycerol-3-P + ADP
3. Glycerol-3-P + Oa > dihydroxyacetone phosphate + H2O2
4. 4-chlorophenol + 4-aminophenazone + H2O2  > quinoneimine
derivative
The first step is catalysed by lipoprotein lipase, the second by glycerol 
kinase, the third by glycerol phosphate oxidase and the fourth by 
peroxidase. The quinoneimine formed absorbs at 500 nm and is
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proportional to the TAG concentration. Intra-assay and inter-assay 
coefficient of variation (CV) were 4.3 % and 4.7 % respectively.
2.7 Analysis of retinyl palmitate
This analysis was carried out by other investigators using the method of De 
Ruyter & De Leenheer (1979) with modifications by Ah-Sing in our 
laboratory. The principle of the assay is that ingested retinyl palmitate (RP) 
is metabolised in a similar fashion to CE. Thus, RP becomes incorporated 
into the core of CM and remains with them throughout their metabolism until 
the CM-remnants are cleared by the liver. Since RP is not re-secreted 
measurement of plasma levels of RP acts as a marker of CM. See Section
6.1.3 for more details.
Measurement of CM-RP was achieved by reverse-phase high performance 
liquid chromatography following chloroform extraction of the CM. The inter­
assay CVs for 4 standards were:
0.19 jig/mL (32.1 %), 0.44 pg/m l (7.9 %), 0.93 pg/mL (6.5 %) and 
1.91 pg/ml (5.0 %).
2.8 Analysis of total serum apo B
This was carried out by another investigator using a reagent kit supplied by
the Boehringer Corporation Ltd., London. It is an immunoturbidimetric assay 
measured on a Cobas Bio automated analyser. The principle of the assay 
relies on the detection of scattered light caused by lattice formation between 
apo B in the serum and an anti-apo B antiserum. The intra-assay CVs
ranged from 1.5 to 10.5 % and the inter-assay CV was 8.9 %.
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2.9 Analysis of lipoprotein lipase activity
This analysis, originally described by Nilsson-Ehle & Schotz (1976) and 
modified by Knapper etal. (1993) was performed by another investigator. 
Briefly, the procedure involved incubating post-heparin plasma with 
3H-triolein (supplied by Amersham International Pic., Little Chalfont, Bucks.) 
and heat-inactivated serum (a source of apo C-ll). After a 30 min incubation 
at 37 °C (pH 8) the reaction was stopped and the amount of radioactive 
oleate liberated was measured. Assay CVs were: 5.9 % for intra-assay and
4.9 % for inter-assay.
Methods which required further development by the investigator are 
described in the relevant results Chapters.
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CHAPTER THREE
PRODUCTION AND 
ASSESSMENT OF A 
SPECIFIC ANTIBODY 
TO APO B-48
3.1 INTRODUCTION
3.1.1 Antibodies to apo B-48
Apo B-48 has an identical amino acid sequence to the N-terminal 2152 
amino acids of apo B-100. Therefore, antibodies raised to the whole apo 
B-48 molecule cross-react with apo B-100 Hardman etal. (1987b). This 
probably explains why no reports of a specific apo B-48 j antiserum have 
appeared in the literature prior to the present study. To recognise apo B-48 
specifically, antibodies must be directed towards a distinguishing feature 
between apo B-48 and apo B-100.
The C-terminal amino acid in apo B-48 is free and has a negative charge 
unlike the corresponding residue in apo B-100 which is involved in a 
peptide bond. This difference may be large enough to constitute a distinct 
epitope. In addition, the charged C-terminus of apo B-48 almost certainly 
lies on the surface of the CM particle, whereas the corresponding amino 
acids in apo B-100 lie in the middle of a hydrophobic sequence and are 
therefore much less likely to be surface orientated. The C-terminus of the 
apo B-48 molecule may also be the site of cleavage by the enzyme 
carboxypeptidase-A, further suggesting its accessibility (Section 1.3.4). 
Therefore, antibodies raised to the C-terminal end of apo B-48 would be 
expected to distinguish between apo B-48 and apo B-100.
3.1.2 Selection of peptide
The antigenic sites or epitopes of a protein correspond to those parts of the 
molecule that are specifically recognised by the binding sites or paratopes of
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antibody molecules. Several methods have been used to predict the 
location of epitopes in proteins and therefore the antigenicity of peptides. 
These are reviewed in Van Regenmortel (1988) and are briefly described 
below:
Hydrophilicity:
Since antibodies bind to the surface of proteins it is to be expected that 
epitopes will tend to consist of residues exposed at the protein surface. 
Hydrophobic amino acids tend to be buried within the native structure of 
globular proteins, whilst hydrophilic side chains are on the exterior where 
they can interact with an aqueous environment. It has been shown that the 
most hydrophilic parts of a protein tend to correspond to epitopes.
Amphipathicity:
Amphipathic segments are where one part of a protein is appreciably more 
apolar than another. It has been shown that antigenic sites tend to be 
located in these segments.
Static surface accessibility and segmental mobility:
Static surface accessibility describes the protrusion of certain protein 
regions which correlate with epitopes, whereas segmental mobility refers to 
highly mobile regions of a protein which usually coincide with the more 
accessible parts of the protein surface.
Chain termination:
The termini of many proteins have also been found to correspond to 
continuous epitopes. This is probably for two main reasons: firstly, the end 
regions of a peptide are less constrained than internal regions and have
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more flexibility. Secondly, in both the native protein and the peptide, the 
termini have identical chemical structures. This is in contrast to the internal 
sequences in a protein where the corresponding amino acids are involved 
in a peptide bond.
Size of peptide:
The number of amino acid residues in a peptide immunogen is usually 
between 6-20. Short peptides, of less than 10 residues, have about 
50-55 % chance of producing positive antisera. Sequences longer than 
10-15 amino acids may have their own secondary structure which is unlike 
that of the complete protein (Palfreyman et ai., 1984).
The hydrophilicity and segmental mobility methods were only correct 43 to 
61 % of the time in predicting the number of residues which were antigenic 
(Van Regenmortel, 1988). However, in a literature survey of 103 
oligopeptides which elicited successful antisera, Palfreyman etal. (1984) 
reported that 100 % of antibodies raised using N and C-terminal peptides 
reacted with the complete protein. In addition, Delpierre etal. (1988) used a 
16-amino acid C-terminal peptide to produce antibodies to apo C-ll.
3.1.3 Selection of carrier protein
In order to produce antibodies against small peptides of Mr 700 to 1500, it is 
necessary to enhance their immunogenicity by coupling them to carrier 
proteins. In addition, when short peptides are used as the immobilised 
antigen in solid-phase immunoassays it also necessary to use 
peptide-carrier conjugates since peptides of 6 to 15 residues generally do
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not bind satisfactorily to plastic surfaces. The most commonly used carriers 
are listed in Table 3.1
Table 3.1 Principal carriers used for coupling peptides
Carrier Mr (kDa) Number of groups
e-NH2 -SH phenol imidazole
bovine serum 
albumin
67 59 * 1 19 17
ovalbumin 43 20 4 10 7
myoglobin 17 19 0 3 12
tetanus toxoid 150 106 10 81 14
keyhole limpet 
haemocyanin **
>2000 6.9 1.7 7.0 8.7
Only 30-35 of the 59 lysyl residues of BSA are accessible
The amino acid composition is expressed in g amino acid/100 g.
Other carriers have also been used such as thyroglobulin, diptheria toxoid, rabbit serum 
albumin, bovine or mouse gamma globulin, poly (L-lysine) and Ficoll.
Table taken from (Muller, 1988a).
The choice of carrier molecules (reviewed by Muller (1988a)) depends on a 
number of factors including: the availability of reactive sites, size, solubility, 
immunogenicity, commercial availability and cost. The chances of 
successful antibody production are higher if a protein carrier is used that is 
foreign to the species (Teale, 1988) e.g. keyhole limpet haemocyanin which 
is highly immunogenic. However, this can also be a disadvantage because 
it can lead to a phenomenon known as antigenic competition. In addition its 
large size can also lead to problems with solubility and its cost generally 
prevents its use in immunoassays. The conjugation method also helps to
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determine which carrier is employed. For example, a procedure which links 
NH2 groups on the carrier to SH groups on the peptide requires the carrier 
to have a high ratio of NH2 to SH groups to prevent the formation of protein- 
protein conjugates. Muller (1988a) recommended using BSA for 
conjugates to be used in assays and ovalbumin for preparing conjugates to 
be used for immunisation (Table 3.1). Both of these proteins have high NH2
to SH ratios, are readily available and inexpensive.
3.1.4 Choice of conjugation methods
In general, bifunctional conjugating agents are required to couple peptides 
to proteins. These reagents either become incorporated into the final 
conjugate or activate certain reactive sites of the carrier protein molecule for 
subsequent linkage with the peptide (Table 3.2). The coupling reaction 
should not affect the configuration of the amino acids that constitute the 
epitope. For this reason it is often advantageous during peptide synthesis to 
add, at one end or the other of the relevant sequence of amino acids, an 
anchor for coupling such as cysteine or tyrosine (Muller, 1988a). Peptides 
and proteins contain several functional groups and to obtain the best 
defined product heterobifunctional cross-linkers, such as N-succinimidyl 
3-(2-pyridyldithio) propionate (SPDP) and 6-maleimidocaproic acyl 
N-hydroxysuccinimide ester (MCS), should be used (Peeters etal., 1989). 
In this way a peptide will be coupled specifically and in a predictable fashion 
to the carrier. Failure to do this (e.g. when using homofunctional reagents 
such as glutaraldehyde or bis diazobenzidine) can result in chaos coupling 
where a number of different products are generated. Whilst it is possible to 
cover the surface of large carriers, such as haemocyanin with as many as 
200-500 peptide molecules, a high peptide density can lead to less soluble
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conjugates and masking of determinants, thereby causing decreased 
immunogenicity (Peeters et al., 1989). Muller (1988a) found a ratio of 5 to 
20 moles of peptide per mole of carrier was suitable for both immunoassay 
and immunisation. It is important to monitor the ratio of peptide conjugated 
to carrier to ensure reproducible batch-to-batch variation. In this respect, 
Peeters eta l. (1989) found spectrophotometric determination was more 
accurate than amino acid analysis used by Briand etal., (1985) , particularly 
if the amino acid composition of the peptide resembled that of the carrier.
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Table 3.2 Principal reagents used for peptide-protein 
conjugation
Coupling agents Modified amino acid
Primary reactions Secondary
reactions
Glutaraldehyde Cys-SH, e-NH2, cc-NHa Tyr, His
Bis imido esters e-NHa, a-NHa negligible
Bis diazobenzidine Cys-SH, a-NHa, e-NHa, 
Tyr, His
Trp, Arg
Carbodiimides a-NHa, e-NHa, COOH Tyr, Cys
m-maleimidobenzoyl N- 
hydroxysuccinimide ester
Cys-SH, NHa, n.o.
N-succinimidyl 3-(2- 
pyridyldithio) propionate & 6- 
maleimidocaproic acyl N- 
hydroxysuccinimide ester
Cys-SH, NHa, n.o.
Imido esters Cys-SH, NHa, n.o.
Isobutylchloroformate COOH, NHa, n.o.
Toluene diisocyanate 6-NHa, a-NHa n.o.
p-nitrobenzoyl chloride Cys-SH, e-NHa, Tyr, 
His,
Trp, Arg
p-aminophenylacetic acid e-NHa, a-NHa His, Tyr
cystamine dihydrochloride Cys-SH n.o.
N-ethylbenzisoxazolium
fluoroborate
e-NHa, a-NHa, COOH n.o.
Abbreviations: n.o., not observed. Table taken from Muller (1988a).
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The production of antibodies is usually monitored using an immunoassay. 
In order to prevent non-specific cross-reactivity with the immunogen, the 
conjugate used in the assay should have a different carrier and conjugating 
agent; this is to prevent binding by anti-carrier and anti-conjugating agent 
antibodies. Briand etal. (1985) also described coupling agent-modified 
residues. This is where antibodies that are specific for the modified carrier 
molecule are unable to recognise the untreated carrier or the peptide 
moiety. Edwards etal. (1989) made a further observation that conjugating 
agents with a similar mode of action can result in cross-reactivity between 
the derivatised groups on the carrier. Therefore, it is also helpful to choose 
conjugating agents which have a different mode of action.
Another problem encountered with peptide conjugates is inadequate 
stability. For example, Briand etal. (1985) found that conjugates made with 
bis diazobenzidine degraded by 80 % after 40 days storage in solution at 
4 °C. The authors recommended that conjugate stability should be 
monitored by amino acid analysis (following dialysis to remove uncoupled 
peptide), since change in molecular weight, as visualised on SDS-PAGE, 
has been found to be unsuitable (Briand etal., 1985; Muller, 1988a).
In a comparison of four bifunctional agents, m-maleimidobenzoyl 
N-hydroxysuccinimide ester, succinimidyl 4-(N-maleimidomethyl)- 
cyclohexane-1 -carboxylate, MCS and SPDP, Peeters et al. (1989) 
concluded that MCS and SPDP were preferable to the other two agents in 
terms of their lower potential for immunogenicity, greater structural flexibility 
and greater stability in aqueous solutions. One disadvantage of SPDP is 
that the resulting disulphide linkage is susceptible to reductive cleavage by 
ubiquitously occurring thiol compounds and therefore it is best suited to
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being the assay conjugate. The thiol-ether linkage resulting from MCS is 
stable for at least 6 months at 4 °C (Peeters etal. 1989). In addition, both of 
these conjugating agents allow spectrophotometric determination of the 
amount coupled and they differ in their modes of action, which should 
reduce the likelihood of the production of coupling agent-modified residues.
3.1.5 Mode of action of MCS
The reaction of MCS is outlined in Fig. 3.1. MCS reacts first by acylation of 
amino groups on the carrier via the N-hydroxysuccinimide ester. This is 
followed by formation of a thiol ether bond through addition of a thiol group 
from the peptide to the double bond of the maleimide (Lee etal., 1980).
This number of peptide molecules coupled and the number of maleimido 
groups joined onto carriers can be estimated. This is achieved using the 
chromophore, 5,5'-dithio-bis-2-nitrobenzoic acid (DTNB), by subtractive 
sulphydryl titration with 2-mercaptoethanol as a source of thiol groups 
(Sedlak & Lindsay, 1968).
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Fig. 3.1 Mode of action of conjugation of peptide
to ovalbumin using MCS
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3.1.6 Mode of action of SPDP
The reaction of SPDP is shown in Fig. 3.2. SPDP reacts with carrier amino 
groups via its N-hydroxysuccinimide ester. The resulting 2-pyridyl 
disulphide structure then reacts with the peptide thiol group via a thiol 
disulphide exchange reaction.
2-thiopyridone is released when SPDP conjugated to the carrier is 
measured in the presence of 2-mercaptoethanol and also when the peptide 
joins to the SPDP (Fig. 3.2). Since 2-thiopyridone absorbs strongly at 
343 nm it can be used to estimate the amount of SPDP conjugated to the 
carrier and also the subsequent conjugation of the peptide (Carlsson et al., 
1978).
3.1.7 Immunisation
Immunisation with conjugates requires consideration of the choice of 
species, form of immunogen, amount and frequency of dose, route of 
immunisation and frequency and timing of bleeds for assessment of 
antisera. Despite the range of methods in the literature there is very little 
objective information regarding these parameters and the quality of the 
antisera produced (Table 3.3).
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Fig. 3.2 Mode of action and estimation of conjugation
of peptide to BSA using SPDP
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Table 3.3 Immunisation programs for peptide conjugates in 
rabbits
Reference Prime
(amount,
adjuvant,
route)
Boosters
(amount, adjuvant, route, 
frequency)
Bleeds
(frequency)
Titre
(Edwards et 
al, 1989)
200 gg 
conjugate in 
CFA, s.c.
200 pg conjugate in IFA, 
s.c., 2 weeks & 200 pg 
conjugate in IFA, ip, 3 
weeks
4 weeks 1:3000-
1:5000
(Fujiwara & 
Saita, 1986)
1 mg conjugate 
in CFA, s.c. 
and i.m.
500 pg conjugate, 2,4, 6 
and 8 weeks
NA 1:3000
(Green et al, 
1982)
200 pg 
conjugate in 
CFA, s.c.
200 pg conjugate in IFA, 
s.c., 2 weeks, 200 pg 
conjugate in alum, ip, 3 
weeks and every 5 weeks
1-2 weeks 
after each 
injection
5-1280
(Humphrey 
et al, 1990)
4 x 250 pg 
peptide in 
CFA, s.c.
4 x 50 pg peptide in IFA, 
33 days
40 & 43 
days
1:6000-
1:50000
(Kardana et 
al, 1988)
40 pg
conjugate in 
CFA, s.c.
40 pg conjugate in IFA, 4 
weeks
6, 8, 10 
weeks etc.
NA
(Limjuco et 
al, 1986)
200 pg 
conjugate in 
CFA, i.d.
200 pg conjugate in IFA, 
s.c., 3 & 5 weeks
6.5 weeks 1:1000
(Muller et 
al, 1986)
100 pg peptide 
in CFA, s.c.
100 pg peptide in IFA, 
s.c., 2, 4, 6 and 8 weeks
regularly 
over 8 
weeks
1:1000
(Smith et al, 
1985)
100-500 pg 
conjugate in 
CFA, s.c.
100-500 pg conjugate in 
IFA, s.c., 1,2 & 3 weeks
4 weeks 
then
periodically
NA
(Van Eldikgf 
al, 1983)
150/50-60 
nmols peptide 
in CFA, s.c.
150 or 50-60 nmols 
peptide in IFA, s.c., 6, 8, 
11, 13, 15 or 14, 16, 18, 
21, 23 days
22, 36, 
51/30 days
NA
Abbreviations: CFA, complete Freund's adjuvant; I FA, incomplete Freund's adjuvant; s.c., 
subcutaneous; i.m., intramuscular; i.d., intradermal; i.p., intraperitoneal
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The main species of animals which have been used include: mice, guinea 
pigs, rabbits, sheep, goats and donkeys. Rabbits are cheap to keep, easy to 
maintain and produce antisera to most large molecular weight compounds 
(Morris, 1985).
For injection the conjugate is normally emulsified in an adjuvant to enhance 
the humoral response. The emulsion ensures slow release of immunogen 
into the systemic circulation and continuous stimulation of the 
reticuloendothelial antibody-production system. The inclusion of bacteria in 
the first injection also stimulates the response (Teale, 1988).
There is no direct relationship between the size of animal and the quantity of 
immunogen required (Muller, 1988b), however, in general peptides are 
normally administered in microgram quantities (Teale, 1988) . The relative 
merits of the different frequency of injections in immunisation schedules are 
rarely compared and unsuccessful attempts are seldom reported. The 
majority of authors (Table 3.3) have boosted regularly to produce a quicker 
response. However, Morris (1985) argued strongly that the quality and 
quantity of antiserum is enhanced if boosting injections are delayed until 
antibodies from the priming injection have fallen to a steady level.
The most common routes of immunisation which have been tried include: 
intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.). 
Intramuscular routes are the most appropriate for using emulsified 
immunogen, particularly when using an adjuvant which has a tendency to 
form abscesses. Subcutaneous injection is often used for booster doses
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since absorption into the circulation is slow, whilst i.d. routes offer an even 
slower stimulation of the immune system and have the added advantage 
that the doses used tend to be smaller, thus conserving immunogen (Teale, 
1988).
It is necessary to bleed immunised animals regularly in order to monitor the 
response to the previous injection. In particular it is important to harvest as 
much blood as possible when antibody levels are high, that is, usually 8 to 
10 days after a boost (Morris, 1985). The antiserum collected can be stored 
at either -22 °C, or at +4 °C with sodium azide as a bacteriostat (Teale, 
1988).
3.1.8 Assessment of antisera
The most important properties of an àntiserum are titre, avidity and 
specificity. The titre is a measure of antibody content. Thus, a high titre 
antiserum can be used at high dilution thereby allowing a large number of 
assays to be performed. The avidity is a measure of the energy of binding 
between antigen and antibody and influences the sensitivity of an assay. 
The specificity relates to the ability of an antiserum to bind to its antigen 
compared to other antigens (Teale, 1988).
Consideration of methods for the assessment of antisera appears in Morris 
(1985). The titre can be determined by means of an antiserum dilution 
curve. It is arbitrarily defined as that dilution of the antiserum which binds 
50 % of the immunoreactive portion of a specified quantity of labelled 
antigen. In ELISA a labelled antigen is not used and the titre can be 
considered as that dilution of the antiserum which binds to 50 % of the
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antigen. The antigen, i.e. peptide conjugate, is bound to the plate so that it is 
present in excess (Fig. 3.3). Then increasing dilutions of rabbit anti-peptide 
antibody are added. Bound antibodies are detected by adding an 
enzyme-labelled anti-rabbit antibody. The amount of enzyme label bound 
is, in turn, detected by addition of a substrate which gives a product with a 
distinct absorbance. The absorbance due to bound antiserum is plotted 
versus the dilution of the antiserum. A sigmoid curve is produced, showing 
highest binding with the most concentrated dilutions of antiserum and the 
lowest binding at the highest dilution. A line is drawn parallel to the x-axis 
from the point which represents 50 % of the maximum bound antiserum. 
The point where this line intersects the dilution curve is the titre of the 
antiserum.
An indirect measure of the avidity of the antiserum is provided from an 
antiserum displacement curve. This curve is obtained by incubating a set of 
wells with the same composition as the antiserum dilution curve, except that 
an aliquot of antigen, in this case free peptide, is added just before the rabbit 
anti-peptide antiserum. The free peptide competes with peptide bound to 
the plate for the available rabbit anti-peptide antisera. This results in less 
rabbit anti-peptide antiserum binding to the peptide on the plate and 
therefore less coloured product is produced. The second set of wells results 
in a similar sigmoid curve, except that its parallel linear portion is displaced 
to the left of the antiserum dilution curve. The degree of displacement 
horizontally is an indirect measure of the avidity of the antiserum, since the 
greater the displacement the greater the avidity for the peptide.
Specificity can be checked in a similar manner except that instead of adding 
antigen an aliquot of likely cross-reactant is added. However, if the
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Fig. 3.3 Format of ELISA for screening titre and 
displacement of antisera
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2. anti apo B-48 antiserum 
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cross-reactant is not available in a purified form then SDS-PAGE and 
Western blotting can be used (Section 2.4).
In the present study the overall objective was to produce antibodies which 
would react specifically with the C-terminal end of apo B-48. The specific 
aims were to:
1. Select peptides corresponding to the two isoforms of apo B-48 and 
conjugate them to ovalbumin and BSA using MCS and SPDP, thereby 
allowing the ratio of conjugated peptide molecules to be monitored.
2. Use the ovalbumin conjugates to immunise six rabbits by two different 
immunising regimes. The first regime should produce one batch of 
antiserum quickly, whilst the second regime, which will take longer, should 
eventually produce a better quality antiserum.
3. To develop an ELISA to monitor the titre and avidity of bleeds taken 
regularly from the rabbits and to use the first batch to check the antisera 
specificity by SDS-PAGE and immunoblotting.
3.2 MATERIALS
Hexa-peptides corresponding to the two possible C-terminal forms of apo 
B-48, with an additional N-terminal cysteine residue for linking, were 
synthesised and verified by the National Institute of Medical Research, Mill 
Hill, London. The two structures were:
HgN+'Cys-Leu-Gln-Thr-Tyr-Met-lle-COO" (lle-peptide)
H3N+-Cys-Gln-Leu-Gln-Thr-Tyr-Met-COO" (Met-peptide)
The amino acid content of the two peptides was verified by HPLC analysis 
(Table 3.4). The low value for cysteine is due to oxidation during peptide 
hydrolysis and the suppliers confirmed this was quite normal. Gel filtration 
chromatography, performed by the suppliers, showed both the He- and 
Met-peptides eluted with a single peak with a retention time of 3.5 minutes. 
This showed each peptide consisted predominantly of a single molecular 
species.
Table 3.4 Amino acid composition of peptides determined by 
HPLC
Amino acid lle-peptide molar ratio Met-peptide molar ratio
Theoretical Measured Theoretical Measured
Thr 1 0.96 1 0.93
Gin 1 1.04 2 2.09
Cys 1 0.39 1 0.51
Met 1 0.99 1 0.87
He 1 0.95 0 0.00
Tyr 1 0.98 1 0.96
Leu 1 1.03 1 0.94
MCS and SPDP were both obtained from Fluka Biochimika, Buchs, 
Switzerland. Ovalbumin, BSA, 2-mercaptoethanol, DTNB, 
dimethylformamide (DMF), Tween 20, alkaline phosphatase-labelled 
anti-rabbit IgG, 4-chloronaphthol tablets and p-nitrophenyl phosphate
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substrate were all obtained from Sigma Chemical Co. Ltd., Poole, Dorset. 
Diethanolamine, methanol, hydrogen peroxide and sodium azide ("Analar 
grade”) were from BDH Laboratory Supplies, Merck Ltd., Lutterworth, Leics. 
The Sephadex G-25 columns (PD-10 columns) were from Pharmacia. The 
spectrophotometer was a Kontron Uvikon Instrument, Zurich, Switzerland. 
Bacillus Calmette-Guérin (BCG) was from Evans Medical Ltd., Greenford, 
Middx, and non-ulcerative Freund's adjuvant (Morris) was a gift from Mr. B. 
Morris, University of Surrey. New Zealand white rabbits were obtained from 
Regal Rabbits, Great Bookham, Surrey. The flat-bottomed flexible PVC 
microtitre plates and Dynatech MR 600 plate reader were both supplied by 
Dynatech, Billingshurst, West Sussex. Anti-total apo B antiserum was 
obtained from Boehringer Corporation Ltd., London. Hypnorm was supplied 
by Janssen Pharmaceutical Ltd., Grove, Oxon. Other materials are listed in 
the relevant sections in Chapter 2.
3.3 METHODS
3.3.1 I Derivatisation of carrier
The peptides were conjugated to carrier molecules in a two-step reaction 
using two different conjugating agents in a procedure modified from Peeters 
etal. (1989).
In a typical conjugation procedure, carrier protein (ovalbumin or BSA) was 
dissolved in 0.1 M phosphate-buffered saline (PBS), pH 8.0-8.5, to achieve 
a concentration of 10 mg/mL. Either MCS or SPDP (corresponding to 
30 molecules of conjugating agent for each carrier molecule) was dissolved
in DMF to achieve a 1 % (w/v) solution. This was added dropwise to the 
stirred protein solution and the reaction was allowed to proceed at RT for 
45 minutes. The volume was then made up to 2.5 mL with 0.1 M PBS, 
pH 8-8.5. The activated carrier was separated from unreacted conjugating 
agent on a 10 cm Sephadex G-25 column (PD-10 column) which had first 
been equilibrated with 25 mL of 0.1 M PBS, 5 mM EDTA, pH 6.66. Eight 
1 mL fractions were eluted with the same buffer and their absorbance was 
measured at 280 nm in a spectrophotometer. The peak value fractions, 
usually numbers 3, 4 & 5, were pooled and their total volume measured.
3.3.2 Estimation of numbers of MCS conjugated to ovalbumin
7 \iL of 2-mercaptoethanol was diluted in 10 mL of 0.2 M phosphate buffer, 
pH 8, to give a 0.01 M solution. This was used to prepare a series of 
mercaptoethanol standards from 0 to 9 mM as follows:
Concentration (mM) 0 4 5 6 7 8 9
2-mercaptoethanol
(mL)
0.00 0.20 0.25 0.30 0.35 0.40 0.45
0.2 M phosphate 
buffer, pH 8 (mL)
0.50 0.30 0.25 0.20 0.15 0.10 0.05
20 mg of DTNB was dissolved in 5 mL of methanol to give a 0.01 M solution. 
To 1 mL of 0.2 M phosphate buffer (pH 8), 100 pi of a 2-mercaptoethanol 
standard and 100 pi of 0.01 M DTNB were added. In a second series of 
cuvettes, 100 pi of the activated carrier (ovalbumin-MCS) was added and 
mixed before the addition of 0.01 M DTNB. Both series of cuvettes were 
prepared in duplicate. DTNB is reduced by SH groups to form 2-nitro-ô-
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mercaptobenzoic acid which has an intense yellow colour and a molar 
absorption coefficient (e) of 14150 IVH cm "1. The absorbance was 
measured 10 minutes after the. addition of DTNB. Using the molecular 
weight and concentration of the carrier protein the difference in absorption at 
412 nm was used to calculate the number of MCS groups coupled to 
ovalbumin. -
3.3.3 Estimation of numbers of SPDP conjugated to bovine 
serum albumin
17 p i  of 2-mercaptoethanol was added to 5 mL of 0.1 M phosphate buffer 
(pH 8-8.5) to give a 0.012 M solution. 200 \i\ of the pooled fractions were 
transferred to a cuvette containing 700 pi of water. To this was added 100 pi 
of 0.012 M 2-mercaptoethanol. The quantity of 2-thiopyridone liberated 
(directly proportional to introduced thiopyridyl groups) was calculated using 
e=8000 M"1 cm-1 by measuring absorbance at 343 nm after 4 hours.
3.3.4 Conjugation of peptide
Peptide, corresponding to a 5 molar excess for each conjugating agent 
coupled, was dissolved in a minimum volume of DMF. This was added 
dropwise to stirred activated carrier solution and stirred for 12 hours at RT 
(pH 6.66).
Detection of peptide coupling to MCS-activated carrier was determined as 
described in Section 3.3.2. However, the difference in absorbance between 
the two standard curves reflected bound MCS molecules which were 
unoccupied by peptide. This was used to estimate the ratio of peptide
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molecules that were bound to MCS. Conjugation of peptide to the SPDP 
conjugate was measured as described in Section 3.3.3.
Un reacted peptide was separated from the conjugates by dialysing over 
24 hours against 3 changes of 1 litre of distilled water. The final ovalbumin 
conjugate was lyophilised and stored at -25 °C. This allowed the dose of 
conjugates for immunisation to be weighed. The BSA conjugate was 
aliquoted and stored at -25 °C for future use in ELISA.
3.3.5 Preparation of immunogens
The immunogen was made up in non-ulcerative Freund's adjuvant (Morris) 
and sterile water in a ratio of 2:1. For priming injections BCG was dissolved 
in 10 % of the aqueous part (Table 3.5). The total volume made depended 
on the route of immunisation and the number of sites injected.
Table 3.5 Examples of the immunogen composition
Aqueous Oil Total volume
H2O BCG
594 jiL 66 pL 1.33 mL 2 mL for prime
1 mL 2.00 mL 3 mL for boost
The solid conjugate was dissolved in the sterile water and transferred to a 
glass syringe. For priming injections the BCG was also added. The oil was 
transferred to another syringe and the two syringes were connected with a
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fine bore emulsifier. The aqueous part was forced into the oil and then the 
aqueous/oil mixture was forced into the empty syringe. This was repeated 
until the mixture became very stiff and formed a single droplet when dropped 
onto the surface of water, showing that a stable emulsion had been formed.
3.3.6 Immunisation
Intradermal (i.d.)
The rabbit was sedated with Hypnorm at a dose of 0.05 mL/kg given in a 
single i.m. site. The fur was clipped from the base of the neck, over the 
shoulders and between half-way and two-thirds along the back. 2 mL of 
immunogen was transferred from the glass syringe to two 1 mL graduated 
syringes with 25 G x 5/8 " needles attached. The rabbit was restrained at the 
back of the head/ears and across the lower back whilst a second person 
pulled the skin on the back tight. Injection was made by placing the tip of the 
needle at 15-20° just under the surface of the skin. 50 juL was injected at 
each of 5 sites across and 8 rows down. Care was taken to ensure that 
none of the sites were closer together than 10 mm. The rabbit was returned 
to its cage to recover from sedation.
Subcutaneous (s.c.)
The scruff on the shoulders was pinched between thumb and forefinger. 
0.5 mL of immunogen was transferred to a 1 mL graduated syringe with a 
25 G x 1" needle attached. This was inserted under the skin at 80-90° and 
injected. This was repeated on the other shoulder. Sedation was 
unnecessary for this method.
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Intramuscular (i.m.)
The rabbit was restrained and the leg presented. 0.5 mL of immunogen was 
transferred from a glass syringe to a 1 mL graduated syringe with a 
23 G x 1 1/4" needle attached. The needle was inserted at 90° and injected. 
This was carried out towards the front and rear of each leg giving four sites 
in all. Sedation was unnecessary for this method.
Six rabbits (numbered 2005-2010) were immunised according to Table 3.6.
Table 3.6 Immunising regime
Isoform Method
Prime: 4xi.m. + 2xs.c.; Prime: 40 x i.d.;
Boost: 4 x i.m. + 2 x s.c. Boost: 4 x i.m. + 2 x s.c.
lle-
peptide
2007, 2008 2005, 2009*
Met-
peptide
2006 2010
* rabbit 2009 was not boosted
Rabbits 2005 & 2010 were boosted once their titre values had returned to a 
steady state, whereas rabbits 2006, 2007, & 2008 were boosted after 6 and 
12 weeks. Rabbit 2009 was not boosted. In general, conjugate equivalent 
to 200 pg of peptide was given in the primes and equivalent to 100 pg in the 
boosts.
94
3.3.7 Collection and treatment of antisera
The rabbit was restrained and its ear warmed by a lamp. A round scalpel 
blade was used to shave away the fur covering the marginal ear vein. A 
separate scalpel blade was used to make an incision across the vein and 
the blood was collected into a 30 m l glass bottle. The amount of blood 
collected was between 5 mL and 30 mL (following a boost). After allowing 
the blood to clot, half the serum was aliquoted and frozen at - 20 °C and the 
other half was stored at 4 °C with 0.1 % (v/v) sodium azide added as 
preservative.
3.3.8 ELISA screening assay
This was used to screen bleeds from the rabbits, with the appropriate lie- or 
Met-peptide conjugates coated onto the solid phase. Flat-bottomed flexible 
PVC microtitre plates were coated with 200 pL of a 1:1600 dilution of 
BSA-peptide conjugate (equivalent to 83 nM of peptide) in sodium 
carbonate/sodium bicarbonate buffer, pH 9.6, and incubated at 4 °C  
overnight. The plate was washed five times with PBS, pH 7.4, containing 
0.05 % Tween 20 (PBST). 100 pL of rabbit serum, serially diluted from 1:25 
to 1:200000, was added to a series of wells. Peptide was dissolved in DMF 
and then PBST was added to give a peptide concentration of 50 pg/mL in 
DMF (5 %)/PBST (95 %). 50 pL of peptide (50 pg/mL) was added to a 
parallel set of wells followed by 50 pL of the serially diluted antisera. The 
microtitreplate was then incubated at 37 °C for 2 hours. Following further 
washing, 100 pL of alkaline phosphatase-labelled anti-rabbit IgG was 
incubated at 37 °C for a further 2 hours. After washing, 100 pi of 
p-nitrophenyl phosphate substrate (1 mg/mL) in 10 % diethanolamine
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solution, pH 9.8, was incubated at 37 oC until the absorbance was greater 
than 1.0, or after 2 hours, depending on which occurred first. The plates 
were read at 405 nm with a Dynatech MR 600 plate reader.
Controls containing either no coating conjugate, no rabbit anti-peptide 
antiserum, no enzyme label, or no substrate were included on each plate. 
The plate was repeated if any of the control values were greater than 
0.1 absorbance units since this would have indicated non-specific binding 
and produced artificially high values.
3.3.8.1 Optimisation of coating concentration
Optimisation experiments were carried out with the lle-peptide conjugate 
and anti-lle-peptide antisera, but the results obtained were used to 
determine the final assay parameters for both anti-lle-peptide and 
anti-Met-peptide screening ELISAs.
An ELISA microtitre plate was coated with increasing dilutions 
(1.50-1:12800 K) of coating lle-peptide-conjugate. Bound antibody was 
detected with a 1:2000 dilution of rabbit anti-lie antibody from rabbit 2007 
(from a bleed taken 8 days following the first boost). Alkaline-phosphatase 
anti-rabbit IgG and p-nitrophenylphosphate substrate were then added to 
visualise bound anti-lie antibody described in Section 3.3.8.
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S.3.8.2 Optimisation of displacement peptide concentration
The ELISA microtitre plate was coated with coating lle-peptide-conjugate at 
1:1600 dilution. Bound antibody was detected with increasing dilutions 
(1:25 to 1:12800) of rabbit anti-lie antibody from rabbit 2008 (from a bleed 
taken 8 days following the first boost). This was co-incubated with either 
zero, 1 pg/mL, 50 pg/mL or 500 pg/mL of competing lle-peptide. The 
lle-peptide conjugate bound anti-lie antibody was visualised with 
alkaline-phosphatase anti-rabbit IgG and p-nitrophenylphosphate substrate 
as described in Section 3.3.8.
The peptide used for displacement was solubilised in 5 % DMF before PBST 
diluent was added. The effect of DMF on the antiserum dilution curve was 
tested in a separate experiment. The ELISA format was identical to that just 
described above, except that a parallel set of wells were set up with the 
anti-lie antiserum diluted in 5 % DMF/95 % PBST.
3.3.9 Preparation of chylomicron-enriched fractions
Lymph and serum CM were prepared by ultracentrifugation at
1.4 x 108 g.min as explained in Section 2.2.
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3.3.10 SDS-PAGE and immunoblotting
The following modifications were made to the method which appears in 
Section 2.4.4.
The transfer was carried out using transfer buffer (pH 8.3) containing 20 % 
(v/v) methanol at a constant voltage of 20 V. The first blocking incubation 
with PBSMT was carried out for 2 hours and the subsequent washes with 
PBSMT were of 3 x 5 mins duration.
The nitrocellulose membranes were incubated with 1:500 dilutions of 
antisera. The anti-lie antibody was from rabbit 2007 (taken 10 days after the 
first boost). The bands on the nitrocellulose were visualised by the addition 
of substrate (0.06 % chloronaphthol (w/v), 16 % methanol (v/v), 0.00004 % 
hydrogen peroxide (v/v) in PBS) and the reaction stopped by washing with 
distilled water. All samples were made up in 2-fold concentrated sample 
buffer in a 1:1 ratio. Usually 20 pL of lymph CM and 100 \xL of plasma CM 
were loaded.
3.4 RESULTS
3.4.1 Addition of conjugating agents to carriers
Activated carrier was separated from unreacted conjugating agent by gel 
filtration chromatography using a PD-10 column. In this validation 
experiment MCS was conjugated to BSA, but for the final conjugates MCS 
was conjugated to ovalbumin and SPDP to BSA. The absorbance (280 nm)
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of the eluted fractions (Fig. 3.4) showed a single peak (fractions 3-6) for BSA 
alone and a double peak for BSA and MCS (fractions 4-6 and 8-10). Since 
MCS has an aromatic group which will absorb at 280 nm, and the 
manufacturers of PD-10 columns claim 3.5 m l is sufficient for elution, it was 
assumed that the second peak was from unconjugated MCS. In future 
experiments only fractions from the first peak were pooled, but this inevitably 
led to some loss of carrier because of imperfect separation. In a separate 
experiment, the amount of carrier in the pooled fractions was estimated to be 
65 % of the amount originally loaded.
Fig. 3.4 Gel filtration of BSA and BSA-MCS conjugate
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Fraction (mL)
Either BSA alone (o) or BSA-MCS (•) conjugate was loaded onto a PD-10 gel filtration column. 
Fractions of 1 mL were collected and the absorbance at 280 nm was measured. Details of 
method can be found in Section 3.3.1.
99
3.4.2 Conjugation of peptides to ovalbumin using MCS
The standard curve for the mercaptoethanol standards produced a straight 
line which passed through all 6 standards (Fig. 3.5a). The addition of 
ovalbumin-MCS conjugate produced a parallel straight line, but with the 
absorbance of each standard being slightly lower. The reduction in 
absorbance represented a reduction in the amount of DTNB which had 
reacted with mercaptoethanol. Less mercaptoethanol had reacted with 
DTNB because some of it had reacted with MCS bound to ovalbumin. 
Therefore, the reduction in absorbance was an indirect measure of the 
amount of MCS bound to ovalbumin.
The standard curve in the presence of peptide-conjugate gave a parallel 
straight line, but which was much closer to the original standard curve 
produced in the absence of conjugate (Fig. 3.5b). This was because MCS 
bound to ovalbumin which was subsequently occupied by peptide could not 
react with mercaptoethanol. This allowed more mercaptoethanol to react 
with DTNB. Therefore, the difference in absorbance reflected the amount of 
MCS bound to ovalbumin which was not subsequently occupied by peptide.
The final molar ratio of ova!bumin:MCS:peptide was 1:12:11. An example of 
the calculation of the molar ratios can be found in Appendix lia.
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Fig. 3.5a Effect of ovalbumin-MCS conjugate on absorbance at 
412 nm by mercaptoethanol standards
0 .6  -i
|
^  °-4 “
8c
i
°  0.2 -  
<
0.0
1 086420
Mercaptoethanol standards (mM)
Fig. 3.5b Effect of ovalbumin-MCS-lle conjugate on absorbance 
at 412 nm by mercaptoethanol standards
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Fig. 3.5a and 3.5b both show the absorbance of a range (4-9 mM) of mercaptoethanol 
standards (o) Fig. 3.5a shows the effect of addition of ovalbumin-MCS (•). The mean 
displacement was 0.119 which is an indirect measurement of the amount of MCS bound to 
ovalbumin. Fig. 3.5b shows the effect of addition of ovalbumin-MCS-lle (•). The mean 
displacement was 0.009 and this is an indirect measurement of the amount of lle-peptide 
bound to MCS.
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3.4.3 Conjugation of peptides to BSA using SPDP
Conjugation of SPDP to BSA was measured directly by liberation of 
2-thiopyridone (Fig. 3.2). The results in Table 3.7 show that whilst the 
mercaptoethanol and BSA-SPDP individually had negligible absorbance at 
343 nm, mixing the two produced an absorbance of 0.583 due to the 
liberation of 2-thiopyridone. Similarly, conjugation of peptide to BSA-SPDP 
caused production of 2-thiopyridone which had an absorbance of 0.2 for a 
1:10 dilution.
Table 3.7 Absorbance values measured at 343 nm for 
BSA-SPDP conjugation
Sample A 343 nm
mercaptoethanol -0.031
BSA-SPDP 0.005
BSA-SPDP + mercaptoethanol 0.583
BSA-SPDP-peptide (1:10) 0.200
The final molar ratio of BSA:SPDP:peptide was 1:10:9. An example of the 
calculation of the molar ratios can be found in Appendix Mb.
One particular batch of ovalbumin-MCS-Met conjugate produced was 
estimated by calculation to have a mass of 7.00 mg. The actual mass 
weighed after lyophilisation was 6.23 mg.
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3.4.4 Development of the screening ELISA
The optimum peptide-conjugate coat concentration was determined by 
incubating decreasing amounts of conjugate with constant amounts of 
anti-lie peptide antibody. The effect of peptide-conjugate coat concentration 
had no effect on the absorbance from dilutions 1:50-1:200 (Fig. 3.6). Further 
dilutions from 1:200 to 1:12800 K resulted in a decreased absorbance. A 
dilution of 1:1600 of the coating lle-peptide conjugate, representing an 
lle-peptide concentration of 83 nM was chosen to coat the plates. This 
particular dilution was chosen because it ensured the conjugate was in 
excess, but was still a reasonably high dilution, thereby conserving 
conjugate. Similarly, a dilution of 1:950 was chosen for the Met-peptide 
conjugate, which also represented 83 nM of Met-peptide.
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Fig. 3.6 The absorbance measured at 405 nm for the screening 
ELISA with varying dilutions of coating lle-peptide 
conjugate
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The ELISA microtitre plate was coated with increasing dilutions (1:50-1:12800 K) of coating 
lle-peptide conjugate. Bound antibody was detected with rabbit anti-lie antibody (1:2000) 
and alkaline-phosphatase anti-rabbit IgG and visualised with p-nitrophenylphosphate 
substrate. See Section 3.3.8 for more details.
The concentration of peptide for displacement was determined by incubating 
antisera with different concentrations of the corresponding free peptide 
(Fig. 3.7). Anti-lie antiserum diluted in the absence of peptide showed a 
plateau from 1:25 to 1:1600, but then the absorbance decreased with further 
dilution, lle-peptide of 1 pg/mL caused the absorbance to begin decreasing 
at a dilution of 1:200 and further dilution resulted in the absorbance values 
being lower than for the same dilutions of antiserum in the absence of 
peptide. This was manifest in the displacement curve being"displaced to the 
left of the antiserum dilution curve. Incubation with peptide at higher 
concentrations of 50 pg/mL and 500 pg/mL showed similar patterns, except 
the absorbance values were further suppressed, resulting in the curve being
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displaced even more to the left. A peptide concentration of 50 pg/mL was 
chosen for future assays since this caused a sufficient displacement of the 
antiserum dilution curve.
Fig. 3.7 Effect of lle-peptide concentration on an antiserum 
dilution curve
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The ELISA microtitre plate was coated with coating lle-peptide conjugate at 1:1600 dilution. 
Bound antibody was detected with increasing dilutions (1:25-1:12800) of rabbit anti-lie 
antibody co-incubated with either zero, 1 pg/mL, 50 pg/mL or 500 pg/mL of competing lle- 
peptide. The lie-conjugate bound anti-lie antibody was visualised with alkaline-phosphatase 
anti-rabbit IgG and p-nitrophenylphosphate substrate. See Section 3.3.8 for more details.
To ensure complete solubilisation it was necessary to dissolve the peptides 
in 5 % DMF before dilution with PBST. In order to check that DMF itself did 
not have an adverse effect on the assay a parallel antiserum dilution curve 
was set up using 5 % DMF in PBST as diluent (Fig. 3.8). Although 
lle-peptide dissolved in DMF caused a displacement of the antiserum 
dilution curve, DMF alone produced a curve superimposable with the 
antiserum dilution curve.
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Fig. 3.8 Effect of DMF on an antiserum dilution curve
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The ELISA microtitre plate was coated with coating lle-peptide conjugate at 1:1600 dilution. 
Bound antibody was detected with increasing dilutions (1:400-1:200 K) of rabbit anti-lie 
antibody co-incubated with either 50 pg/mL of competing lle-peptide dissolved in 5 % 
DMF/95 % PBST or with 5 % DMF/95 % PBST alone. The lie-conjugate bound anti-lie 
antibody was visualised with alkaline-phosphatase anti-rabbit IgG and p- 
nitrophenylphosphate substrate. See Section 3.3.8 for more details.
An example of an antiserum dilution curve and a displacement curve 
produced under the final conditions of the assay are shown in Fig. 3.9.
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Fig. 3.9 Example of an antiserum dilution and displacement 
curve
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The ELISA microtitre plate was coated with coating lle-peptide-conjugate at 1:1600 dilution. 
Bound antibody was detected with increasing dilutions (1:25-1:200 K) of rabbit anti-lie 
antibody either co-incubated with 50 pg/mL of competing lle-peptide or with an equal volume 
of PBST. The lie-conjugate bound anti-lie antibody was visualised with alkaline-phosphatase 
anti-rabbit IgG and p-nitrophenylphosphate substrate. See Section 3.3.8 for more details.
3.4.5 Assessment of bleeds
The titre and avidity of the bleeds were assessed using the screening 
ELISA. The 3 rabbits (2006, 2007, 2008) which were boosted after 6 weeks 
showed a similar pattern of response (Fig. 3.10 a-c). In each case the 
displacement curve was approximately parallel to the antiserum dilution 
curve. There was a modest response to the prime, with a more pronounced 
effect to the first boost. Rabbit 2008 did not respond to the second boost and 
2007 only showed a small transient rise in titre.
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Rabbits 2005, 2009 and 2010 all responded to the prime and their titre 
values returned to a steady state by about 100 days (Fig. 3.10 d-f). Apart 
from one bleed from 2005, the pattern of displacement values was similar to 
the titre values. Boosting 2005 and 2010 had virtually no effect on either the 
titre or displacement values. Rabbit 2009 was not boosted.
All three rabbits boosted after 6 weeks (2006, 2007 & 2008) had higher 
displacement and titre values than those boosted after a steady state had 
been achieved (2005 & 2010) (Table 3.8).
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Fig. 3.10 a-f Titre and displacement values of bleeds from six
rabbits
Fig. 3.10 a Rabbit 2006
Prime
Boost r  206 0 0 0  i
5 0 0 0  -
4 0 0 0  -
2  3 0 0 0  -
2000 -
1000 -
1000
Day
Fig. 3.10 b Rabbit 2007
Prime
Boost Boost
r  202000
2 -1 0  jg
Q .
1000 -
F
2001 000
Day
Legend to Fig. 3.10 a-f
The titre (o) and displacement values (•) (arbitrary units) were assessed by ELISA as 
described in Section 3.1.8. The arrows denote when boosts were given and the immunising 
regimes can be found in Table 3.6.
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Fig. 3.10 c Rabbit 2008
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Boost .Boost10000 -, r  5 0
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Fig. 3.10 d Rabbit 2005
I Prime
6 0 0 0  - , Boost
5 0 0 0
4 0 0 0  -
£ 3 0 0 0  -
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1
1
1Q
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Legend to Fig. 3.10 a-f
The titre (o) and displacement values (•) (arbitrary units) were assessed by ELISA as 
described in Section 3.1.8. The arrows denote when boosts were given and the immunising 
regimes can be found in Table 3.6.
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Fig. 3.10 e Rabbit 2009
I Primef
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Fig. 3.10 f Rabbit 2010
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Legend to Fig. 3.10 a-f
The titre (o) and displacement values (•) (arbitrary units) were assessed by ELISA as 
described in Section 3.1.8. The arrows denote when boosts were given and the immunising 
regimes can be found in Table 3.6.
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Table 3.8 Titre and displacement values of the best bleeds from
each rabbit
Rabbit 
(peptide C- 
terminal)
Best bleed *
Titre Displacement Bleed
2005 (lie) 3020 5.8 8 days following prime
2006 (Met) 3800 15.1 8 days following first 
boost
2007 (lie) 1900 14.5 12 days following first 
boost
2008 (He) 8710 43.6 8 days following first 
boost
2009 (He) 2100 6.9 4 weeks following prime
2010 (Met) 1200 3.6 8 weeks following prime
* chosen for a combination of highest displacement with adequate titre.
The specificity of the antiserum was tested by SDS-gel electrophoresis 
followed by either protein staining or immunoblotting and is illustrated in 
Fig. 3.11. Lanes 1 and 2 are from an SDS electrophoresis gel stained for 
total protein with Coomassie Blue. Lanes 3 and 4 are nitrocellulose 
membranes which have been immunostained. Standard molecular weight 
markers are shown in lane 1. In lane 2 the lymph CM have 3 main bands 
which correspond to apo B-48 , A-IV and A-l. Lane 3, which has been 
immunostained with anti-lie antibody, has a single band corresponding to 
apo B-48. Lane 4, stained with an anti-total apo B antibody, shows two main
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Fig. 3.11 Specificity of anti-apo B-48 antibody
1 2 3 4
Lane 1, Molecular weight markers (kDa) indicated by arrows on left 
hand side
Lane 2 CM-enriched fraction from lymph on a gel stained with 
Coomassie Blue
Lane 3 CM-enriched fraction from lymph on an immunoblot stained 
with anti-lie peptide antibody.
Lane 4 CM-enriched fraction from lymph on an immunoblot stained
with an anti-total apo B antibody. ? denotes unidentified band.
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bands, which correspond to apo B-100 and apo B-48, and an unidentified 
lower molecular weight band.
Two bleeds from each rabbit were also tested by immunoblotting of human 
lymph and serum CM (Table 3.9). All lanes on the immunoblot had a single 
apo B-48 band. In general the anti-lie peptide antisera revealed a band 
against human lymph chylomicrons, but not human serum chylomicrons 
whilst the anti-Met peptide antisera had a band with serum chylomicrons, but 
not with lymph chylomicrons. Overall the bands were less intense for serum 
chylomicrons compared to lymph chylomicrons. The intensity of the bands 
with different antisera from each rabbit also correlated with the titre and 
displacement values obtained by ELISA.
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Table 3.9 Presence of apo B-48 band on immunoblots probed 
with different bleeds
Rabbit (isoform) Bleed* Presence of apo B-48 band
CM-enriched lymph CM-enriched serum
2005 (lie) 8/52 (dark & broad) none
6/52 (dark & broad) none
2006 (Met) 1B + 8d none dark
4/52 none very faint
2007 (He) 1B + 12d (dark & broad) none
1B + 15d (dark & broad) none
2008 (lie) 1B + 8d (dark & broad) none
1B + 10d (dark & broad) none
2009 (lie) 4/52 (dark & broad) none
6/52 (dark & broad) none
2010 (Met) 8/52 none dark
4/52 none very faint
‘ Notation for bleeds: d = days; 52 = weeks and B = boost. Thus 4/52 means four weeks after 
the prime and IB  + 8d means eight days following the first boost. Lymph and serum were 
obtained from patients (Section 2.1.1). CM-enriched fractions were prepared by 
ultracentrifugation at 1.4 x 108 g.min as described in Section 2.2.3.
A further gel, loaded with plasma chylomicrons prepared from blood 
samples taken following a high fat meal is shown in Fig. 3.12a (protein stain) 
and an immunoblot of a duplicate gel is shown in Fig. 3.12b. The protein 
stain showed that apo B-100 had a similar band intensity at all time points. 
At 2-5 hours following the meal an even higher molecular weight band was 
visible, which may have been apo (a). The apo B-48 band was only just
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Fig 3.12 a Protein stain of postprandial samples
(a)
B-100
B-48
F 1 5 hr
See next page for legend
A-IV
A-l
Fig 3.12 b Immunoblot of postprandial samples
F 1
«
4 5 hr
B-100
B-48
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Legend to Fig 3.12 a & b
Lanes loaded with CM enriched samples prepared by ultracentrifugation at
1.4 x 108 g.min from plasma taken at hourly intervals from a healthy volunteer 
following a 1.2 g/kg body weight fat-rich meal. F represents a fasting sample. 
625 \xg of protein was loaded into each lane.
116b
visible, but seemed to be most intense at 1-2 hours. A lower band, probably 
apo A-IV, was slightly darker and this seemed to increase in intensity from 
1-5 hours. The lowest band, probably apo A-l, was also very faint and its 
pattern seemed to follow that of apo A-IV. The immunostain showed only 
two bands: a very faint apo B-100 band and a much more intense apo B-48 
band. The apo B-iOO was relatively constant at all time points. Apo B-48 
was not visible in the fasting sample, but then increased up to 2 hours before 
decreasing to 5 hours.
3.5 DISCUSSION
Several lines of evidence show that an anti serum has been raised which 
specifically recognises apo B-48:
1. A single band was observed on an immunoblot of the anti-peptide 
antisera against chylomicrons. This band had a similar molecular size to 
apo B-48 and corresponded to the apo B-48 band on another immunoblot 
stained with an antibody for total apo B.
2 . The intensity of the apo B-48 band in the immunoblot changed in intensity 
following a high fat meal in an anticipated manner.
3. The apo B-48 antisera raised to the peptides corresponding to the 
different C-terminal isoforms of apo B-48 reacted with either lymph or serum 
chylomicrons in a manner which was predicted.
The SDS-PAGE and immunoblotting showed that the antisera are specific 
for apo B-48. A commercially available antibody raised to LDL-apo B-100 
had both an apo B-48 and apo B-100 band. This would be expected since 
apo B-48 is identical to the N-terminal of apo B-100. There was some
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reactivity of the anti-apo B-48 antisera with apo B-100 in CM-enriched 
plasma. However, this was negligible when the relative amounts of apo 
B-48 and B-100 loaded onto the gel (as shown by the protein stain) were 
taken into account. There was no cross-reaction of the anti-lie peptide 
antibody with other apolipoproteins present in lymph CM (apo A-IV and apo 
A-l).
The apparent molecular weight of apo B-48 on the Coomassie Blue stained 
gel was 200 kDa, which differed from the previously published value of 
264 kDa (Kane et al., 1980). However, it is difficult to estimate molecular 
sizes above 200 kDa on SDS-PAGE gels (Section 5.5). Therefore, an 
immunoblot of plasma samples taken after a high fat meal was carried out to 
further verify the specificity of the antiserum. This showed that apo B-48 
levels fluctuated following a meal whilst a protein stain of the same samples 
showed that apo B-100 levels were relatively constant.
The anti-lie peptide antisera reacted only with lymph chylomicrons whereas 
the anti-Met peptide antisera reacted only with serum chylomicrons. This 
supported the hypothesis of Chan (personal communication, 1990) that apo 
B-48 is secreted into lymph with lie as its C-terminus and this is processed in 
the vascular compartment to the Met isoform (Section 1.3.4). It also justified 
the approach of raising antibodies to both isoforms of apo B-48, which had 
not been considered before in the literature.
Peptides corresponding to the C-terminal isoforms of apo B-48 were chosen 
for synthesis because it was felt that this region of the protein offered the 
only chance of the resulting antisera being able to distinguish between apo 
B-48 and apo B-100. In addition, Palfreyman et a i (1984) had reported that
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N-and C-terminal peptides had a success rate of 100 % in producing 
antisera. Ovalbumin and BSA were chosen as the immunising carrier and 
assay carrier, respectively, because it had been reported that this is a 
successful combination of proteins to use (Muller, 1988a). MCS and SPDP 
were chosen as the conjugating agents because of their heterobifunctional 
nature, different mode of action, lower potential for immunogenicity (Peeters 
et al., 1989) and they were easily obtainable. Both these reagents also 
allowed simple determinations of the amount of peptide coupled (Carlsson 
et al., 1978; Lee et al., 1980). The peptides were supplied with N-terminal 
cysteine residues which allowed specific coupling with MCS and SPDP so 
that the C-terminal lie or Met were orientated free of the carrier protein 
surface. For conjugation with MCS previous workers had relied on a single 
value to estimate the amount of MCS coupled to carrier protein (Lee etal., 
1980). In the present study a series of duplicate standards were used to 
improve the estimation.
Twelve molecules of MCS were conjugated to ovalbumin. This compared to 
an average of 16 molecules of MCS coupled to each tetanus toxoid 
molecule by Peeters etal. (1989). Part of this difference may be explained 
by the greater number of NHg groups on tetanus toxoid (106) compared to 
ovalbumin (20). Peeters etal. (1989) obtained a 100 % occupation of MCS 
by peptide compared to 92 % in this experiment. This could be due to the 
different peptides used. Ten molecules of SPDP were successfully 
conjugated to each BSA molecule with 90 % subsequent occupation by 
peptide compared to an average of 14 mois of SPDP and 100 % occupation 
reported by Peeters etal. (1989). The values for molar ratio achieved for 
both conjugates fell within the 5-15 mois of peptide per carrier 
recommended by Muller (1988a) . The results reported in this experiment
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have since been successfully repeated by other workers in our laboratory. 
Although it must be remembered that these values are only estimations, 
Peeters etal. (1989) reported very similar results for spectrophotometric 
determination compared to those obtained by amino acid analysis of the 
final conjugate. In addition the weight of freeze-dried conjugate differed by 
only 12 % from the theoretical amount calculated from the molar values.
All six rabbits responded to priming injections. One of the most striking 
observations was that rabbits 2006, 2007 & 2008 responded well to the 
boost injections given after 6 weeks, but did not respond to boosts given at 
12 weeks. Rabbits 2005 & 2010, which were boosted at about 26 weeks 
also failed to respond. This was disappointing because it was anticipated 
that the bleeds following the boosts in rabbits 2005 and 2010 would produce 
the best quality antisera, with the highest avidity. This is most readily 
explained by instability of the conjugates. A criticism of the present study is 
that the conjugate stability should have been monitored, as recommended 
by Briand etal. (1985) . An alternative would have been to synthesise 
conjugate prior to each immunisation. Fresh conjugates have since been 
prepared by another worker in our laboratory and used to boost rabbits 
2005, 2009 and 2010. These elicited very high titre (1:25 K, 1:125 K and 
1:30 K) and high avidity antisera.
A comparison of the choice between the different routes of priming injection 
was not possible because rabbits 2006, 2007 & 2008 were boosted too 
soon after the prime. The variation in size of response between the different 
rabbits emphasised the importance of immunising more than one animal 
with the same conjugate. The results also illustrated the importance of 
taking frequent bleeds for screening. However, in the present study avidity
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usually matched the titre for any particular bleed. This could imply that the 
ELISA was not giving a true indication of avidity, or that it was unnecessary 
to measure avidity independently. One explanation for inaccurate 
measurement of avidity could be inadequate mixing of the peptide and 
rabbit anti-peptide antisera in the displacement series of wells. In future 
experiments this could be achieved by using an automated microtitre plate 
mixer or by mixing the peptide and antisera in a separate tube before 
addition to the conjugate-coated plate. Since an absorbance value of 1.0 
could not always be obtained with low titre antisera a further improvement 
on this assay would be to include duplicate wells containing standard anti­
peptide antisera. This would allow the other values on the same plate to be 
compared and would reduce variation between different plates and 
overcome the problem of low titre bleeds.
The main aim of producing antibodies which would specifically react with the 
C-terminal end of apo B-48 has been achieved. The antibodies were shown 
not to significantly cross-react with other apolipoproteins present in lymph or 
plasma. The choice of peptide length and of conjugation procedure was 
justified. The use of MCS and SPDP allowed monitoring of conjugate 
synthesis and this has helped other investigators to successfully repeat the 
conjugation. It was predicted that the better quality antiserum, with higher 
titre and avidity, would come from later bleeds. However, though early 
bleeds provided specific antisera of adequate titre most of the boosting 
injections were unsuccessful. This may have been due to degradation of the 
conjugates. The fresh conjugates were used by another investigator to 
boost the same rabbits and this elicited very high titre antisera, as predicted. 
Although a peptide conjugate was used by Delpierre etal. (1988) to raise
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specific antibodies to apo C-ll, this is the first report of an antiserum which 
specifically recognises apo B-48.
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CHAPTER FOUR
INVESTIGATION OF A 
SOLID-PHASE ASSAY 
FOR APO B-48
4.1 INTRODUCTION
4.1.1 Immunoassay of apo B
An immunoassay of apo B-48 has not previously been published because 
an antibody specific to apo B-48 has not been produced prior to the present 
research. However, immunoassays of total apo B have been reviewed by 
Rosseneu et al. (1983) and Labeur et al. (1990) and an outline of the 
different methods is shown in Table 4.1.
Of the methods in Table 4.1 electroimmunoassay and radial 
immunodiffusion are not suitable for measuring large numbers of samples. 
Immunonephelometry and immunoturbidimetry both require the formation of 
antigen-antibody lattices. This is not directly possible for apo B-48 because 
each apo B-48 molecule can only bind a single antibody, thus preventing 
lattice formation. Radioimmunoassay requires radiolabelled purified apo 
B-48 which is not presently available. Therefore, ELISA presents the best 
opportunity for initial assay development.
4.1.2 ELISA assays for apo B
The basic principles of ELISA are explained in Section 2.5.1. Several 
different formats of ELISA have been used and examples of published 
assays are shown in Table 4.2. Most authors have used microtitre plates for 
a solid-phase, though polystyrene particles were used by Fie vet et al. 
(1984), Hallaway etal. (1992) and Vander Heiden eta l. (1984) and 
polypropylene sticks were utilised by Fievet etal. (1986).
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The majority of the assays are two site non-competitive with an anti-apo B 
antibody bound to the solid phase. Assays with LDL bound to the solid 
phase as the antigen and then sample incubated with anti-LDL antibodies in 
a competitive format have also been used. The amount of apo B present is 
either detected by direct labelling of the anti-apo B (Fievet et al., 1986) or by 
a subsequent incubation with an enzyme-labelled anti-species antibody 
(Unune etal., 1986; Young etal., 1986; Bojanovski etal., 1987; Waterson et 
al., 1987). A different competitive format was described by Rojas etal. 
(1992) where the sample was co-incubated with enzyme-labelled LDL. 
Monoclonal antibodies have been used as capture antibodies (Duriez et al., 
1987; Albers etal., 1989; Rojas etal., 1992) and as the enzyme label 
(Young etal., 1986; Bojanovski etal., 1987; Waterson etal., 1987; Albers et 
al., 1989; Hallaway et al., 1992). The CVs are similar to the other 
immunoassay methods and the limit of detection is as good as with 
radioimmunoassay.
The slot blot technique used in this chapter has a similar principle to the 
antigen-coated plate ELISA, except in this instance the solid-phase is a 
nitrocellulose membrane. The method resembles the original 
dot-immunobinding assay described by Hawkes etal. (1982), but differs in 
that the antigen is loaded into a slot, thus allowing more accurate 
quantification by densitometric scanning.
The aim of the research described in this chapter was to use the anti-apo 
B-48 antiserum to develop a solid-phase immunoassay capable of 
specifically measuring apo B-48. Initial development was carried out using 
lymph, but it was intended that the final assay would be capable of
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measuring apo B-48 in plasma or serum. Some of the experimental work in 
this chapter was done by a student as part of her undergraduate project.
4.2 MATERIALS
Anti-lie and anti-Met antisera were from bleeds collected 8 days after the first 
boost from rabbits 2008 and 2006 respectively. Anti- total apo B was from 
Boehringer Corporation Ltd., London. Other materials used in this chapter 
have been listed in Section 2.5.2.
4.3 METHODS
Preparation of stock solutions and blocking buffers can be found in 
Section 2.5.3. IgG fractions and HRP-conjugates of anti-lie, anti-Met and 
anti-total apo B were prepared as described in Section 2.5.4. CM-enriched 
fractions from plasma were prepared by ultracentrifugation for 30 minutes 
(2.1 x 106 g.min), as described in Section 2.2.3. Delipidation, unless stated 
otherwise, was carried out following the method in Section 2.3.2. A general 
ELISA protocol is given below and details for individual experiments are 
given in the table legends. Three different ELISA formats (antigen-coated 
plate, two-site antibody and reagent excess) and a slot blot method were 
used. Controls used in the methods had the named component omitted, e.g. 
the coat control did not contain any coating antibody.
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4.3.1 General ELISA protocol
The numbered steps in the section below correspond to those on Fig. 4.1 
which outlines the three types of ELISA format used in the present study. 
The assay buffer used was PBST, unless otherwise stated.
(1) The inner sixty wells of 96-well microtitre plates were used. The plates 
were wiped with a damp towel before use and placed on this towel 
throughout the rest of the procedure.
(2) Coat antibody or antigen was diluted in 0.5 M carbonate buffer, pH 9.6. 
100 p i  was added to each well and the plate was incubated in a humid 
chamber at 4 °C for 16 hours.
(3) Each well was washed either 3 or 5 times with PBST using a manual 
plate washer.
(4) Unoccupied sites were blocked by incubating with 150 pL of blocking 
agent at 37 °C for 1 hour.
(5) The plate was washed as in step 3.
(6) Sample was diluted in PBST and 100 pL was added to each well. The 
plate was incubated at 37 °C for 2 hours.
(7) The plate was washed as in step 3.
(8) Enzyme-labelled detector antibodies were added in 100 p i  aliquots. 
The plate was incubated at 37 °C for two hours and washed after each 
addition.
(9) The plate was washed as in step 3.
(10) 100 pL of TMB substrate was added to each well and incubated at 
37 °C. The reaction was stopped by adding 50 pL of 2.5 M sulphuric acid 
and the absorbance was read at 450 nm with an automated reader.
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Fig. 4.1 The three different ELISA formats used
(a) Antigen-coated plate
(10)
r-HRP
(8)
(6)
(b) Two-site
(10) 
1—1D p
For abbreviations and numbers 
see Section 4.3.1
(6)
(c) Reagent excess
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4.3.1.1 Antigen coated plate format
An outline of this method can be seen in Fig. 4.1a. Antigen (lymph or 
peptide conjugate) was coated directly onto the solid-phase. HRP-labelled 
anti-apo B-48 was added, incubated and washed. The complex was 
washed and HRP-substrate was added.
4.3.1.2 Two-site format
An outline of this method is shown in Fig. 4.1b. The solid-phase was coated 
with a capture antibody, either to total apo B or to apo B-48. Following 
incubation and washing, either lymph or plasma was added. Bound antigen 
was subsequently detected by addition of an enzyme-labelled antibody to 
either apo B-48 or to total apo B.
The following components of this assay format were tested systematically: 
use of anti-total apo B or anti-apo B-48 as capture antibody, different types of 
microtitre plate, different blocking buffers, dilution of enzyme label and 
sample pre-treatment by delipidation.
4.3.1.3 Reagent excess format
An outline of this method is shown in Fig. 4.1c. The solid-phase was coated 
with excess Met-peptide conjugate. In separate tubes CM-enriched samples 
were incubated with an excess of anti-Met antibody. An aliquot of this 
sample was then added to the Met-peptide conjugate coated plate. Anti-Met 
antibody, which had not reacted with apo B-48 in the CM-enriched sample,
131
could bind to the Met-peptide conjugate. Following incubation bound 
anti-Met antibody was detected with biotinylated anti-rabbit IgG and 
streptavidin-biotin HRP complex.
The dilution of anti-Met antibody was first optimised in a separate 
experiment. CM-enriched samples taken 3 hours after a meal and fasting 
samples were compared and sample pre-treatment by delipidation was 
investigated.
4.3.2 Slot blot
The slot blot apparatus was used in accordance with the manufacturer's 
(Schleicher and Schuell) instructions. Briefly, a piece of nitrocellulose was 
placed on top of two sheets of filter paper, clamped between the two-halves 
of the manifold and a vacuum attached. Samples were loaded onto the 
nitrocellulose through slots in the top part of the manifold. Immunostaining 
of the nitrocellulose was carried out as described in Section 2.4.4. The 
following controls were used unless otherwise stated: Met-peptide
conjugate was diluted 1:2500 in PBS and used as a positive sample control. 
BSA was dissolved in PBS to a concentration of 50 mg/mL. CM-enriched 
fractions were prepared from postprandial plasma samples collected at 
hourly intervals for 11 hours following a mixed meal containing 40 g fat. 
These were either diluted 1:25 with PBS and loaded directly onto the slot 
blot or were pre-treated by delipidation using either SDS or 
butanol/diisopropyl ether.
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wells containing capture antibody (Table 4.3). The absorbance of the 
sample control was much lower with the anti apo B-48 capture format than 
for the anti-apo B capture format. Neither capture with anti-total apo B or 
anti-lie peptide antibodies produced an absorbance which was significantly 
higher than the coat controls. When the plate was coated with serial 
dilutions of the anti-lie peptide antibody the absorbance decreased in a 
uniform manner (Fig. 4.2). The anti-apo B-48 antibodies were used for 
coating in future assay development because theoretically the specificity of 
the assay should have been improved if just apo B-48 molecules were 
captured rather than apo B-48 and apo B-100.
Table 4.3 Absorbance values (450 nm) for the comparison of 
anti-apo B and anti-apo B-48 as capture antibodies
Capture Antibody
Anti-apo B Anti-apo B-48
HRP-enzyme Label Anti-Met Anti-lie Anti-apo B
Sample 0.71 0.43 0.45
Coat control 0.51 0.35 0.22
Sample control 1.35 0.15 0.05
For capture with anti-total apo B antibody: (1) Dynatech microtitre plate (2) Anti-total apo B 
(1:100 K) (4) Blocked with PBSBCT (6) Undiluted plasma taken from a healthy volunteer 3 
hours after a mixed meal containing 1.2 g fat/kg body weight (8) HRP-anti-Met or HRP-anti-lle 
(1:10).
For capture with anti-lie antibody: (1) Dynatech microtitre (2) Anti-lie IgG (1:10) (4) Blocked 
with PBSBC (6) Undiluted lymph delipidated with butanol/diisopropyl ether (Section 2.3.2) 
(8) HRP-anti-apo B IgG (1:100).
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Fig. 4.2 Absorbance values at 450 nm with serial dilutions of
capture anti-lie peptide IgG
0 . 5 - ,
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0.0
1000010001001 0
Dilution of anti-lie peptide IgG
(1) Dynatech microtitre (2) Anti-lie IgG (1:10-1000) (4) Blocked with PBSBC (6) Undiluted 
lymph delipidated with butanol/diisopropyl ether (Section 2.3.2) (8) HRP-anti-apo B IgG 
(1:100).
A variety of manufacturer's plates were compared in an attempt to obtain a 
strong absorbance value with lymph samples, but low absorbance values for 
sample controls and a coat controls (Table 4.4). The Polysorp plate had the 
third highest signal and the lowest binding with the coat control, resulting in 
the highest sampleicoat control ratio. Three of the other four plates had very 
similar sampleicoat control ratios, but Immulon 1 had a coat control value 
higher than the sample. The Maxisorp plate had a high value for the sample 
control, but the other four plates had similar sampleisample control ratios. 
Although Immulon 1 had the highest sampleisample control ratio, the 
Polysorp was chosen because it had a high sampleisample control ratio and 
the highest sampleicoat control ratio.
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Table 4.4 Absorbance values (450 nm) obtained with a variety
of different plates
Plate Sample Coat
control
Sample
control
Sample :
Coat
Control
 Control ratios
Sample
Control
Microtitre 0.96 0.44 0.03 2.2 32.0
Maxisorp 0.73 0.34 0.57 2.2 1.3
Polysorp 0.74 0.17 0.02 4.4 37.0
Immulon 1 0.65 0.75 0.01 0.7 65.0
Immulon 2 0.87 0.35 0.05 2.5 17.4
(1) Dynatech microtitre, Nunc Polysorp, Nunc Maxisorp, Dynatech Immulon 1, Dynatech 
Immulon 2 (2) Anti-lie IgG (1:100) (4) Blocked with PBSBCT (6) Undiluted lymph delipidated 
using butanol/diisopropyl ether (Section 2.3.2) (8) HRP-anti-apo B IgG (1:50).
To further improve the sampleicontrol absorbance ratios several different 
blocking buffers were compared. However, there were no major differences 
in the sampleicoat control ratio values between the different buffers used 
(Table 4.5). None of the buffers lowered the coat control absorbance value 
below 0.25 . The highest sample to coat control ratio of 3.2 was from PBS 
and casein. The highest sample absorbance was for PBS-BT at 1.50, but 
this also had a high coat control of 0.94, resulting in a ratio of 1.6. The 
addition of casein, in PBS-BCT, lowered both the sample signal and coat 
control absorbance values resulting in a improved ratio of 3.0. Since 
blocking buffers failed to make a significant improvement on the use of PBS 
alone they were omitted from future assay development.
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Table 4.5 Comparison of absorbance (450 nm) values obtained
with different blocking buffers
Buffer Sample Coat control Sample :coat 
control ratio
PBS 1.07 0.33 3.2
PBS-T (0.05 %) 1.20 0.47 2.6
PBS-T(1 %) 1.07 0.37 2.9
PBS-BT 1.50 0.94 1.6
PBS-FFBT 0.97 0.40 2.4
PBS-CT 1.20 0.40 3.0
PBS-GT 1.14 0.40 2.9
PBS-BCT 1.20 0.40 3.0
PBS-BCT (Gly) 1.37 0.54 2.5
Casein 0.87 0.27 3.2
Casein/thiomers
al
0.94 0.30 3.1
(1) Nunc Polysorp (2) Anti-lie IgG (1:100) (4) Blocked with either PBS, PBST (0.05 %), PBST 
(1 %), PBSBT, PBSFFBT, PBSCT, PBSGT, PBSBCT, PBSBCT (Gly), Casein, or 
Casein/Thiomersal (see Section 2.5.3) (6) Undiluted lymph delipidated using 
butanol/diisopropyl ether (Section 2.3.2) (8) HRP-anti-apo B IgG (1:50).
A range of HRP-labelled anti-total apo B IgG dilutions were set up. 
Increasing dilutions of the enzyme label resulted in a uniform decrease in 
absorbance (Fig. 4.3). Although a 1:12.5 dilution resulted in the maximum 
absorbance a working dilution of 1:100 was chosen for future assays in 
order to conserve the antiserum.
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Fig. 4.3 Absorbance (450 nm) with serial dilutions of HRP-
labelled anti-total apo B
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(1) Dynatech microtitre (2) Anti He IgG (1:100) (4) Blocked with PBSBCT (6) Undiluted lymph 
delipidated using butanol/diisopropyl ether (Section 2.3.2) (8) HRP-anti total apo B IgG 
(1:12.5-1:400).
Both lymph and plasma samples were pre-treated by delipidation in an 
attempt to maximise epitope exposure. Plasma taken 3 hours after a high-fat 
meal was used because this should contain high levels of apo B-48 and 
fasting plasma was included since this should have a very low apo B-48 
concentration. Three of the four samples tested had a similar absorbance, 
whilst delipidated 3 hour postprandial plasma was lower (Table 4.6). Three 
of the pre-treated samples had absorbance values which were lower than 
for their coat control. Only the lymph sample gave a slightly higher 
absorbance than its control. It was expected that lymph would have had 
much higher absorbance values than fasting plasma because the 
lle-peptide form of apo B-48 predominates in lymph (Table 3.9). The capture
138
anti-lie peptide antibody failed to specifically interact with apo B-48 in the 
samples, even after delipidation was used to maximise epitope exposure.
Table 4.6 Absorbance (450 nm) values with different pre-treated 
samples
Sample Absorbance
Sample Coat control
Lymph 0.72 0.67
Delipidated lymph 0.79 1.24
Fasting plasma 0.63 0.90
Delipidated fed plasma 0.39 0.43
(1) Nunc Polysorp (2) Anti-lie IgG (1:100) (4) No block used (6) Lymph, delipidated lymph, 
fasting plasma, delipidated 3 hour postprandial plasma (all undiluted). Samples were 
delipidated using butanol/diisopropyl ether (Section 2.3.2) (8) HRP-anti-apo B IgG (1:50).
4.4.3 Reagent excess format
In this assay format apo B-48 in the sample should bind to anti-peptide 
antibodies, so that less of these antibodies bind to the peptide conjugate 
coated on the plate, thereby resulting in a decrease in absorbance. The first 
experiment was to find a dilution of the antibody for which presence of apo 
B-48 in the sample would cause the greatest decrease in absorbance and 
so enhance the sensitivity of the assay. Apart from with high concentrations 
of anti-Met peptide antibody, there was a uniform decrease in absorbance 
with increasing dilution (Table 4.7). The largest decrease in absorbance 
was between dilutions of 1:100 and 1:200. Therefore, 1:100 was chosen as
the optimal dilution because the presence of apo B-48 in the sample should 
cause the largest decrease in absorbance.
Table 4.7 Absorbance (450 nm) values with serial dilutions of 
anti-Met peptide IgG
Anti-Met dilution Absorbance
1:25 1.67
1:50 >2.00
1:100 >2.00
1:200 1.46
1:400 1.15
1:800 0.84
1:1600 0.46
1:3200 0.26
1:6400 0.15
1:12800 0.10
1:25000 0.06
(1) Dynatech microtitre (2) Anti-Met conjugate (1:1600 dilution, equivalent to 83 nM of 
peptide) (6 & 8) Anti-Met IgG (1:25 - 25000); Biotinylated anti-rabbit IgG (1:3500); 
Streptavidin-biotin HRP complex (1:2500).
Delipidated and non-delipidated CM-enriched samples from 3 hour 
postprandial and fasting plasma were measured using this format. As 
expected, the fasting CM-enriched sample had a similar absorbance to the 
PBS control, whilst the 3 hour postprandial CM-enriched sample had a 
lower absorbance (Table 4.8). However, both the delipidated 3 hour
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postprandial CM-enriched sample and the delipidated fasting CM-enriched 
sample had a lower absorbance than the PBS control and this suggested 
that the decreased absorbance for the non-delipidated 3 hour postprandial 
CM-enriched sample may have been due to interference by lipid. 
Alternatively, the decreased absorbance by the delipidated samples could 
have been caused by residual organic solvent as a consequence of 
delipidation.
Table 4.8 Absorbance (450 nm) with different pre-treated 
samples
Sample Absorbance
PBS 1.10
fasting CM 1.15
postprandial CM 0.74
delipidated fasting CM 0.64
delipidated postprandial CM 0.67
(1) Dynatech Microtitre (2) Anti-Met conjugate (1:1600 dilution, equivalent to 83 nM of 
peptide) ) (6) 120 pL of Anti-Met IgG (1:200) +120 pL of either fasting CM, or 3 hour 
postprandial CM, or delipidated fasting CM, or delipidated 3 hour postprandial CM (all 
undiluted) were incubated in a separate tube at 4 °C for 2 hr. 100 pL aliquots of each were 
then added to the plate Samples were delipidated using butanol/diisopropyl ether (Section 
2.3.2) (8) Biotinylated anti-rabbit IgG (1:3500); Streptavidin-biotin HRP complex (1:2500).
4.4.4 Slot blot
The first experiment with the slot blot was to optimise the anti-Met peptide 
antiserum dilution and to establish the dilution of Met-peptide conjugate
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which was to be used as a positive control. As expected, band intensity 
decreased with increasing dilutions of Met-peptide conjugate (Fig. 4.4). 
Similarly, for Met-peptide conjugate dilutions greater than 1:20 K, the band 
intensity decreased with increasing dilutions of anti-Met peptide antiserum. 
A dilution of 1:5000 was chosen for the anti-Met peptide antiserum and 
1:2500 for the Met-peptide conjugate.
Fig. 4.4 Band intensity with different dilutions of anti-Met
peptide antibody and serial dilutions of Met-peptide 
conjugate
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Met-peptide conjugate was diluted 1:2500 - 320000 in PBS and 50 pL loaded onto the 
nitrocellulose. Anti-Met peptide antibody was diluted 1:5000 - 40000. Binding was detected 
by biotinylated anti-rabbit IgG (1:1000) and streptavidin-biotin HRP complex (1:1000) (Section
2.4.4).
CM-enriched fractions prepared from postprandial plasma samples from two 
separate subjects following a mixed-meal containing 40 g fat were 
measured (Fig. 4.5 a&b) .  A BSA control of 50 mg/mL was included to give
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an indication of potential non-specific binding to human albumin in the 
CM-enriched samples. Most of the bands were sharp and well defined, 
though some (5 & 6 hr for subject 1 and 2 hr for subject 2) were bleached 
which gave an inappropriate negative band intensity value. Both subjects 
had zero hour levels which were similar to the BSA control and each had 
three postprandial peaks. These were at 0.5, 3 and 9 hours for subject 1 
and 1, 6 and 8 hours for subject 2. Levels returned to the BSA control value 
after 10-11 hours for subject 1 and after 10 hours for subject 2 and then 
dropped below the control value for subsequent time points. The large 
intra-assay variation is reflected in the standard deviation (SD) of duplicate 
values (Fig. 4.5 a & b).
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Fig. 4.5 a Slot blot of postprandial CM-enriched plasma
samples from subject 1
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Fig. 4.5 b Slot blot of postprandial CM-enriched plasma 
samples from subject 2
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The postprandial samples were from two healthy subjects after a mixed-meal containing 40 g 
fat. The CM-enriched samples and BSA control were diluted 1:25 with PBS and 25 pL was 
loaded. Anti-Met-peptide antibody was used at a 1:5000 dilution. Binding was detected by 
biotinylated anti-rabbit IgG (1:1000) and streptavidin-biotin HRP complex (1:1000) (Section
2.4.4). Each point represents the mean of duplicate wells and the bars are standard 
deviations.
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The effect of SDS as a delipidating agent was assessed on a single 
postprandial and a fasting CM-enriched sample from both subjects 1 & 2. 
White patches were seen on the nitrocellulose around the slots where SDS 
had been used. Apart from the BSA control, SDS caused an increase in 
band intensity with all the other samples (Table 4.9). For both subjects the 
postprandial sample had a higher band intensity than the fasting sample. 
The proportional difference between postprandial and fasting values was 
increased by SDS for subject 2, but not for subject 1.
Table 4.9 Band intensities following delipidation with 
SDS in PBS
Sample PBS PBS + SDS
PBS 6.3 16.8
BSA control 15.6 6.4
Met conjugate control 387.5 432.1
Subject 1 fasting 21.2 30.8
Subject 1 postprandial 44.5 46.2
Subject 2 fasting 18.9 37.2
Subject 2 postprandial 32.9 97.3
Samples and controls are the same as for Fig. 4.5 a&b, except only a single postprandial 
CM-enriched sample from each subject was used: taken at 2 hour for subject 1 and 1 hour for 
subject 2. The PBS sample represents just PBS loaded onto the slot blot. Samples were 
delipidated by using PBS containing 2 % (w/v) SDS as a diluent (denoted by PBS + SDS). 
Control samples were diluted with just PBS (denoted by PBS).
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Since SDS increased the band intensity of the PBS control, in a further 
experiment SDS was removed after delipidation (Table 4.10). Following 
SDS removal, all the samples still had a higher band intensity than when 
PBS alone was used as a diluent. However, the difference between fasting 
and postprandial samples was proportionally decreased after SDS had 
been removed compared to the use of PBS alone. Even after delipidation 
with SDS the postprandial samples did not have a significantly higher band 
intensity than fasting samples.
Table 4.10 Band intensities following removal of SDS
Sample PBS PBS - SDS PBS + SDS
PBS 21.7 25.0 54.4
BSA 34.0 * 51.4
Met conjugate control 435.2 633.5 964.2
Subject 1 fasting 4.1 95.0
Subject 1 postprandial 13.5 111.6
Subject 2 fasting 13.7 90.5
Subject 2 postprandial 28.0 138.7
Legend is the same as for Table 4.9, except with one set of samples (PBS - SDS) the SDS 
was removed after delipidation by cooling to 4 °C and centrifuging at 13000 rpm for 2 mins 
(2.1 x 104 g.min). * denotes missing sample .
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Pre-treatment by delipidation with butanol/diisopropyl ether was investigated 
with CM-enriched plasma samples, from a third healthy subject, prepared 
following a mixed meal containing 40 g of fat. Organic delipidation caused a 
decrease in band intensity in all the controls (Table 4.11).
Table 4.11 Effect on band intensity of pre-treatment with 
butanol/diisopropylether
Sample No treatment Delipidation
PBS 16.0 7.0
BSA 54.7 33.2
Met conjugate control 205.0 167.0
Controls are the same as for Fig. 4.5 a&b.
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For subject 3, all the time points had higher band intensities than the BSA 
control (Fig. 4.6). The highest band intensity occurred at 3 hours and the 
levels returned to the zero hour level between 7 and 8 hours.
Fig. 4.6 Postprandial CM enriched samples from subject 3 
delipidated with butanol/diisopropyl ether
120 - i
Subject 3 
BSA control£  100 -
80
Oi 40 -
4 1 0 122 6 80
Time (hours)
Samples and BSA control prepared the same as for Fig. 4.5 a&b,  except before dilution with 
PBS the CM-enriched samples were delipidated as described in Section 2.3.2.
4.5 DISCUSSION
Three different ELISA formats were tried in an attempt to obtain specific 
detection of apo B-48. In order to enhance the chances of being able to 
detect apo B-48, lymph or CM-enriched plasma samples were often used.
The antigen-coated plate format potentially offered the simplest and quickest 
kind of assay. A positive reaction was obtained with peptide conjugates, but 
this could not be repeated with lymph. The absence of a specific antibody
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interaction with the apo B-48 epitope could have been because the epitope 
was obscured by other lymph proteins or lipid.
The two-site format, commonly used in total apo B ELISAs, requires that two 
antibodies react with apo B-48. Bury & Rosseneu (1988) favour the 
non-competitive two-site format because apolipoproteins have limited 
stability in solution. A commercially available polyclonal anti-apo B antibody 
and the specific anti-apo B-48 antibodies were compared as the capture 
antibody and the enzyme label. None of the capture antibodies significantly 
enhanced the signal compared to the coat controls. This was possibly 
because of a lack of recognition of apo B-48 by the capture antibody. 
Anti-apo B-48 was chosen as the capture antibody for future experiments 
because it was felt the specificity of the assay would be improved if apo B-48 
was captured alone, rather than apo B-48 and apo B-100.
Although the dilution of capture anti-apo B-48 IgG which gave the maximum 
absorbance was 1:10, a working dilution of 1:100 was chosen in order to 
conserve the antisera. This was equivalent to 1.5 pg/mL and compares with 
5-20 pg/mL used by other workers. Therefore, the coating concentration 
may have been insufficient and this could have contributed to the 
non-specific binding.
To reduce the high values being obtained with the coat control samples, a 
range of microtitre plates was assessed. The Dynatech Microtitre had been 
used for the successful screening assay developed in Chapter 3, but for this 
assay the Nunc Polysorp plate was shown to have less non-specific binding 
of sample and was used in further assay development. The Polysorp plate 
is less polar than the Maxisorp plate, and had a lower coat control value, but
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the same sample absorbance. This could be evidence that the high coat 
control absorbance is due to the anti-apo B enzyme label binding to proteins 
with a polar nature which have bound non-specifically to the plate.
In a further attempt to prevent non-specific binding a range of blocking 
buffers were investigated. None of the buffers prevented binding of sample 
to the plate in the absence of coating antibody. Furthermore, none of the 
buffers designed for blocking could improve on PBS alone. Kenna et al. 
(1985) compared several methods for reducing non-specific binding and, in 
agreement with the findings in this chapter showed that Tween actually 
increased non-specific binding. However, unlike the findings of Kenna etal. 
(1985), non-specific binding was not significantly reduced by casein buffer in 
the present study, even if thiomersal was included. Bury & Rosseneu (1988) 
recommended the use of fatty acid-free albumin since other albumin 
preparations may contain contaminating apolipoproteins. In the present 
study non-specific binding was no lower with fatty acid-free albumin than 
with conventional BSA. Even the addition of glycine as a small molecular 
weight agent, which should have been able to penetrate the spaces 
between the large lipoprotein molecules on the plate, failed to make a 
significant difference.
It would be expected that lymph and postprandial CM-enriched plasma 
samples would have much higher apo B-48 concentrations than fasting 
plasma. However, the absorbance signal from lymph was not significantly 
higher than that of fasting plasma and delipidation of lymph failed to 
increase the signal. In three of the four samples, the coat control value was 
higher than the samples in wells coated with capture antibody. Clearly, the 
capture anti-apo B-48 antibody was failing to specifically interact with apo
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B-48 in the samples, even when delipidation was used to maximise epitope 
exposure. In addition, the results suggested that the capture antibody was 
preventing non-specific binding to the plate.
The third assay format was based on the successful screening ELISA 
previously used in Chapter 3 and the presence of apo B-48 in the sample 
should have resulted in a decreased final absorbance. This assay required 
that the enzyme-labelled anti-apo B-48 was in excess of the apo B-48 in the 
sample, but not in excess of the coated conjugate. A preliminary experiment 
was conducted to optimise the enzyme-labelled anti-apo B-48 concentration 
for sensitivity. In agreement with the expected findings, fasting CM-enriched 
plasma had a similar absorbance value to the PBS control, whereas 
postprandial CM-enriched plasma gave a lower value. To test whether this 
effect was attributable to a greater amount of lipid in the postprandial 
CM-enriched sample, delipidation of samples was carried out. Both fasting 
and postprandial CM-enriched plasma had similar absorbance values 
following delipidation. However, in the case of fasting CM-enriched samples 
the absorbance values were markedly lower following delipidation. This 
could mean that delipidation had an adverse effect on the assay, possibly by 
interference with residual organic solvent on antibody-antigen interactions.
After the failure to measure apo B-48 using microtitre plates in a 
conventional ELISA and following the successful immunodetection following 
SDS-PAGE electrophoresis in Chapter 3, slot blot assays were investigated 
using nitrocellulose as the solid phase.
After an initial experiment to optimise the anti-Met peptide antibody 
concentration, measurement of postprandial samples from two subjects
151
revealed changes in band intensity at different time points. Both subjects 
had high levels a few hours after the meal, but there was also an 
unexpected higher band intensity at 0.5-1 hour. In order to assess possible 
interference by cross-reactivity with human serum albumin, a BSA control 
was included at an equivalent concentration to albumin in blood. This had a 
significant band intensity and may indicate that there was non-specific 
binding of the anti-apo B-48 antiserum to albumin in CM-enriched plasma. 
Although such cross-reactivity might have been expected since the 
antiserum was raised using ovalbumin as a carrier molecule, this has since 
been shown by other workers in our laboratory not to be the case.
Delipidation by SDS resulted in an increase in band intensity in fasting as 
well as fed samples. To assess whether this was an effect of SDS on the 
sample proteins, or on the subsequent immunodetection, it was removed by 
cold treatment. In comparison to dilution with PBS alone, the difference in 
band intensity between fed and fasting samples, was proportionally 
decreased after removal of SDS. Therefore, the effect of SDS did not 
specifically enhance apo B-48 epitope exposure.
Delipidation with organic solvents decreased the band intensity of control 
samples. The delipidated postprandial samples from subject 3 did not show 
increased band intensities as much as the untreated samples from subjects 
1 and 2, but the variation between duplicates was lower than for untreated 
samples.
The basis of a successful immunoassay is a good interaction between 
antigen and antibody. This was never conclusively demonstrated for any of 
these assays. The assay formats attempted were broadly similar to those
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used by other authors for the measurement of total apo B. However, there 
are major problems faced in measuring apo B-48.
Firstly, the anti-apo B-48 antisera is monospecific and this prevented its use 
as both capture and detector antibody in the same assay. This meant a 
second antibody had to be used which reacted with both apo B-48 and apo 
B-100. Whilst the anti-apo B antisera reacted predominantly with apo B-100 
and apo B-48, immunoblotting analysis (Fig. 3.1) revealed that the anti-apo 
B antisera cross-reacted with other proteins. An improvement on the anti- 
apo B antibody would be to obtain a mono-specific antibody to the 
N-terminal of apo B-100. This would also react with apo B-48 and would 
help to eliminate cross-reactivity with other proteins. Using the reagent 
excess format, others in our laboratory have confirmed that the anti-apo B-48 
antisera does not cross-react with human serum albumin. If absence of 
cross-reactivity can be confirmed for apo B-100 this antiserum will be 
suitable for further assay development in its present form.
Secondly, apo B-48 circulates in much lower concentrations than apo 
B-100. Plasma samples contain VLDL and LDL and therefore have high 
levels of potential cross-reacting apo B-100. In addition, it means that an 
apo B-48 ELISA will have to be much more sensitive than existing apo 
B-100 ELISAs. The use of lymph and CM-enriched samples to overcome 
this problem presented their own difficulties because of correspondingly 
high lipid concentrations.
Thirdly, the lack of a suitable sample stripped of apo B-48 hampered the 
assay development. The use of high and low apo B-48 containing samples 
is a good compromise, but these should have been compared by
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SDS-PAGE and immunoblotting. The high duplicate variation means the 
slot blot assay is probably unsuitable for quantitative analysis, but it could 
possibly be used as a fast qualitative analysis to monitor ELISA assay 
development. The reagent-excess format assay would be suitable for 
testing epitope accessibility by investigating sample pre-treatments, or 
longer incubation times.
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CHAPTER FIVE
QUANTIFICATION OF 
APO B-48 BY SDS-PAGE 
FOLLOWED BY 
IMMUNOBLOTTING
5.1 INTRODUCTION
Following the unsuccessful attempts at developing a solid-phase assay 
(Chapter 4) it was decided to quantify apo B-48 by immunoblotting after 
SDS-PAGE. The principles of SDS-PAGE and immunoblotting have been 
described in Section 2.4. Several groups have quantified apo B-48 after 
separation by SDS-PAGE.
Kane et al. (1980) were the first group to describe apo B-48 visualisation on 
a gel. They loaded chylomicrons (equivalent to 20 pg of apo B) onto a 3 % 
SDS gel and identified apo B-48 by staining the separated proteins with 
Coomassie Blue. This method was later adopted by Simons et al. (1987) 
who scanned their gels with a densitometer and expressed their results as a 
ratio of apo B-48 to apo B-100.
The use of a linear gradient gel was described by Cohn et al. (1988b). They 
loaded 25 pg of TRL in each lane of a 4-20 % gradient SDS gel. It had been 
previously reported by Poapst etal. (1987) that apo B-48 and apo B-100 had 
different chromogenicities after staining with Coomassie Blue. Cohn and 
colleagues overcame this problem by making no attempt to quantify the 
apolipoproteins in absolute terms. Instead, they expressed postprandial 
changes in apo B-48 in qualitative terms by calculating the concentration of 
apo B-48 as a percentage of its zero-hour (fasting) concentration. The apo 
B-48 band intensity was linear up to the maximum amount of TRL loaded 
(75 jig). Although this method was subsequently used in postprandial 
studies (Cohn etal., 1989; Krasinski etal., 1990) no indication of the inter- or 
intra-assay variability was given.
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Demacker et al. (1991) loaded postprandial TRL samples onto 4 % SDS 
disc gels and stained bands with Coomassie Blue. Densitometric scanning 
showed that absorbance areas of the apo B-48 band increased steadily for
2-70 fig of TRL loaded. The CV for the apo B-48 band was 6.2 % (n=8).
Zilversmit & Shea (1989) compared gel scanning with radio-iodination. 
Intact lipoproteins were iodinated prior to being loaded onto a 5 or 7.5 % 
SDS-polyacrylamide gel. Following electrophoresis, individual bands were 
cut out and measured using a gamma counter. Four to 40 pg of apo B were 
loaded into each lane. They found that at relative apo B-48 concentrations 
higher than 10 % of total apo B, both scanning and radio-iodination gave 
reliable results. At lower relative apo B-48 concentrations, the 
radio-iodination method appeared to be superior to scanning, but at low total 
apo B concentrations, the efficiency of radio-iodination for detecting apo 
B-48 was low.
Quantification of apo B-48 after immunoblotting has been described by 
Cartwright & Higgins (1992). They loaded 1-40 pg of total apo B onto a
3-20 % gradient gel. Following electrophoresis the proteins were 
transferred onto a nitrocellulose membrane and the protein bands were 
stained with Amido Black. Following destaining and blocking, the 
membrane was incubated sequentially with sheep anti-apo B antiserum, 
donkey anti-sheep IgG and 125l-Protein A. The Amido Black-stained bands 
were cut from the membrane and measured in a gamma counter. These 
authors were mainly interested in subcellular fractions of rat liver and human 
postprandial samples were not measured.
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The aim of the present study was to develop a quantitative assay for apo 
B-48 based on SDS-PAGE and immunoblotting. The assay should be 
capable of detecting apo B-48 in small volumes of postprandial 
CM-enriched samples from normal human subjects. It should be sufficiently 
reproducible to detect the difference in apo B-48 in CM-enriched plasma 
samples following test meals of different composition. In addition, it would 
be useful if large numbers of samples could be processed using the assay.
5.2 MATERIALS
Anti-lie and anti-Met antisera were from bleeds collected 8 days after the first 
boost from rabbits 2008 and 2006 respectively. Other materials are listed in 
Section 2.4.2.
5.3 METHODS
Methods were carried out as described previously (preparation of 
CM-enriched sample, Section 2.2.3; SDS-PAGE, protein staining, 
immunoblotting and densitometry, Section 2.4.4; estimation of sample 
protein content, Section 2.3.2) with the following modifications:
5.3.1 Preparation of the standard-chylomicron-enriched 
fraction
A healthy subject was fed a mixed meal containing 1.2 g fat/kg body weight. 
The standard-CM-enriched fraction was prepared by ultracentrifugation 
(1.4 x 108 g.min) of plasma as described in Section 2.2.3. This was mixed
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with sample buffer, as described in Section 2.4.4, aliquoted and stored at 
-20 °C until required.
5.3.2 Electrophoresis sample preparation
100 gl_ of CM-enriched samples were mixed with 300 pL of sample buffer 
(two-fold concentrated) in an Eppendorf tube and heated at 95 °C for 2 mins 
to denature the proteins. After allowing the samples to cool to RT, 50 pL of 
each CM sample, 10 p i  of the molecular weight markers and 30 pL of the 
standard CM preparation were loaded into separate wells with the aid of gel 
loading tips.
5.3.3 Calibration curve of molecular weight markers
A standard mixture of molecular weight markers (29 kDa-205 kDa), to which 
bovine thyroglobulin (330 kDa) was added, was loaded onto a gel. The 
acrylamide concentration (% T) at the position of each marker was 
calculated following the method of Hames (1990).
5.3.4 Comparison of an immunoblot with a protein stain
Hourly blood samples were taken from a healthy subject following a mixed 
meal containing 1.2 g fat/kg body weight. CM-enriched fractions were 
prepared by ultracentrifugation (1.4 x 108 g.min) of plasma as described in 
Section 2.2.3. This was mixed with sample buffer, as described in 
Section 5.3.2 and 100 pL loaded into each lane. Two gels were prepared, 
one was stained for protein using Coomassie Blue and the other was 
electrotransferred and immunostained with anti-Met antiserum.
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5.3.5 Immunostaining for different isoforms of apo B-48
Regular blood samples were taken from eleven healthy subjects following a 
mixed meal containing 40 g fat (Section 6.3 for details) CM-enriched 
fractions were prepared from plasma by ultracentrifugation (2.1 x 106 g.min) 
as described in Section 2.2.3. This was mixed with sample buffer, as 
described in Section 5.3.2 and 50 \iL loaded into each lane. Two 
immunoblots were prepared, one was immunostained using anti-lie 
antiserum and the other with anti-Met antiserum. A further gel was loaded 
with 7 hr postprandial CM-enriched samples taken from ten subjects and 
immunostained with anti-Met antiserum.
5.3.6 Comparison of transfer buffers
Four different transfer buffers based on 192 mM glycine and 25 mM Tris 
(pH 8.3) containing different combinations of methanol and SDS were used. 
Elution from the acrylamide gel and subsequent binding to the nitrocellulose 
membrane was compared using the different buffers.
5.3.7 Protein load and exposure time
A gel with different amounts (62.5-500 pg) of the standard CM-enriched 
fraction (Section 5.3.1) was prepared and immunoblotted with anti-lie 
antiserum. This was exposed to ECL film for 7,15, 30 and 60 seconds.
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5.3.8 Reproducibility of immunoblots
A set of postprandial CM-enriched plasma samples, taken from a healthy 
subject (see Section 6.3) following a mixed meal containing 40 g of fat, were 
used to prepare duplicate immunoblots and detected using anti-lie 
antiserum.
5.3.9 Intra- and inter-assay variation
Quadruplicate samples of standard CM-enriched fraction (Section 5.3.1) 
were loaded onto four separate gels and immunoblotted with anti-lie 
antiserum.
5.4 RESULTS
5.4.1 Calibration curve of molecular weight markers
There was a linear relationship between log molecular weight of standard 
molecular weight markers and log polyacrylamide concentration (Fig. 5.1).
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Fig. 5.1 Calibration curve of molecular weight markers on a 
5-20 % linear gradient gel
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The molecular weight markers used were a standard mixture containing: myosin (205 kDa), 
p-galactosidase (116 kDa), phosphorylase-B (97.4 kDa), BSA (66 kDa), ovalbumin (45 kDa), 
carbonic anhydrase (29 kDa) to which bovine thyroglobulin (330 kDa) was added. Log 
molecular weight is plotted on the x-axis and log % T on the y-axis. % T is the polyacrylamide 
concentration at the position of the marker.
From the calibration curve (Fig. 5.1) the apparent molecular mass of apo 
B-48 was estimated to be 245 kDa.
5.4.2 Comparison of the immunoblot with a protein stain
Staining of CM apolipoproteins with Coomassie Blue revealed five major 
bands (Fig. 5.2 a). Using a calibration curve these were estimated to have 
molecular weights of > 330 kDa for the first two bands, 245 kDa, 45 kDa and 
25 kDa. These were probably apo (a), apo B-100, apo B-48, apo A-IV and 
apo A-l. Immunoblotting revealed a major apo B-48 band and a much 
fainter apo B-100 band (Fig. 5.2 b). The apo B-48 bands on the immunoblot
161
Fig 5.2 a Protein stain of postprandial samples
it:
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Fig 5.2 b Immunoblot of postprandial samples
(a)
B-100 
B-48
A-IV
A-l
-B-100 
-B-48
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See next page for legend
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Legend to Fig 5.2 a & b
Lanes loaded with CM enriched samples prepared by ultracentrifugation at
1.4 x 108 g.min from plasma taken at hourly intervals from a healthy volunteer 
following a 1.2 g/kg body weight fat-rich meal. F represents a fasting sample. 
625 |xg of protein was loaded into each lane.
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had very similar relative band intensities to apo B-48 bands visualised with 
Coomassie Blue (Fig. 5.3). The calculated correlation coefficient was 
r=0.76.
Fig. 5.3 Comparison of apo B-48 band intensity with ECL 
detection of an immunoblot and Coomassie Blue 
staining of protein bands
Immunoblot
300 -1
■F x 200 -
1i
I k
Üi 100 -
Time (hr)
CM enriched samples were prepared by ultracentrifugation at 1.4 x 108 g.min from plasma 
taken at hourly intervals from a healthy volunteer following a 1.2 g/kg body weight fat-rich 
meal. 625 ng of protein was loaded into each lane. Band intensity is expressed in arbitrary 
units.
5.4.3 Immunostaining for different isoforms of apo B-48
Postprandial CM samples from a healthy subject, following a meal 
containing 40 g fat, were immunoblotted with both the anti-lie and anti-Met 
antibodies (Fig. 5.4 a & b). There were strong bands at many time points for 
the anti-lie antibody, but there were no bands with the anti-Met antibody. 
Experience had shown that samples taken seven hours after a meal had
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Fig 5.4 a Immunoblot with anti-lie antibody
S F -0 .17  0.5 1 2 3 4 5 6 7 8 9 hr
Fig 5.4 b Immunoblot with anti-Met antibody
—  T]
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See next page for legend
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Legend to Fig 5.4 a & b
Lanes loaded with CM enriched samples prepared by ultracentrifugation at
2.1 x 106 g.min from plasma taken at hourly intervals from a healthy volunteer 
following a mixed meal containing 40 g of fat. S represents the standard
CM-enriched sample and F represents a fasting sample. 312.5 pg of protein |
was loaded into each lane. I
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consistently high apo B-48 levels. Therefore, seven-hour postprandial 
samples from a further 10 subjects were screened with the anti-Met isoform. 
None of the samples had a detectable apo B-48 band when immunoblotted 
with the anti-Met isoform.
5.4.4 Comparison of transfer buffers
To ensure the best transfer conditions a combination of methanol and SDS 
in the transfer buffer were investigated. (+) methanol (-) SDS caused most 
of the apo B-48 and apo B-100 to remain in the gel (Table 5.1). Inclusion of 
SDS ((+) methanol (+) SDS and (-) methanol (+) SDS), resulted in efficient 
transfer of the proteins out of the gel, but low binding to the membrane. 
When both SDS and methanol were absent ((-) methanol (-) SDS), there 
was both efficient transfer out of the gel and efficient binding to the 
membrane.
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Table 5.1 Presence of bands on gel and membrane after
transfer with different buffers
Gel Membrane
Conditions apo B-100 apo B-48 apo B-100 apo B-48
+  Methanol 
-  SDS
+ + +  + + + +
+  Methanol 
+  SDS
+
-  Methanol 
+  SDS
-  Methanol
-  SDS
+ + + +  + +
CM-enriched samples from a healthy subject were prepared by ultracentrifugation at (1.4 x 
1 o8 g.min) from plasma taken 3 hr following a meal containing 1.2 g fat/kg body weight. Each 
lane was loaded with 375 pg of protein. Methanol or SDS was added to the transfer buffer at 
20 % (v/v) and 0.1 % (w/v), respectively. (-) Methanol/SDS denotes absence of 
methanol/SDS and (+) methanol/SDS denotes presence of methanol/SDS. Absence of apo 
B-100 and apo B-48 is shown by a -  sign and the intensity of the bands present is proportional 
to the number of +.
5.4.5 Protein load and exposure time
The concentration of protein in the CM-enriched fraction was 6.25 pg/pL. 
Band intensity increased with increasing protein load (62.5-500 pg) and 
produced sigmoid curves (Fig. 5.5). The sigmoid shape was exaggerated 
with longer exposure times causing the linear range of protein load to 
decrease with increased exposure time. The main linear portion for each 
exposure time existed between 0-250 pg. The 250 pg load produced bands 
with rectangular, evenly stained profiles when exposed for 15-60 seconds,
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but the apo B-48 band was uneven when exposed for 7 seconds. A 
7 second exposure of the 375 pg load resulted in evenly stained bands.
Fig. 5.5 Apo B-48 band intensity after different exposure times
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CM-enriched samples from a healthy subject were prepared by ultracentrifugation at (2.1 x 
106 g.min) from plasma taken 3 hr following a meal containing 1.2 g fat/kg body weight. 
Different amounts of CM protein (62.5-500 pg) were loaded onto a gel (x-axis). After 
exposing film for different amounts of time (7-60 secs) the apo B-48 band intensity was 
measured by densitometry (y-axis).
5.4.6 Reproducibility of immunoblots
In order to improve reproducibility, immunoblots were loaded with a 
standard CM-enriched sample. Band intensities were calculated as a 
percentage of this standard. An example of the results obtained from 
duplicate immunoblots is shown in Fig. 5.6. The values for blot two were 
consistently lower than those for blot one, however the general patterns 
were similar. This is reflected in the correlation between the two blots shown 
in Fig. 5.7.
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Fig. 5.6 Comparison of band intensity of the same set of
samples from duplicate immunoblots
■  Blot One 
B  Blot Two
-0.170 0.5 1 2 3 4 5 6 7 8 9
Time (hr)
Apo B-48 band intensities measured by densitometry on duplicate immunoblots. The 
CM-enriched samples were prepared by ultracentrifugation at 2.1 x 106 g.min from plasma 
taken at hourly intervals from a healthy volunteer following a meal containing 40 g of fat. 312.5 
pg of protein was loaded into each lane. Band intensities (arbitrary units) are plotted as a 
percentage of a standard-CM-enriched fraction loaded onto each gel.
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Fig. 5.7 Correlation of band intensity of the same set of samples
from duplicate immunoblots
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The data plotted are from the apo B-48 band intensities shown in Fig. 5.6. The correlation 
coefficient was r=0.68.
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5.4.7 Intra- and inter-assay variation
The mean within-assay CV was 28.3 % (n=4) and mean between-assay 
variation was 22.3 % (n=4) (Table 5.2).
Table 5.2 Intra- and inter-assay variation
Blot Number
Sample
Set
1 2 3 4 CV
(inter­
assay)
A 71.9 63.0 111.8 94.9 25.9
B 90.7 71.4 145.9 84.1 33.6
C 65.8 90.0 91.8 95.1 15.7
D 119.8 163.0 137.1 126.8 13.9
CV
(intra­
assay)
27.4 47.0 20.2 18.4
CM enriched samples were prepared by ultracentrifugation at 1.4 x 10  ^g.min from plasma 
taken at hourly intervals from a healthy volunteer following a meal containing 1.2 g fat/kg body. 
187.5 pg of protein was loaded into four lanes in quadruplicate blots. The values are a 
percentage of a standard CM-enriched sample included on each blot (Section 5.4.6). The 
intra-assay CV represents variation between the four samples loaded onto one immunoblot 
whilst the inter-assay CV represents variation between a corresponding lane on four different 
immunoblots.
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5.5 DISCUSSION
Although several groups have successfully analysed apo B-48 on low 
concentration polyacrylamide gels (Kane etal., 1980; Simons etal., 1987; 
Zilversmit & Shea, 1989; Hidaka etal., 1990) , such low concentrations of 
acrylamide produce a very fragile gel which is difficult to handle in an 
immunoblotting procedure. Aburatani etal. (1983) reported that SDS 
gradient gel electrophoresis was more suitable than ordinary SDS PAGE for 
the analysis of apo B-48. In the present experiment,a 5-20 % gradient was 
used to separate proteins between 29 kDa and 330 kDa. This wide range of 
molecular weight separation was useful because it allowed assessment of 
reactivity of the anti-apo B-48 antibody with other CM apolipoproteins, such 
as apo B-100 (549 KDa), apo A-IV (46 kDa) and apo A-l (28 kDa).
When log molecular weight was plotted versus log polyacrylamide 
concentration, a linear relationship was seen for molecular weight markers 
within the range 29-330 kDa. From this, the apparent molecular mass of apo 
B-48 was estimated to be 245 kDa. This compares favourably with that 
found by other authors: 264 kDa (Kane et al., 1980) and 260 kDa (Simons 
et al., 1987), both measured on 3 % gels; 220 kDa measured by gel 
permeation HPLC (Hidaka etal., 1990) and 189 kDa measured on a 3-30 % 
gel (Aburatani etal., 1983). The discrepancies in molecular size may be 
explained by the lack of precision in measuring the migration distance of 
high molecular weight proteins. In this instance, only 4 mm separated the 
205 kDa marker from the 330 kDa marker.
173
Most other groups analysing apo B-48 by gradient gel electrophoresis have 
measured band intensity directly on the gel following protein staining with 
Coomassie Blue. Poapst etal. (1987) reported difficulties in this method 
because of the different chromogenicities of apo B-48 and apo B-100, 
though this problem was not found by another group (Zilversmit & Shea, 
1989). Measurement of apo B-48 by this method was not suitable for our 
purposes for two main reasons: firstly, in order to visualise apo B-48 by 
Coomassie Blue staining it is necessary to have relatively high 
concentrations of apo B-48 to other proteins in the CM preparation. Cohn et 
al. (1988b) achieved this by using an 18 hour (1.2 x 108 g.min) 
ultracentrifugation spin. However, such a long centrifugation time was 
impractical for processing the large numbers of samples in our study 
(Chapter 6). The shorter ultracentrifugation time of 30 min left a significant 
amount of contamination by non-apo B-48 proteins, particularly albumin. 
This meant that apo B-48 was in a relatively low concentration and could not 
be detected reliably with Coomassie Blue. Secondly, it was important to 
assess the postprandial changes in immunoreactive apo B-48 since this 
would allow comparisons to be made for future development of an 
immunoassay.
A comparison of the immunoblot with Coomassie Blue staining of CM 
proteins showed that there was a very similar pattern in the apo B-48 levels. 
This confirmed that the immunoblot gave comparable results to the 
previously published method of Cohn etal. (1989) for measuring apo B-48 
following SDS-PAGE.
The anti-lie antibody was found to produce a much stronger apo B-48 band 
intensity than the anti-Met antibody when measured in postprandial
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plasma-CM samples. This was surprising and contradicted earlier results 
(Table 3.9) where the anti-lie had reacted only with lymph and only the 
anti-Met reacted with serum-CM. Reasons for the difference between 
anti-apo B-48 isoform reactivity in earlier experiments (Table 3.9) and in the 
present experiments were investigated in collaboration with another 
investigator. Ultracentrifugation conditions, use of plasma or serum and the 
inclusion of preservative were not proven to be responsible. A possible 
explanation is that serum-CM from the hyperlipidaemic patient, used in the 
earlier experiments (Table 3.9), may exist primarily with an apo B-48 Met 
C-terminus. This could be because delayed CM removal from the circulation 
of the patient may have allowed processing of the apo B-48 C-terminus from 
lie to Met. A further possibility is that the patient may have suffered from 
pancreatic disease which could elevate plasma levels of 
carboxypeptidase-A. It has been suggested this enzyme may convert the 
apo B-48 lle-terminus to the Met-terminus (Section 1.3.4). Unfortunately, a 
shortage of hyperlipidaemic serum has prevented confirmation of this 
hypothesis.
Under the conditions of the final assay, there was no cross-reactivity of the 
anti-apo B-48 antibody with other apolipoproteins on the immunoblots. On 
some blots a small amount of cross-reactivity with albumin was observed. It 
is not known whether this was due to specific cross-reactivity or non-specific 
binding of either the anti-apo B-48 antiserum, the secondary biotinylated 
anti-rabbit IgG, or the tertiary Extravidin peroxidase conjugate. In any event, 
the binding was insignificant when the relative amounts of albumin and apo 
B-48 loaded onto the gel, were taken into account. The apo B-48 bands had 
a sharp, well formed appearance and were superior to those which would 
have been obtained had a uniform concentration gel been used.
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To obtain the optimum electrophoretic transfer of apo B-48 variations of 
transfer buffer were investigated. The standard buffer used by many 
investigators is based on 192 mM Glycine and 25 mM Tris, pH 8.3 (Towbin 
etal., 1979). Sodium dodecyl sulphate was used to enhance elution of apo 
B-48 from the gel and methanol was used to increase the binding capacity of 
nitrocellulose for protein. Although SDS did result in efficient transfer of apo 
B-48 out of the gel it reduced protein binding to the nitrocellulose. Methanol, 
on the other hand, reduced the efficiency of transfer so that much of the apo 
B-48 remained in the gel. Overall, buffer containing neither SDS or 
methanol was the most efficient; most of the apo B-48 was eluted out of the 
gel and there was good subsequent binding to the nitrocellulose membrane.
The main aim of investigating sample load was to achieve a linear response 
of apo B-48 band intensity with amount of protein loaded and sufficient 
sensitivity. Sigmoid curves were produced which had sharply increasing 
band intensities with increasing protein loads. The shortest exposure time of 
7 seconds gave the straightest curve. Although all the exposure times were 
linear up to 250 pg of protein loaded, the apo B-48 band did not have a 
rectangular evenly stained profile after a 7 second exposure. The 375 pg 
protein load had even exposure at times greater than 7 seconds and it was 
decided to choose a sample volume of 50 pL, which was equivalent to
312.5 pg of protein. This was much higher than the 25 pg of TRL loaded by 
Cohn etal. (1988b). However, as already explained, the amount of protein 
loaded was higher in this study because of the lower relative concentration 
of apo B-48 in the CM-enriched sample used. About half the samples 
measured in eleven subjects after two test meals (Chapter 6) had band 
intensities which were outside the range of the standard curve for a
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7 second exposure (Appendix III). This was a reflection on the steep nature 
of the curve since a small change in amount of apo B-48 caused a large 
change in band intensity.
The short exposure time of 7 seconds indicated that ECL was probably 
unnecessary and that detection with a chromogenic substrate, such as
4-chloronaphthol may have been sufficient. Enhanced chemiluminescence 
was initially employed to ensure adequate sensitivity during development of 
this method, and its use was continued because of its greater flexibility in 
varying exposure times when necessary.
There was a marked difference in the size of band intensities for the same 
samples measured on duplicate immunoblots. However, the pattern of 
response was similar and there was a reasonable correlation (r=0.68) 
between the two blots. Apo B-48 values were expressed as percentages of 
a standard CM sample included on each gel. The low percentage values 
obtained for blot two indicated that the standard had a higher band intensity 
relative to the samples than on blot one.
Most of the variation with this method would seem to be within-assay rather 
than between-assay, as indicated by similar inter and intra-assay CVs. In 
this multi-stage method it is difficult to pinpoint any particular step as being 
largely responsible for the source of error. The error could be a summation 
of inconsistencies in several steps including: separation of chylomicrons, 
addition of sample buffer to chylomicrons, loading sample onto the gel, 
elution of apo B-48 out of the gel and subsequent binding to the 
nitrocellulose membrane, binding of either primary, secondary or tertiary 
antibodies, irrigation with ECL reagents and densitometric scanning.
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This assay is capable of specifically measuring apo B-48 in postprandial CM 
samples from normal human subjects. However, bearing in mind the large 
intra-assay variation, quantitative results will have to be treated with caution. 
The main virtues of this method are that it will allow good semi-quantitative 
analysis and assessment of patterns of apo B-48 response, in relatively 
large numbers of samples produced from postprandial studies. In addition, it 
will greatly aid the development of further immunoassays by allowing direct 
comparison of results.
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CHAPTER SIX
APPLICATION OF THE 
APO B-48 ASSAY IN A 
POSTPRANDIAL 
STUDY WITH TEST 
MEALS OF 
DIFFERENT FATTY 
ACID COMPOSITION
6.1 INTRODUCTION
CM are the principal carriers of dietary lipid and are a major contributor to 
postprandial lipaemia. Diet can therefore play a major role in determining 
the composition and metabolism of CM. In spite of the strong evidence that 
postprandial TAG and CM remnants are involved in the development of 
CHD (Section 1.9) there have been relatively few studies on the effect of diet 
on these parameters.
6.1.1 Effect of fish oils on postprandial lipoprotein 
metabolism
Fish oils are unique fats in the human diet because they are a rich source of 
n-3 polyunsaturated fatty acids (PUFAs). This family of fatty acids is 
characterised by a high degree of unsaturation with a double bond three 
carbon atoms away from the terminal methyl group. The major n-3 PUFAs 
found in fish oil are eicosapentaenoic acid (EPA, C 20:5) and 
docosahexaenoic acid (DMA, C 22:6). In a review by Harris (1989) it was 
concluded that administration of fish oils resulted in a mean reduction of 
25 % of TAG in forty-one studies on normolipidaemic subjects. Other effects 
were a slight rise in HDL cholesterol (3 %) and no overall change in total or 
LDL cholesterol. Fish oils also lower the secretion of VLDL although the 
exact mechanism has not been elucidated. Harris (1989) proposed that fish 
oils may selectively reduce the secretion of larger VLDL particles (which 
account for most of the plasma TAG) and increase the output of smaller 
VLDL particles. The large VLDL particles are not converted into LDL as 
readily as small VLDL and this may explain the increase in LDL cholesterol 
seen in some studies after fish oil feeding.
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It is worth noting that fish oils also have other beneficial effects which lead to 
a decreased risk from CHD. These include: reduced platelet aggregation, 
reduced blood pressure, decreased blood viscosity and a lower incidence of 
cardiac arrhythmias (Weber & Leaf, 1991).
6.1.2 Studies of fish oils on chylomicron metabolism
Specific effects of n-3 PUFA on CM metabolism in normal healthy volunteers 
has been addressed in only two previous studies (Weintraub et al., 1988; 
Brown & Roberts, 1991). Weintraub et al. (1988) placed eight subjects on 
either a saturated fat or n-3 polyunsaturated fat diet for 25 days. Compared 
with the SFA diet the n-3 PUFA diet reduced levels of CM-retinyl palmitate 
(RP) by 54 % after an acute SFA load. Following 25 days on the n-3 PUFA 
diet an acute n-3 PUFA load reduced CM-RP levels by 27 % compared to an 
acute SFA load. They explained their results by a combination of decreased 
competition for clearance from endogenous VLDL and an increased 
susceptibility of n-3 PUFA-rich CM to lipolysis by LPL.
Brown & Roberts (1991) gave 25 subjects either fish oil or olive oil 
supplements for 6 weeks after which they had an acute test meal which was 
neither rich in SFA or PUFA. Compared to the olive oil diet, the fish oil diet 
reduced CM-TAG levels by 31 % and CM-RP levels by 20 %. The authors 
could not distinguish between increased clearance or decreased TRL 
synthesis as the reason for decreased TRL levels with n-3 PUFA 
supplementation.
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One of the main components involved in CM metabolism is LPL. This 
enzyme hydrolyses TAG on CM and VLDL and generates CM-remnants, IDL 
and LDL (Section 1.4.2). Most previous studies on humans (Harris et al., 
1988; Weintraub et ai, 1988; Bagdade etal., 1990; Nozaki etaL, 1991) have 
failed to find an increase in LPL activity following n-3 PUFA 
supplementation, however n-3 PUFA-enriched CM may be more susceptible 
to hydrolysis by LPL (Weintraub efa/., 1988). Herzberg (1991) reported that 
LPL activity was increased in skeletal muscle and heart, but not in adipose 
tissue in rats fed fish oil compared to corn oil. Therefore there is a need for 
more studies on the effects of n-3 PUFA on LPL activity.
6.1.3 Measurement of chylomicron metabolism
Theoretically one of the best ways to study CM metabolism is to 
exogenously label the CM particles. Haffner et al. (1984) harvested 
autologous CM from diabetic patients and re-injected them following 
radioiodination. Total apo B radioactivity was measured following 
ultracentrifugation. There is an obvious radioactive hazard associated with 
this technique which makes it impractical for large scale studies. To date, 
the most common way of measuring CM has been to label them with RP. 
Like cholesterol, when vitamin A is ingested in esterified form, as retinyl 
ester, it is initially hydrolyzed in the small intestine. It is then co-absorbed 
with cholesterol and monoacylglycerol into the mucosal cells, where both 
are largely re-esterified and co-secreted into the intestinal lymph in the 
hydrophobic CM core. Subsequently, the retinyl esters are taken up by 
parenchymal cells in the liver via receptor-mediated endocytosis. In the 
liver, the retinyl esters are hydrolyzed to vitamin A alcohol (retinol) and either 
released into plasma bound to retinol-binding protein, or re-esterified and
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stored in the liver (Hazzard & Bierman, 1976; Krasinski etal., 1990). Since 
retinyl esters did not appear to be re-secreted by the liver and because their 
exchange among lipoproteins was thought to be minimal they have been 
used in many investigations for studying specifically the plasma metabolism 
of CM and CM remnants. However, some recent studies of postprandial 
lipoprotein metabolism in human subjects have shown that the timing of 
peak CM concentrations of TAG and RP did not always coincide (Weintraub 
etal., 1987; Krasinski etal., 1990; Schrezenmeir ef a/., 1992; Chen etal., 
1993). Furthermore, Krasinski etal. (1990) found that a large percentage of 
retinyl esters could be found in LDL (9 % after 3 hours; 9 % after 6 hours; 
19 % after 9 hours and 32 % after 12 hours). They concluded that retinyl 
esters in plasma do not necessarily indicate the presence of particles of 
intestinal origin.
As previously explained (Chapter 4), because of the inability to raise a 
specific antiserum to apo B-48, an immunoassay for apo B-48 has not been 
reported. However, some authors have measured postprandial apo B-48 by 
densitometric scanning of SDS-PAGE gels. Using this method, Cohn etal. 
(1988b) demonstrated a postprandial rise in apo B-48, but later work has 
found discrepancies with RP concentrations: Krasinski etal. (1990) found in 
TRL that apo B-48 and TAG peaked after 3 hours, whereas RP did not peak 
until 6 hours; Cohn etal. (1989) found that peak values for TRL-apo B-48 
always coincided with TAG, but plasma-TAG did not always coincide with 
plasma-RP; Demacker et al. (1991) found that apo B-48 was significantly 
lower (p<0.05) whereas TRL-TAG and TRL-RP was unchanged following a 
9-day diet of n-6 PUFA compared to saturated fat.
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Previously, the most common method for monitoring CM metabolism was 
using the RP assay. The lack of a specific antibody has prevented other 
workers from measuring immuno-reactive apo B-48. In Chapter 5 an assay 
for apo B-48 based on SDS-PAGE was developed. Since there have been 
criticisms of the RP assay, it was important to compare apo B-48 and RP 
measurements. The need for more emphasis on postprandial lipaemia as a 
risk factor for CHD and the potential for its dietary modification was 
discussed in Chapter 1. In recent years there has been much interest in the 
potential anti-atherogenic effects of n-3 PUFA. Although CM remnants have 
been implicated in atherogenesis there has been very little work done on the 
effects of n-3 PUFA on CM metabolism. Measurement of apo B-48 in 
particular will help to clarify whether the hypotriacylglycerolaemic effects of 
n-3 PUFA are due to modification of intestinal, as opposed to hepatic 
lipoproteins.
The aims of this study were therefore to:
1. Compare RP and apo B-48 as methods for measuring CM.
2. Study the effects on CM metabolism of a fish oil test meal compared to a 
meal which was representative of the current U.K. fatty acid intake. In 
addition to apo B-48 and RP, TAG, post-heparin LPL and serum total apo B 
were also measured.
The overall study design was done in collaboration with another PhD 
student. A team of investigators was involved in collecting samples and 
carrying out some of the laboratory analysis.
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6.2 MATERIALS
Palm oil, coconut oil, corn oil and olive oil were purchased from standard 
food retail outlets. The fish oil was MaxEPA from British Cod Liver Oils, Hull, 
Humberside. The milk shakes were Slenderplan produced by Carnation 
Ltd. Croydon, Surrey. Other materials are listed in Chapter 2.
6.3 METHODS
6.3.1 Subjects
Eleven healthy male student subjects were recruited. Their average age 
was 22.5 years (range 21-25) and they had an average body mass index of
23.8 kg/m^ (range 19.0-26.2). Their habitual dietary fat intake was assessed 
by the completion of food diaries for three weekdays and one weekend day. 
The energy derived from dietary fat ranged from 33 to 45 %.
Other inclusion criteria included: no previous history of endocrine or liver 
disease, hyperlipidaemia, or alcoholism; consumption of less than 30 units 
of alcohol per week; no more than ten hours per week of vigorous exercise 
and the subjects had not been following any form of exclusion diet or taking 
dietary supplements of evening primrose oil, fish oil or sunflower oil in the 
month preceding the study.
Ethical consent was obtained from the University of Surrey and the Royal 
Surrey County Hospital Ethics Committees.
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6.3.2 Meals
The subjects consumed two test meals in a single-blind randomised order. 
On each study day all the subjects consumed the same breakfast, lunch and 
snacks (Table 6.1) and continued with their normal activities. At 1900 hours 
of each study day a test meal was consumed at the Clinical Investigation 
Unit at the Royal Surrey County Hospital. The two test meals differed only in 
their fatty acid composition (Table 6.2). The mixed oil meal was a mixture of 
palm oil, coconut oil, olive oil and corn oil which was designed to represent 
the current fatty acid composition of the typical U.K. diet. The dietary fat of 
the fish oil meal came from fish oil concentrate which was provided in a 
deodorised form. The oil under investigation was given as 40 g with a 
rice-based meal: 20 g in a milk-shake and 20 g as a salad dressing. The 
milk shake was prepared immediately before consumption by adding 84 g of 
milk shake powder, 20 g of test oil and 700 I.U./kg body weight of RP. 
Wholemeal bread was provided to ensure that all the oil added to the salad 
was consumed.
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Table 6.1 Nutrient composition of the standard meals consumed 
during the day of each test meal
Meal Energy Protein Fat Carbohydrate Fibre
(kcal) (g) (g) (g) (g) _
Breakfast 581.5 17.5 11.2 110.2 4.9
Snack 248.0 4.0 10.0 38.0 1.0
Lunch 833.0 34.0 31.5 111.5 14.8
Snack 287.0 4.7 12.9 41.0 1.1
Test meal 1349.7 34.5 43.7 207.8 11.1
Total 3299.2 94.7 109.3 508.5 32.9
Table 6.2 Fatty acid composition (%) of the two test meals
Mixed oil Fish oil
SFA 43.2 28.8
MUFA 39.6 26.7
n-3 PUFA 0.0 31.0
n-6 PUFA 12.0 9.1
SFA, saturated fatty acids; MU FA, monounsaturated fatty acids; PUFA, polyunsaturated fatty 
acids. Remaining percentage made up of traces of other fatty acids.
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6.3.3 Study procedure
To reduce within-subject variation, subjects were asked to ensure they had a 
similar food intake for the four days prior to each test meal. They were also 
asked to refrain from excessive alcohol intake during the whole period of the 
study and not to drink any alcohol on the day before each test meal. The 
study design is outlined in Table 6.3. At 0900 hours a fasting venous blood 
sample (20 m l) was taken from the forearm of the subject after which they 
were given a standard breakfast. They were supplied with a standard 
pre-packed lunch and snacks and asked not to consume any additional 
food. At 1800 hours they were transported to the Investigation Unit where 
after a period of rest a cannula was inserted into the antecubital vein and 
two preprandial blood samples were taken. After eating the test meal, 
20 mL blood samples were taken after 0 .5 ,1 ,2 ,3 , 4, 5, 6, 7, 8 and 9 hours. 
During the night the subjects slept most of the time. After 12 hours, 100 I.U. 
heparin/kg body weight were injected into the mid-arm vein. After a further 
15 mins a 5 ml blood sample was taken for LPL analysis. The subjects were 
then given breakfast and taken back to the University.
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Table 6.3 Summary of study procedure
Time Activity
0900 fasting blood sample taken
0915 consumed standard breakfast
1300 consumed standard packed lunch
1830 cannulated
1850 - 1900 two preprandial blood samples taken
1900 consumed test meal
1930 - 0400 blood samples taken
0700 given heparin
0715 blood sample taken for LPL analysis
Each 20 mL blood sample was divided into 10 mL for a heparinised tube 
and 10 mL for a serum tube. The heparinised tubes were spun immediately 
at 3000 g.min in a bench centrifuge and the plasma was transferred to 
10 mL glass tubes containing no anti-coagulant. The CM-enriched fraction 
was prepared by ultracentrifugation at 2.1 x 106 g.min (Section 2.2.3) from 
plasma thé following day and 0.4 mL transferred to each of three LP3 tubes 
for subsequent analysis of TAG, RP and apo B-48. Samples for RP analysis 
were protected from light by wrapping the tubes in aluminium foil. 
Preservative was added to the apo B-48 CM (Section 2.1.2).
After allowing the 10 mL of blood in the serum tube to clot the tubes were 
centrifuged at 3000 g.min. The serum was transferred into an LP3 tube for 
total apo B analysis. The 5 mL of blood taken for LPL analysis was
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processed as described above for plasma. The samples were frozen at 
-20 °C after processing.
6.3.4 Analysis of samples
TAG and RP were measured in the CM-enriched samples as described in 
Section 2.6 & 2.7 respectively. Serum total apo B and post-heparin plasma 
LPL were measured as described in Section 2.8 & 2.9 respectively. Apo 
B-48 was measured in CM-enriched plasma samples by the method 
described in Section 2.4.4.
Measurements were made of apo B-48, TAG and total apo B in the fasting 
sample and two preprandial samples and in the 0.5, 1 ,2 ,3 , 4, 5, 6, 7, 8 and 
9 hr postprandial samples. RP was measured in the fasting and 0 hr sample 
and in the 0.5, 1,3, 5, 7 and 9 hr postprandial samples. Post-heparin LPL 
was measured in a single sample taken 12.25 hr after the test meal.
6.3.5 Statistical analysis
Distribution of the data was tested using Kolmogorov-Smirnov Goodness of 
Fit Test and log transformed where necessary. Repeated measures analysis 
of variance was used to assess whether there was a difference between 
meals that changed over time. Area under the curve (AUC) was calculated 
using the trapezoid rule. The mean of the -10 min and 0 min sample was 
taken as baseline for the incremental AUC calculation. Only subjects with 
full sets of data were included in the statistical analysis, but all subject data 
is shown in the figures. The mathematical manipulations were performed by 
another investigator using an SPSS statistical package. A p-value of less
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than 0.05 (p<0.05) was taken as the level of statistical significance. Any data 
which did not conform to homogeneity of variances was transformed by 
logarithms. A peak value was arbitrarily defined as a value which was 
higher than the two values either side of it.
6.4 RESULTS
The figures in this section have been presented as mean values with 
standard error of the mean bars (SEMs) for clarity. Standard deviations are 
quoted in the text and individual subject data can be found in Appendix III.
6.4.1 Chylomicron-triacylglycerol
Fasting values prior to the mixed oil meal were 1.32 ± 0.60 mmol/L 
(mean ± SD) and 0.97 ± 0.74 mmol/L prior to the fish oil meal. These values 
were not statistically significantly different.
Following the mixed oil meal (Fig. 6.1), CM-TAG rose to a maximum of 
2.52 ± 1.09 mmol/L after one hour and decreased to 1.55 ± 0.67 mmol/L at 
three hours. Levels rose again to reach 2.42 ± 1.02 mmol/L after five to six 
hours and then fell gradually to 1.53 ± 0.78 mmol/L at nine hours. Seven 
subjects had 2 peak values, three subjects had 3 peak values and one 
subject had 4 peak values. The first peak occurred between 0.5-2 hours and 
the second peak at 3-5 hours.
Following the fish oil meal, CM-TAG had a first peak value of 
1.69 ± 0.76 mmol/L at one to two hours and decreased to
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1.28 ± 0.71 mmol/L at four hours. Levels rose again steadily to reach a 
maximum of 1.76 ± 1.05 mmol/L after 6 hours and then decreased to 
0.84 ± 0.43 mmol/L at nine hours. One subject had only 1 peak value, eight 
subjects had 2 peaks, one had 3 peaks and one had 4 peak values.
The first peak was sharper with mixed oil and broader following fish oil, but 
the second peak had a similar shape for both meals. Repeated measures 
analysis of variance did not reveal any difference between the meals over 
time. Although there was a trend to lower levels following the fish oil meal 
this did not reach statistical significance for either total AUC (Fig 6.2, 
Table 6.4) or incremental AUC (Table 6.5). CM-TAG returned to baseline 
between 8-9 hours after both meals.
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Fig. 6.1 CM-TAG measured at different times following test 
meals of different fatty acid composition
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The points are mean values for 11 subjects and the error bars are SEMs. Mixed oil is 
represented by (o) and fish oil by (•). F represents the fasting samples
Fig. 6.2 Total AUC for triacylglycerol
o
20 -
■  0-9 hr 
H  0-3 hr 
E  3-9 hr
mixed oil fish oil
Data for 0-9 hr is taken from Table 6.4. Data for 0-3 hr and 3-9 hr is taken from Table 6.6. The
error bars are SDs.
Table 6.4 Total AUC for 0-9 hr
Mixed oil Fish oil p-value
TAG 17.5 ±7.3 (8) 12.9 ±5.8 (10) NS
RP 6.1 ±4.9 (9) 8.0 ±4.3 (10) NS
Apo B-48 592 ±527 (10) 320 ± 329 (9) NS
Total apo B 552 ± 184 (6) 512 ±226 (4) NS
Values are mean ± SD with number of subjects used in statistical analysis shown in brackets. 
NS denotes not-significant
Units: TAG, mmol/mL x hr; RP, pg/mL x hr; Apo B-48, % band intensity x hr; Apo B, mg/dL x hr
Table 6.5 Incremental AUC for 0-9 hr
Mixed oil Fish oil p-value
TAG 2.5 ±7.1 (8) 4.0 ±4.6 (10) NS
Apo B-48 399 ±411 (10) -8.4 ±211 (9) NS
Values are mean ± SD with number of subjects used in statistical analysis shown in brackets. 
Units: TAG, mmol/mL x hr; RP, pg/mLx hr; Apo B-48, % band intensity x hr; Apo B, mg/dL x hr
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6.4.2 Chylomicron retinyl palmitate
The fasting values for RP were zero for both meals. Following the mixed oil 
meal (Fig. 6.3), the values were very low up to three hours, rising to a 
maximum of 1.31 ± 1.16 jig/mL at seven hours and decreasing to 
0.49 ± 0.48 pg/mL at nine hours. There was only one peak value for each 
subject, although the timing of this varied between three and nine hours.
There was a similar pattern with the fish oil meal, except the maximum value 
of 1.42 ± 0.98 pg/mL occurred at five hours and the concentration after nine 
hours was 0.53 pg/mL Nine subjects had one peak value (between three 
and seven hours) and two subjects had two peak values.
The curves had a similar shape and repeated measures analysis of variance 
did not reveal any difference between the meals over time. There was a 
trend towards higher levels following the fish oil meal, but the total AUC was 
not significantly different between the two meals (Table 6.4, Fig 6.4). RP 
concentration declined at a similar rate after both meals and was still 
elevated above baseline levels after 9 hours.
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Fig. 6.3 CM-retinyl palmitate measured at different times
following test meals of different fatty acid composition
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The points are mean values for 11 subjects and the error bars are SEMs. Mixed oil is 
represented by (o) and fish oil by (•). F represents the fasting samples.
Fig. 6.4 Total AUC for retinyl palmitate
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Data for 0-9 hr is taken from Table 6.4. Data for 0-3 hr and 3-9 hr is taken from Table 6.6. The
error bars are SDs.
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6.4.3 Chylomicron apo B-48
The apo B-48 values are expressed as a percentage of a standard CM 
preparation which was loaded onto each gel. Fasting values before the 
mixed oil meal were 20.6 ± 20.1 % and 11.5 ± 25.3 % before the fish oil 
meal and were not statistically significantly different.
After mixed oil (Fig. 6.5), apo B-48 rose sharply to 64.5 ± 59.1 % at one hour 
and decreased steadily to 39.1 ± 43.9 % after three hours. Levels rose 
again to a maximum value of 91.1 ± 69.8 % at six hours, dipped at seven 
hours before rising again to 90.9 ± 81.0 % at eight hours. Four subjects had 
1 peak value, four had 2 peaks and three subjects had 3 peaks.
Following fish oil, apo B-48 increased steadily to reach a maximum value of
51.9 ± 54.5 % at one hour and remained high at two hours before 
decreasing and levelling out. Levels then increased again to a second peak 
of 45.5 ± 60.4 % at six hours before decreasing to 5.9 ± 9 % at nine hours. 
Two of the subjects had no obvious peak values, two subjects had 1 peak, 
five subjects had 2 peaks, one had three peaks and one had four peaks.
The first peak was a similar shape following both meals. However, the 
second peak was much larger following mixed oil and repeated measures 
analysis of variance showed there was a significant difference (p<0.001) 
between the test meals that varied over time. Although there was a strong 
trend towards lower levels following the fish oil meal neither total AUC 
(Table 6.4, Fig. 6.6) nor incremental AUC (Table 6.5) reached statistical 
significance. It took between 7-8 hours for the apo B-48 levels to return to 
baseline after fish oil, but they were still elevated at 9 hours after mixed oil.
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Fig. 6.5 CM apo B-48 measured at different times following test 
meals of different fatty acid composition
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The points are mean values for 11 subjects and the error bars are SEMs. Mixed oil is 
represented by (o) and fish oil by (•). F represents the fasting samples. Apo B-48 is the band 
intensity measured by densitometry and is plotted as a percentage of a control.
Fig. 6.6 Total AUC for apo B-48
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Data for 0-9 hr is taken from Table 6.4. Data for 0-3 hr and 3-9 hr is taken from Table 6.6. The
error bars are SDs. * represents p<0.05
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6.4.4 Serum total apo B
The fasting serum total apo B concentrations were 64 ±16 mg/dL prior to the 
mixed oil meal and 66 ± 18 mg/dL before the fish oil meal and were not 
statistically significantly different. The values ranged between 56-66 mg/dL 
after mixed oil and 53-64 mg/dL after the fish oil meal (Fig. 6.7).
The curves had a very similar shape after the two test meals and there was 
no significance difference between the meals by repeated measures 
analysis of variance. There was a slight trend for lower levels of total serum 
apo B following the fish oil meal but the total AUC was not significantly 
different (Table 6.4, Fig. 6.8).
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Fig. 6.7 Serum total apo B measured at different times following 
test meals of different fatty acid composition
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The points are mean values for 11 subjects and the error bars are SEMs. Mixed oil is 
represented by (o) and fish oil by (•). F represents the fasting samples.
Fig. 6.8 Total AUC for total apo B
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Data for 0-9 hr is taken from Table 6.4. Data for 0-3 hr and 3-9 hr is taken from Table 6.6. The
error bars are SDs.
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6.4.5 Analysis of area under the curve for 0-3 and 3-9 hr
Figs. 6.1, 6.3 & 6.5 showed that there ; were clearly two postprandial peaks for 
TAG and apo B-48, but only one peak for RP. Further AUC measurements 
were calculated by dividing the postprandial curve into two parts i.e. from 
0-3 hr and 3-9 hr (Tables 6.6 & 6.7). Total AUC measurements showed that 
TAG levels were only slightly lower following fish oil compared to mixed oil 
for the 0-3 hr period, but about 30 % lower for 3-9 hr, though there was no 
significant difference (Table 6.6). RP total AUC was higher for 0-3 hr 
following fish oil, but this difference was not statistically significant, whereas 
the total AUC was similar after both meals for 3-9 hr. Apo B-48 total AUC 
was similar for 0-3 hr, but was significantly (p<0.05) lower for 3-9 hr following 
the fish oil meal.
Incremental AUC showed TAG was higher (not statistically significant) 
following fish oil for both 0-3 hr and 3-9 hr periods (Table 6.7). Apo B-48 
had a significantly (p<0.05) lower incremental AUC for 3-9 hr after the fish oil 
test meal, though there was no difference for the 0-3 hr period.
There was no significant difference in AUC or incremental AUC for total apo 
B over any time period.
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Table 6.6 Total AUC for 0-3 hr and 3-9 hr
Mixed oil Fish oil p-value
TAG 0-3 hr 5.4 ±2.3 (10) 4.3 ±1.7 (10) NS
3-9 hr 12.1 ±5.0 (9) 8.7 ±4.2 (11) NS
RP 0-3 hr 0.5 ±0.4 (10) 1.1 ±0.8 (11) NS
3-9 hr 5.7 ±4.2 (10) 6.9 ±3.8 (10) NS
Apo B-48 0-3 hr 128 ± 111 (11) 139 ±135 (10) NS
3-9 hr 469 ±422 (10) 181 ±234 (10) 0.03 *
Total apo B 0-3 hr 185 ±57 (9) 165 ±72 (7) NS
3-9 hr 363 ±120 (7) 372 ±149 (5) NS
Values are mean ± SD with number of subjects used in statistical analysis shown in brackets. 
Units: TAG, mmol/mL x hr; RP, jug/mL x hr; Apo B-48, % band intensity x hr; Apo B, mg/dL x hr
* obtained after log transformation
Table 6.7 Incremental AUC for 0-3 hr and 3-9 hr
Mixed oil Fish oil p-value
TAG 0-3 hr 0.7 ±2.1 (10) 1.4 ±1.4 (10) NS
3-9 hr 1.6 ±4.9 (9) 2.6 ±3.5 (11) NS
Apo B-48 0-3 hr 55± 85 (11) 20 ±64 (10) NS
3-9 hr 340 ±342 (10) -17 ±201 (10) 0.01
Values are mean ± SD with number of subjects used in statistical analysis shown in brackets. 
Units: TAG, mmol/mL x hr; RP, pg/mL x hr; Apo B-48, % band intensity x hr; Apo B, mg/dL x hr
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6.4.6 Post-heparin plasma lipoprotein lipase
LPL had an activity of 161.8 ± 33.4 nmol oleate re leased/m in/mL of plasma 
at 37 °C following mixed oil and 223.4 ± 39.8 nmol oleate released/min/mL 
of plasma at 37 °C after fish oil (Fig. 6.9). The activity following fish oil was 
significantly higher (p<0.01).
Fig. 6.9 Post-heparin plasma LPL activity following test meals of 
different fatty acid composition
300 n
250 -
Mixed oil Fish oil
Units of LPL activity are nmol oleate released/min/mL plasma at 37°C. Error bars are SEMs.
* denotes p<0.01.
6.5 DISCUSSION
The main findings from this study were that levels of apo B-48 in the 
CM-enriched fraction were lower following fish oil compared to the mixed oil 
meal. CM-enriched plasma apo B-48 levels changed significantly over time,
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but total serum apo B remained relatively constant and did not differ 
between the meals. Although RR levels changed significantly during the 
postprandial period, there was no statistically significant effect of the two test 
meals. Both TAG and apo B-48 showed two main postprandial peaks, 
whereas there was only one main peak in RP concentration.
Circulating levels of TAG, RP, apo B-48 and total apo B are a reflection of 
both absorption and elimination. Therefore, the lower levels of TAG and apo 
B-48 in the CM-enriched fraction following the fish oil test meal could have 
been due to either a decreased rate of absorption or increased rate of 
elimination. The concentration of RP was higher following fish oil for the first 
five hours after the meal. Since RP is a marker of newly secreted CM, this 
would tend to suggest that absorption of TAG following fish oil occurred at a 
faster rate than for the mixed oil meal. This is in agreement with Herzberg et 
al. (1992) who found that rats fed a fish oil diet absorbed a greater 
proportion of a test dose of fish oil than those on a corn oil diet. 
Concentrations of CM-enriched TAG returned to preprandial levels 9 hours 
following both test meals. After 9 hours RP was still elevated, but 
concentrations were very similar for both meals. Apo B-48, on the other 
hand, returned to preprandial levels 7-8 hours after fish oil, but was still 
elevated 9 hours after the mixed oil test meal. Taken together these findings 
may suggest that the lower postprandial levels of TAG and apo B-48 in the 
fish oil group were due to increased elimination.
Increased elimination of CM could be explained by the observation that 
unsaturated fatty acids tend to result in larger CM than SFAs (Ockner etal., 
1969; Ockner & Jones, 1970) which consequently seem to be cleared faster 
than small CM (Quarfordt & Goodman, 1966). One of the factors which
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determines the rate of elimination of CM from the circulation is the activity of 
LPL. In the present study, LPL activity was significantly enhanced 12 hours 
following the fish oil test meal compared to the mixed oil test meal. Most 
previous studies (Harris etal., 1988; Weintraub etal., 1988; Bagdade etal., 
1990; Nozaki etal., 1991) have failed to find an increase in LPL activity 
following n-3 PUPA supplementation. However, Weintraub etal. (1988) 
found an increase in in vitro lipolysis of n-3 PUPA enriched CM and 
concluded that although n-3 PUPA may not actually cause an increase in 
LPL activity, the n-3 PUPA enriched CM may be more susceptible to 
lipolysis. In addition, Herzberg (1991) found that there was preferential 
removal of EPA compared with oleate in perfused hindquarters of rats. This 
was regardless of dietary fat and the removal of either fatty acid was 
enhanced in animals fed a fish oil diet. Furthermore, Levy et al. (1991) 
found that rats fed on a diet rich in n-6 PUPA from safflower oil resulted in 
larger CM which had a shorter half-life than those produced on a SPA diet of 
coconut oil.
Fish oils lower hepatic secretion of VLDL (Harris, 1989) and the mechanism 
of increased elimination of CM might be explained by decreased 
competition for LPL by VLDL. Harris (1989) argued that this was not a valid 
explanation because LPL is not saturated during the postprandial period in 
normolipidaemic subjects. However, this contrasts to observations of other 
workers. Schneeman etal. (1993) found a postprandial rise in apo B-100 
measured in TRL, which reflects increased VLDL levels and interpreted their 
observation as being due to increased competition for LPL by CM. This is 
also supported by the work of Potts etal. (1991) who reported that after a 
fat-rich meal the elimination of CM-TAG into human subcutaneous tissue 
was increased, whereas that of VLDL-TAG was reduced.
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Schneeman et al. (1993) have estimated that up to 80 % of postprandial 
TAG is attributable to apo B-100 containing particles. In conjunction with this 
observation Karpe etal. (1993a) pointed out an alternative hypothesis for 
VLDL elevation in postprandial lipaemia. They suggested that newly 
secreted CM might displace bound VLDL from LPL and thus increase the 
plasma concentration of VLDL. This is an attractive theory because it 
explains the absence of increased LPL activity seen in other postprandial 
studies and also the enhanced in vitro rate of CM lipolysis. In addition, it 
should be noted that most other studies have not measured late 
postprandial LPL.
A further explanation might also be considered. It is unlikely that a 
significant amount of n-3 PUPA remained in CM twelve hours after the test 
meal. Murphy etal. (1993) demonstrated an increase in LPL mRNA in rats 
fed a fish oil diet. Therefore the apparent increased activity of LPL seen in 
the present study could have been caused by an increase in the amount of 
LPL protein synthesised, rather than effects on enzyme activity itself.
The commercial anti-total apo B antibody was raised to the whole apo B-100 
molecule and has been shown to cross-react with apo B-48 (Fig. 3.11). The 
large fluctuations in apo B-48 in the CM-enriched fraction were not evident 
in serum total apo B which remained at a constant level throughout the 
postprandial period. This has been demonstrated previously (Cohn etal., 
1988b) and emphasises that apo B-48 is at a much lower concentration than 
apo B-100 in serum. The pattern of CM-enriched plasma apo B-48 levels 
was very similar to TAG and this is in agreement with other workers
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(Weintraub etal., 1988; Cohn etal., 1989; Krasinski etal., 1990; Karpe etal., 
1993a; Schneeman etal., 1993).
Although previous workers have found that CM-TAG and RP do not always 
peak at the same time point, the majority of postprandial studies have shown 
only one peak in CM-TAG or RP. One of the most intriguing findings in the 
present study was the appearance of more than one peak in CM-enriched 
plasma TAG and apo B-48, but only a single peak for RP. The range in the 
number of peaks (1-4) in individual subjects might be explained by 
inconsistent CM separation especially since a peak was defined arbitrarily 
as a value which was higher than the two at the time points either side of it. 
However, for the pooled data there were clearly two peaks in apo B-48 and 
TAG. Two postprandial peaks in plasma TAG, at 1 and 5 hours, were first 
demonstrated by Olefsky et al (1976). They concluded that the second peak 
was due to VLDL. Cohn et al. (1989) further tested the hypothesis that early 
peaks may represent TAG from the intestine whereas later peaks may 
represent TAG from the liver. They found that intestinal lipoproteins, as 
shown by the presence in plasma of both RP and apo B-48, made a 
significant contribution to both earlier and later peaks in postprandial TAG 
concentration. However, they took samples every 3 hours up to 15 hours 
and may therefore have been looking at different types of peaks compared 
to the present study.
The present study was designed to represent the normal pattern of meal 
intake in humans, i.e. breakfast, lunch and a main evening meal. The study 
by Cohn et al. (1989) and most of the other postprandial studies have been 
carried out in subjects following an overnight fast, or have taken samples 
only every few hours. In common with the present study, two groups
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(Olefsky etal., 1976; Chen et al., 1993;) who have taken hourly blood 
samples in the non-fasting state have both demonstrated two postprandial 
TAG peaks. Furthermore, Chen et al. (1993) found only a single CM-RP 
peak, but they did not discuss this finding. The present study was conducted 
overnight, but diurnal variation is an unlikely explanation of the results since 
the study of Chen etal. (1993) was conducted during the day. Williams etal. 
(1992) discussed the possibility that their early plasma TAG peak in 
non-fasted subjects could represent the late part of the lunch-time 
postprandial TAG response. This is unlikely to have been the reason in this 
study because the 0-3 hour CM-TAG and apo B-48 ADCs are much smaller 
than the 3-9 hour peaks.
Another interesting finding was that there was no significant difference 
between the apo B-48 AUC for the 0-3 hour peak, but the second peak was 
significantly smaller (p<0.05) following fish oil. This evidence, in conjunction 
with the absence of an early RP peak, suggests that the first peak may not be 
derived from the most recently consumed meal. The first peak could be 
derived from TAG or apo B-48 which had been stored in the enterocyte from 
the previous meal. Using CaCo-2 cells, a cell culture model of the small 
intestinal enterocyte, Murthy etal. (1992), proposed that there could be a 
preformed pool of apo B-48 and TAG in the intestine. Their findings have 
been summarised in Fig. 6.10. Interestingly, they found that EPA inhibits the 
formation of newly formed apo B-48, but has a neutral effect on the assembly 
and secretion of apo B-48 containing CM. They also found that EPA 
promotes the degradation of apo B mRNA. This was also found in 
hepatocytes of fish oil fed rats by Ribeiro etal. (1991). In the present study it 
would have taken a few hours for EPA from the fish oil test meal to enter the 
enterocyte and exert its inhibitory effect on apo B-48 synthesis. This could
207
Fig. 6.10 Model for enterocyte CM synthesis based on 
results of Murthy ef a/ (1992)
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The effects of the fatty acids described are in comparison to an albumin control. Both 
oleic acid (OA) and eicosapentaenoic acid (EPA) stimulated formation of triacylglycerol 
(TAG) from fatty acids (FA) and glycerol to form an intracellular pool of TAG 
(represented in box). OA had a neutral effect on apo B transcription whereas EPA 
inhibited transcription and promoted degradation of apo B mRNA. OA also inhibited 
degradation of newly synthesised apo B-48. EPA inhibited the formation of an 
intracellular storage pool of apo B-48 whilst OA had a neutral effect. EPA had a 
neutral effect on apo B-48 in the assembly and synthesis of chylomicrons (CM), but 
OA stimulated these processes. OA also stimulated the TAG assembly and secretion 
in CM formation whilst EPA had less of a stimulatory effect.
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help to explain why the TAG and apo B-48 total AUC for 3-9 hr was lower 
following the fish oil meal, compared to the mixed oil meal, but that the total 
AUC for 0-3 hours was not significantly different. On the other hand the RP 
data suggested that synthesis of CM was not inhibited by EPA.
Thus, cell and tissue culture along with this normal human subject study 
provide evidence that there is a pre-formed pool of apo B-48 and possibly of 
TAG in intestinal enterocytes. Murthy et al. (1992) described how the 
pre-formed apo B-48 is called upon during times of fatty acid influx. For 
normal absorption to occur, the cell must re-esterify fatty acids, assemble 
and package CM and secrete them into lymph. To synthesise a protein the 
size of apo B-48 each time an intestinal cell is exposed to a large influx of 
fatty acids would seem to be impractical and inefficient.
This study has shown that postprandial intestinal lipoprotein levels, as 
measured by apo B-48, can be lowered by a fish oil test meal. This could be 
due to increased elimination possibly by a mechanism involving LPL. 
Alternatively, it could be due to inhibitory effects on CM synthesis in the 
enterocyte. Clearly, further work is required to clarify the exact mechanism. 
In addition, major differences between the most specific marker for intestinal 
lipoproteins (apo B-48) and the most widely used marker (RP) have been 
demonstrated. The potential for modification of CM metabolism by diet was 
outlined in Chapter 1. In the present study apo B-48 measurements were 
the only analysis which showed a statistically significant effect of n-3 PU FA. 
Demacker etal. (1991) found that apo B-48 levels were significantly lower 
following an n-6 PUFA diet, although TRL-TAG was not different. However, 
there is a large amount of inter- and intra-assay variation associated with 
this apo B-48 assay (Section 5.3.9) which should be borne in mind when
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interpreting the results of the present study. Nevertheless, use of a specific 
antibody has demonstrated a previously undescribed early postprandial 
peak in apo B-48 and a possible physiological explanation has been 
proposed.
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CHAPTER SEVEN 
GENERAL DISCUSSION
CHD is one of the major causes of death in Westernised civilisations. 
Dietary therapy is the first line of treatment of high blood cholesterol, but 
most of the previous work has concentrated on effects of dietary fat on LDL 
metabolism. CM are the principal carriers of dietary lipid and their possible 
involvement in the pathogenesis of atherosclerosis was first postulated by 
Zilversmit in 1979. Since it takes about 6-8 hours for a mixed meal to be 
completely digested and absorbed, human subjects in Westernised 
countries spend most of their time in the postprandial state. The first stage of 
CM degradation takes place in contact with the vascular endothelium; 
therefore, following a meal the vascular endothelium is exposed to CM and 
CM remnants for long periods of time and it can be appreciated that CM 
have a major potential role to play in the development of atherosclerosis. 
Furthermore, the lipid composition of CM is directly related to the type of lipid 
in the diet. Since the lipid composition of CM can directly affect their 
metabolism (Section 1.5.1), a relationship between diet and the potential to 
develop atherosclerosis is apparent.
For a number of years high fasting TAG levels have been suspected as 
being a risk factor for CHD. However, statistical correlation had been difficult 
to demonstrate once HDL-cholesterol levels were taken into account. Over 
the past ten years a hypothesis has been developed by Patsch and 
co-workers (Miesenbock etal., 1993) which links elevated postprandial TAG 
levels, HDL and the incidence of CHD. This further emphasises the 
potentially large influence diet could have on the development of 
atherosclerosis.
It had been observed that Eskimos, who have high dietary intakes of fish 
oils, have a particularly low risk of developing CHD (Anonymous, 1983) and
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in recent years there has been much research into the effects of fish oils on 
lipid metabolism. Much of this research had concentrated on fasting TAG 
levels and cholesterol concentrations in LDL and HDL. Only two previous 
studies had specifically looked at the effects of n-3 PUFA on CM metabolism 
in healthy volunteers.
One of the troublesome features in studying CM metabolism has been the 
difficulty in distinguishing CM from VLDL. Measurement of other lipoprotein 
particles, such as HDL and LDL, is easier because a relatively good 
separation can be achieved by ultracentrifugation. This is not possible for 
CM because their density range overlaps with that of VLDL. A major step 
forward in this area was the discovery by Kane et a /(1980) that apo B exists 
in two forms: apo B-100, which is mainly associated with lipoprotein particles 
of endogenous origin and apo B-48 which is associated with particles of 
dietary origin. Apo B-48 appeared to represent a potential marker for CM 
since it seemed to be uniquely associated with these particles.
Measurement of apo B-48 has previously been achieved either by protein 
staining of SDS-polyacrylamide gels or by gas chromatography-mass 
spectrometry of apo B-48 labelled with a stable isotope of leucine. Both of 
these techniques require sample pre-treatment by overnight 
ultracentrifugation and the latter method uses equipment which is not 
routinely available in most laboratories. Immunoassay of apo B-48 offers a 
rapid and sensitive method for measuring large numbers of samples. 
However, prior to the present research there had been no previous report of 
a specific antibody to apo B-48. LDL particles, which possess only apo 
B-100, can be isolated simply by ultracentrifugation and commercially 
available antibodies to apo B-100 have been produced by injecting whole
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LDL particles. A similar approach could not be used with CM because they 
possess apolipoproteins A-l, A-ll, A-IV, C-l, C-ll, C-lll and E in addition to apo 
B-48. Furthermore, there was the major problem that apo B-48 is identical to 
the N-terminal 2152 amino acids of apo B-100. Therefore attempts at 
producing specific antisera by injecting isolated apo B-48 have resulted in 
antibodies which cross-reacted with apo B-100 (Hardman et al., 1987b). 
Even a small amount of cross-reactivity with apo B-100 is unacceptable 
because circulating plasma levels of apo B-100 are around 1000-fold higher 
than those of apo B-48.
The initial aim of this piece of research was to raise antibodies which were 
specific to apo B-48 (Chapter 3). The C-terminal of apo B-48 was identified 
as a potential region for discriminating between the two apo B polypeptides. 
This was for two main reasons:
1. The C-terminal amino acid residue of apo B-48 would be negatively 
charged, whereas the corresponding residue in apo B-100 would lie in the 
middle of a polypeptide and therefore be involved in a peptide bond.
2. The negative charge would increase the chances that this residue would 
be orientated towards the aqueous environment around the CM particle. 
This would be important when the antibody was used in an assay for CM 
apo B-48.
It had previously been reported (Palfreyman etal., 1984) that antibodies 
raised to C-terminal peptides were highly successful at recognising the 
parent protein. Two peptides, corresponding to the two C-terminal forms of 
apo B-48, were custom synthesised by a supplier. These were used to 
prepare peptide-conjugates and immunise rabbits following two different 
regimes. A screening ELISA was developed to monitor the antibody
213
response by individual rabbits. For the first immunising regime, the animals 
were boosted after only 6 weeks and this produced useful antisera within 
8 weeks of the priming injection. In the second regime the rabbits were 
boosted only after antibody concentrations had fallen to a steady level. The 
reason different regimes were used was that the first approach should have 
yielded antibodies relatively quickly, whilst the second approach should 
have produced much better quality antisera with high avidity and titre. 
Unfortunately, the animals did not respond to the boosts by the second 
method and this may have been because of degradation of the immunogen 
conjugates. This theory is supported by work of a co-investigator who has 
subsequently synthesised fresh conjugates and obtained antisera with titre 
values around 15-fold higher.
The specificity of the antisera was tested by SDS-PAGE followed by 
immunoblotting. A commercially available anti-total apo B antibody showed 
reactivity with both apo B-100 and apo B-48. Antibodies to the lle-peptide 
conjugate were specific only for apo B-48 found in lymph, whilst anti-Met 
peptide antibodies were specific only for apo B-48 found in serum. These 
findings were not unexpected because Chan (personal communication, 
1990) believed that "newly secreted human apo B-48 has lle-2152 as its 
C-terminus which is cleaved inside the vascular compartment to leave Met- 
2151 as the new C-terminal residue".
In contrast, later work from Chapter 5 showed that the anti-lie peptide 
antibody reacted strongly with plasma-enriched CM samples on an 
immunoblot. Furthermore, reactivity of the anti-Met peptide antibodies with 
the same samples could not be demonstrated. This presented an 
inconsistency which, at first, was difficult to explain. A co-investigator
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performed a series of experiments to replicate the conditions of CM-enriched 
fraction preparation used in Chapter 3 and Chapter 5. Specifically, the 
effects of the timing of preservative addition, the use of either plasma or 
serum and the length of ultracentrifugation time were investigated. The 
results of these studies were inconclusive and did not explain the anomaly. 
The most plausible explanation was that the experiments in Chapter 3 were 
performed using CM-enriched samples from a hyperlipidaemic patient 
whereas those in Chapter 5 were from healthy subjects. If the patient had 
delayed clearance of CM from her circulation this may have allowed an 
increased proportion of apo B-48 to be processed from lle-2152 to Met-2151 
by carboxypeptidase-A. This enzyme is produced by the pancreas and is 
not normally present at detectable levels in the serum of normal individuals, 
but levels are dramatically increased in patients suffering from pancreatitis 
(Peterson et a!., 1982). Pancreatitis is not uncommon in hyperlipidaemic 
subjects and this may explain why the CM-enriched serum used in 
Chapter 3 reacted most with anti-Met peptide antibodies.
This still leaves the apparent reactivity of the anti-Met antibody with the 
postprandial CM-enriched plasma samples described in Chapter 3 
unexplained. This might be explained by the fact that the samples used in 
Chapter 3 were relatively enriched in apo B-48, compared to those used in 
Chapter 5. This was because of a longer ultracentrifugation time 
(1.4 x 108 g.min versus 2.1 x 106 g.min) and that more protein was loaded 
into each lane of the gel (625 pg versus 312.5 pg). Thus, if the gel in 
Chapter 3 had been immunoblotted with anti-lie antibodies a reaction might 
very well have been observed. However, this was not done at the time 
because earlier experiments had suggested that serum did not contain any
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of the lle-terminus apo B-48. Unfortunately the samples are no longer 
available to confirm this theory.
The careful choice of peptides, carrier proteins and method of conjugation 
was justified because of the excellent specificity of the final antisera 
obtained. Recent work by another investigator, as part of her final year BSc. 
project, has been done with the latest boost high titre antisera and the 
reagent excess format ELISA used in Chapter 4. It was demonstrated that 
the anti-Met antibody reacted with the Met-peptide conjugate by 94 %, 
compared to 66 % for the lle-peptide conjugate and that the anti-lie antibody 
reacted with the lle-peptide conjugate by 94 % compared to 13 % for the 
Met-peptide conjugate. Met and lie peptides with a C-terminal amide, 
instead of a carboxyl group, were also tested for cross-reactivity. The 
anti-Met antiserum cross-reacted by only 11 % with the Met-amide peptide 
and the anti-lie antiserum cross-reacted by only 16 % with its amide peptide. 
This work has clearly emphasised the importance of the negatively charged 
C-terminal amino acid residue.
The second aim was to develop an immunoassay for apo B-48. Usually the 
major hurdle in immunoassay development is obtaining good antisera in the 
first place. However, for apo B-48, development of the assay system 
provided the greatest challenge. ELISA assays have been developed for 
most other apolipoproteins (Bury & Rosseneu, 1988), but a number of 
characteristics made development of an apo B-48 assay particularly difficult:
1 • Lack of a good negative control. It was often difficult to assess why a 
specific signal was not being obtained. Samples with very low or zero levels 
of apo B-48 would have helped in this respect. Now much larger amounts of
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the antisera have been obtained by a co-investigator, a negative control of 
apo B-48 stripped samples could be produced by using affinity 
chromatography.
2. Low relative plasma concentration of apo B-48 to apo B-100. This meant 
that even slight cross-reactivity of anti-apo B-48 antisera would have 
resulted in false positive values.
3. The monospecific nature of the anti-apo B-48 antibody. This precluded 
the use of the anti-apo B-48 antibody for both capture and detection in the 
same two-site format ELISA.
4. Shortage of antisera. It was apparent that for the two-site assays it was 
important to have a high concentration of coating antibody to reduce 
non-specific binding. This was often not achieved and the recent production 
of very high titre antisera by co-workers should greatly aid ELISA 
development.
5. Large size and hydrophobic nature of apo B. This generally made assay 
development difficult and probably contributed to the non-specific binding 
which was frequently encountered.
6. Lack of a standard apo B-48 assay. This hindered progress because it 
was often difficult to make comparisons with a second reliable assay.
7. Lack of pure apo B-48 for use as a standard. Until fairly recently the 
plasma concentration has only been roughly estimated.
A critical part of any immunoassay is recognition of an epitope by the 
antibody. This was not demonstrated conclusively for any of the assay 
formats used. However, the reagent excess format does offer a good way of 
testing epitope accessibility. Various pre-treatments and optimisation of 
dilutions could be tried using this format. In parallel, SDS-PAGE and 
immunoblotting could be used for comparative purposes. A two-site ELISA
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still probably offers the best theoretical way of measuring apo B-48 (Bury & 
Rosseneu, 1988). With the improvements mentioned above and the 
acquisition of an anti-apo B antibody specific to the N-terminal end of apo 
B-100, this assay format could be reassessed.
Some of the results of postprandial samples using the slot blot indicated an 
apparent double peak in apo B-48. This was unexpected and accredited to 
assay development problems. However, with the benefit of hindsight of the 
results obtained in Chapter 6, it can be appreciated that some of the slot blot 
profiles of postprandial samples may have been quite accurate. It should 
also be pointed out that the slot blot assay development was performed 
using anti-Met antibodies. Future investigation into slot blot assays might 
prove fruitful, since these assays could be employed as rapid qualitative 
assays to monitor ELISA development.
The SDS-PAGE and immunoblotting method developed in Chapter 5 
overcame the problems mentioned above. A number of factors, including, 
protein load, exposure time to the photographic film and buffers used in the 
electrotransfer, were optimised. This method was extremely successful in 
demonstrating semi-quantitative changes in apo B-48 concentrations, as 
demonstrated in Chapter 6. Overall a greater number of samples could be 
measured using this assay compared to the published method of 
Coomassie Blue staining of SDS-polyacrylamide gels. This was because 
preparation of the CM-enriched samples required ultracentrifugation for 
30 minutes, rather than 16 hours used by other investigators. However, 
there are still some disadvantages with this assay and further improvements 
could be made:
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With this assay it was still not possible to process large numbers of samples 
in a reasonable time. In addition the assay CVs were very high (28 % for 
intra-assay and 22 % for inter-assay). This was probably because of the 
large number of individual steps in the assay, each of which could introduce 
variation. Another disadvantage was that the band intensity changed 
dramatically with small changes in apo B-48 concentration resulting in a 
standard curve which had a small linear range. Consequently, many of the 
subject samples measured in Chapter 6 were outside the linear range of the 
standard curve. It was necessary during development of the SDS-PAGE 
immunoblot method to ensure adequate sensitivity. Unfortunately the 
amplification by the secondary and tertiary antibodies probably contributed 
to the steep curve. Moreover, the final assay is now probably too sensitive 
since an exposure time of only 7 seconds for the ECL blot is very difficult to 
reproduce consistently. Replacement of the secondary and tertiary 
antibodies with a single incubation of HRP-labelled anti-apo B-48 might 
improve this assay. This could potentially reduce the total assay time, 
improve the inter- and intra-assay variation and increase the linear range of 
detection. A further improvement would be to use a swing-out rotor for 
ultracentrifugation rather than the fixed-angle type which is currently used. 
This would result in a CM-enriched sample which had less contamination 
from albumin and other non-CM proteins. The reduction in contaminating 
proteins would also aid ELISA development.
The majority of previous studies on CM had used the RP assay. However, 
this assay involves pre-treatment by organic extraction and has recently 
been criticised on physiological grounds by Krasinski ei al. (1990). One of 
the aims of the present study was to compare the RP and apo B-48 assay in 
the measurement of CM metabolism. This was accomplished by measuring
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CM-enriched samples from subjects following test meals which differed in 
their fatty acid composition.
There was a trend towards a lower total AUC for both apo B-48 and TAG 
following the fish oil meal compared to the mixed oil test meal. For RP, there 
was a trend towards a higher total AUC following the fish oil test meal. The 
lower levels of apo B-48 were probably due to increased elimination, rather 
than decreased absorption. This was because RP, which is a marker for 
newly synthesised CM, had higher levels for the first 7 hr following the fish 
oil test meal. In addition post-heparin LPL levels were higher following the 
fish oil meal. This would support evidence for an increase in the rate of 
lipolysis of n-3 PUFA enriched CM.
Perhaps one of the most intriguing findings from this study was the 
appearance of two postprandial peaks for TAG and apo B-48, but only one 
for RP. More than one postprandial peak in TAG had been observed 
previously (Cohn etal., 1989), but few studies had demonstrated one as 
early as 1 hr. This was probably because the large majority of studies had 
either been performed following an overnight fast, used meals that were 
predominantly liquid, or had not taken samples frequently enough. The apo 
B-48 results in the present study suggested that the 1 hr peak was of 
intestinal origin. Furthermore, the absence of an early peak in RP may mean 
that the origin of the first peak is not from the most recently ingested meal. 
Additional evidence for this phenomenon from cell culture work was 
discussed in Chapter 5. Clearly more experimental work is needed to 
confirm this and several different lines of work could be followed up. Firstly, 
volunteers could be given the same total fat load on successive occasions: 
the first time as a mixed meal following an overnight fast, the second time as
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a mixed meal in the non-fasting state and a third time in the form of a liquid 
in the non-fasting state. This would confirm whether the meal composition or 
preprandial state was influential. Secondly, subjects in the non-fasting state 
could be given the same mixed meal containing RP on 2 successive 
occasions. If the hypothesis was correct one would expect to see a single 
late RP peak after the first meal and both an early and a late RP peak after 
the second meal. After each meal there would be two apo B-48 peaks. A 
third meal, without RP, could then be given. After this meal there should only 
be a single early RP peak, but still two apo B-48 peaks. Obviously such an 
experiment would require very good compliance from the volunteers. A 
further test could be to give volunteers two meals with different fatty acid 
compositions. Analysis of TAG in CM-enriched samples would be expected 
to show a similar fatty acid composition for the second peak from the first 
meal with the first peak from the second meal. Furthermore, these should 
differ in composition to the second peak from the second meal.
Some of the widely held beliefs about CM and apo B-48 do not appear to 
have been properly validated. The anti-apo B-48 antibody could be used to 
answer some of these important questions:
1. Do CM-remnants actually enter the endothelium of blood vessels and 
thereby contribute to atherosclerosis? The possession of a specific antibody 
to apo B-48 would allow this hypothesis to be confirmed. This could be 
done by staining the atherosclerotic tissue with a suitably labelled form of 
anti-apo B-48, or if necessary by using an amplification system. Such a 
method has been described by Pitas & Mahley (1992) for the staining of 
other apolipoproteins in tissues. An alternative approach could be to extract 
apo B-48 and detect it by using the SDS-PAGE immunoblotting method.
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Linden et al., (1986) have described a similar method for detection of apo 
B-100 in arterial tissue. For both these methods non-diseased tissue 
(obtained surgically from vascular reconstruction operations) in conjunction 
with pre-immunisation normal rabbit antiserum could be used as negative 
controls.
2. Does the number of CM rise after a meal or do they accommodate the 
increased lipid load merely by increasing in size? If CM only increase in 
size there might be an apparent increase in number as a result of their 
propensity to float during ultracentrifugation. The assumption that the 
number of CM increases after a meal is based on early work by Gage & Fish 
(1924) who used a dark field microscope to count CM in whole blood at 
half-hourly intervals following meals of different composition. Recent work 
by Hayashi et al. (1990), using rats infused with a lipid emulsion, 
demonstrated that the size of CM was increased, but the number of particles 
was unaltered. In light of these findings and with the benefit of the anti-apo 
B-48 antibody and modern technology, it is important to reassess the work of 
Gage & Fish.
3. Does each CM particle contain only a single molecule of apo B-48? This 
assumption, which is often stated by other investigators, is based on work by 
Elovson et al. (1988). However this was conducted by measurement of total 
apo B on rat VLDL. Furthermore, earlier work by Bhattacharya & Redgrave 
(1981) had proposed that each rat CM contained two apo B-48 molecules. 
Elovson et al. (1988) concluded that the number of apo B-48 molecules per 
CM particle needs to be examined by a more direct method. This could be 
achieved by electron microscopy of CM particles with the anti-apo B-48 
antibody and a suitable gold-labelled detection system. Immunoelectron
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microscopy of apo B-100 on LDL particles has previously been described by 
Chatterton ef a /(1991).
The initial aim of producing an antibody specific for apo B-48 was achieved. 
The second aim of using the antibody in an immunoassay was not totally 
successful. Suggestions of how this could be accomplished have been 
given for future work. A semi-quantitative assay for apo B-48 was used in a 
postprandial study. Results for apo B-48 compared well with TAG, but there 
were significant differences with RP.
Lipoprotein metabolism is a closely integrated multi-component system 
which makes it extremely difficult for the biochemist to study. To obtain a 
more complete understanding of the mechanisms involved an array of 
measurements needs to be made on more extensively sub-fractionated 
samples. Unfortunately such work is difficult to carry out with large numbers 
of samples. Therefore the best way forward would seem to lie in much 
greater resources and collaboration between centres of excellence.
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APPENDICES
Appendix I
Parameter settings on the densitometric scanner
See Chapter 2 for details
P A R A M E T E R  R E P O R T -  Shimadzu CS-9001PC
Meth Name: 
Operator :
PPB48.2 
ANDY
Date: 3/2/93
Photo Mode Transmission Scan Type Zig Zag
Scan Mode Normal
Linear izer Off ZZ Width 9
Lamp Mode Visible BC Smooth 8
Y Resolutn 0.20 Zero Mode Off
Wave 1ength Sett ings
Wave Mode : S i ng1e
Wave : 1 Y Position: 0.0mm Sample Wvlen: 550 Onm
Peak Detection Parameters
Y Posn Sens Drift Line Min Width Min Area
5.0 100.000 0.500 2.000 1000.000
Appendix H  a
Example of the calculation for conjugation of De-peptide to ovalbumin using
MCS
1. Addition of MCS to ovalbumin
18 mg ovalbumin = 18 x 10 "3 = 4.0 x 10 mois 
45000
A 30 mol excess of MCS is 30 x 4.0 x 10 -? = 1.20 x 10"5 mois
The mass of MCS added was 1.20 x 10*5 x 308 = 3.70 x 10"3 g or 3.7 mg
2. Estimation of MCS coupled to ovalbumin
The mean decrease in absorbance was 0.119. This represents a reduction in the 
amount of DTNB which has reacted with mercaptoethanol. Less mercaptoethanol has 
reacted with DTNB because some of it has reacted with MCS bound to ovalbumin. 
Therefore, the reduction in absorbance is an indirect measure of the amount of MCS 
bound to ovalbumin.
Using Beer-Lambert Law for cells with a 1 cm pathlength: 
concentration (mol /  L) = absorbance /  molar absorption coefficient 
c = A A /  8
c = 0.119 = 8.41 x 10-6 m ol/L  
14150
In a cuvette containing 1.12 mL, there was
8.41 x 10~6 x 1.12 = 9.42 x 10"9 mois of MCS bound 
1000
II
This was from 10 ]xL of the original ovalbumin MCS mixture which had a total 
volume of 3.2 mL from the three fractions which were pooled. So the actual amount 
of MCS bound was
9.42 x 10-9 x 3200 = 3.01 x 10"6 mois MCS 
10
3. Ratio of MCS coupled to ovalbumin
It was estimated that 65 % of the initial amount of ovalbumin is collected in the three 
fractions. i.e.
4.0 x 10 "7 x 0.65 = 2.60 x 10"7 mois ovalbumin 
Ratio MCS : ovalbumin = 3.01 x 10"6 : 2.60 x 10"7 
=  12 : 1
4. Amount of Ile-peptide added
There were 3.01 x 10'6 mois of MCS originally bound to ovalbumin in a volume of 
3200 |iL, however, 140 pL were removed for spectrophotometry.
Mois of MCS bound to ovalbumin = 3200-140 x 3.01 x 10"6 = 2.88 x 10~6 mois
3200
A 5 molar excess of Ile-peptide was added for each MCS already coupled. i.e.
2.88 x 10'6 x 5 = 1.44 x 10'5 mois of Ile-peptide 
The molecular weight of the Ile-peptide is 870.
Mass of Ile-peptide added was 1.44 x 10"  ^x 870 = 0.0125 g or 12.5 mg
5. Detection of the amount of Ile-peptide coupled
MCS bound to ovalbumin, which has subsequently been occupied by Ile-peptide 
cannot react with mercaptoethanol. This allows more mercaptoethanol to react with 
DTNB. The difference in absorbance was 0.009 and this reflects the amount of MCS 
bound to ovalbumin, but which has not subsequently been conjugated to Ile-peptide.
c = A A /  8
c = 0.009 = 6.36 x 10-7 mol /  L 
14150
In cuvette containing 1.12 mL there was
6.36 x 10-7 x 1.12 = 7.12 x lO"10 mois 
1000
After removal of 140 pL ovalbumin-MCS for spectrophotometry and addition of 440 
|iL of Ile-peptide solution the volume containing ovalbumin-MCS-peptide was 3500 
pL.
Since the difference in absorbance was from 10 pL of ovalbumin-MCS-peptide the 
actual amount of MCS unoccupied by Ile-peptide is
7.12 x IQ-IO x 3500 = 2.49 x 10"7 mois 
10
Amount of MCS occupied by Ile-peptide = total MCS bound - MCS unoccupied by 
Ile-peptide
= 2.88 x 10"6 - 2.49 x 10"7 = 2.63 x 10"6 mois 
Therefore, the amount of Ile-peptide coupled was 2.63 x 10"6 mois.
IV
6. The final molar ratio
After two spectrophotometric tests the remaining mois of ovalbumin was
3200- ( 2 x  1401 x 2.60 x lO"7 = 2.37 x 10"7 mois 
3200
After the second spectrophotometric test the remaining amount of MCS bound to 
ovalbumin was
3060 - 140 x 2.88 x 10“6 = 2.75 x lO'6 mois 
3060
After the second spectrophotometric test the remaining amount of Ile-peptide bound 
to MCS was
3060 - 140 x 2.63 x lO"6 = 2.51 x 10"6 mois 
3060
Molar ratio of ovalbumin : MCS : Ile-peptide
2.37 x 10-7 : 2.75 x 10"6 : 2.51 x 10"6 mois 
1 :12:11
V
Appendix I I  b
Example of the calculation for conjugation of Met-peptide to bovine serum
albumin using SPDP
1. Addition of SPDP to BSA
10.8 mg BSA = 10.8 x 10 ~3 = 1.61 x 10 mois 
67000
A 30 mol excess of SPDP is 30 x 1.61 x 10 "7 = 4.83 x 10"6 mois 
The mass of SPDP was 4.83 x 10"6 x 312 = 1.51 x 10-3 g or 1.5 mg
2. Estimation of SPDP coupled to BSA
Mercaptoethanol reacts with SPDP bound to BSA and liberates 2-thiopyridone. The 
absorbance from 2-thiopyridone was 0.578. This is directly proportional to the 
thiopyridol groups introduced into the BSA.
c = A A /  e
c = 0.578 = 7.23 x 10"5 mol /  L 
8000
In a cuvette containing ImL, there was
7.23 x IQ-5 = 7.23 x 10"8 mois of SPDP bound 
1000
This was from 200 |iL of the original BSA-SPDP mixture which had a total volume 
of 3 mL from the three fractions which were pooled. So the actual amount of SPDP 
bound was
7.23 x 10-8 x 3000 = 1.08 x 10"6 mois SPDP 
200
VI
3. Ratio of SPDP coupled to BSA
It was estimated that 65 % of the initial amount of BSA is collected in the three 
fractions. i.e.
1.61 x 10 "7 x 0.65 = 1.05 x 10~7 mois BSA 
Ratio SPDP : BSA = 1.08 x lO’6 : 1.05 x 10-7 
= 10:1
4. Amount of Met-peptide added
Only 0.6 mL of the original BSA-SPDP was used for conjugation to the Met-peptide. 
Therefore the amount of SPDP conjugated to BSA was
0.6 x 1.08 x 10"6 = 2.16 x 10"7 mois 
3
A 5 molar excess of Met-peptide was added for each SPDP already coupled. i.e.
2.16 x lO-7 x 5 = 1.08 x 10"6 mois of Met-peptide 
The molecular weight of the Met-peptide is 885.
Mass of Met-peptide added was 1.08 x 10"6 x 885 = 9.56 x 10"4 g or 956 jig
5. Detection of the amount of Met-peptide coupled
When Met-peptide conjugates to SPDP which is already bound to BSA, 2- 
thiopyridone is liberated. Thus the absorbance due to 2-thiopyridone is a direct 
measure of Met-peptide conjugated to SPDP.
A 1:10 dilution of BSA-SPDP-Met-peptide gave an absorbance of 0.200.
VII
c = A A / e
c = 0.200 = 2.50 x 10~5 mol /  L 
8000
Li cuvette containing ImL there was
2.50 x 10~5 = 2.50 x 10"^  mois 
1000
Correcting for the 1: 10 dilution gives
2.50 x 10-7 mois of Met-peptide bound as measured in cuvette
After removal of 100 |iL BSA-SPDP for spectrophotometry and addition of 255 jliL 
of Met-peptide solution had 755 pL of BS A-SPDP-peptide.
The amount of Met-peptide actually bound in the total BSA-SPDP-Met-peptide was
2.50 x 1Q-7 x 755 = 1.89 x 10"7 mois 
1000
6. The final molar ratio
After the second spectrophotometric test the remaining mois of BSA were
0.6 x 755-100 x 1.05 x 10"7 = 1.82 x 10"8 mois 
3 755
After the second spectrophotometric test the remaining amount of SPDP bound to 
BSA was
755-100x2.16 x 10"7 = 1.87 x 10-7 mois 
755
VIII
After the second spectrophotometric test the remaining amount of Met-peptide bound 
to SPDP was
755-100 x 1.89 x 10~7 = 1.64 x 10"7 mois 
755
Molar ratio of BSA : SPDP : Met-peptide
1.82 x 10-8 :1.87 x 10-7 : 1.64 x 10-7 
1:10  : 9
IX
Legend for Appendix III
The numbers across the top of each table refer to individual subject values. 
The time of samples is shown down the left-hand side. Missing values are 
represented by a blank space. The units are as follows:
III a & b Triacylglycerol: mmoL/L
III c & d Retinyl palmitate: pg/mL
III e & f Apo B-48: band intensity is in arbitrary units
III g & h Apo B-48: values are a percentage of a standard CM-enriched
plasma sample 
III i & j Total apo B: mg/dL
III k LPL: nmol oleate released/min/mL plasma at 37 °C 
Further details can be found in Chapter 6
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Table III a Triacylglycerol measured in CM-enriched plasma samples
following a mixed oil test meal
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Table III b Triacylglycerol measured in CM-enriched plasma samples
following a fish oil test meal
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Table III c Retinyl palmitate measured in CM-enriched plasma samples
following a mixed oil test meal
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Table III d Retinyl palmitate measured in CM-enriched plasma samples
following a fish oil test meal
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Table III e Apo B-48 band intensity measured in CM-enriched plasma
samples following a mixed oil test meal
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Table III f Apo B-48 band intensity measured in CM-enriched plasma
samples following a fish oil test meal
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Table III g Apo B-48(as a % of a standard)measured in CM-enriched
plasma samples following a mixed oil test meal
T- 05 i - ■cl- ■cj" 05 N 05 00 00 O 05
SD
o
C M
N o
C O
l O
C M
05
t o
O
Tf
C O
Tl"
O
C D N
05
C D
C O
C O 00 N
C O 1- 05 C O C M C M C O N t o ' t N
C D i n 05 N N C M C O 00
C M C M
C D
C M
T t
C M C M
C D C M O L O t o T - t o 05 05 05 C O
i f i
O
C M C M
N
C M
C O
C M
c t
C D
C M
' d -
05
C O
O
C D
O05 05 00N O05 N
1
C M o
o
O
d
O
d 0.
4
0.
6 SO
1.
7
7.
3
27
.8 5.
4
5.
5 00
C M
O N C D 05 C O o t o 00 05 05 C M C O
§
O O C O O t o N 05
C M
l O
C O
o
C M
C M O C O
H
L O C O C O 05 C O t o C D 05 05 T- C O C M
NI
NE
C O
C O
C M-cl- Ot o C D 05 05 N t o C MT f 00C O 00t o O 00
O C O C O t o t o C D N C D 05 t o i - 00 05
EI
GH
T "M- 00 00N C D t o00
C D
C M
C M
T f
0505 t oC O
C M
T l -
I O
C M
t o
C M
t o
t o
C M
C O
t o
C M
SE
VE
N C O C O 05 C O 05 C O C M i - 00 05 C O 05
C M
C M
C O00
05
C M
Is'-
00
05
C O
05
C M C O
c o
C M
t o
C D
05
00 00C O
O
N C D
C D C O O i - N i - TT t o O O C D 05 C O
SI
X
C M C O C M C M
C M
T f I O
C M
t T
C M
O
■M"
C O05 OTÎ- C Mh - t ot o OO
N C D C D T - t o M - 00 O 05 00 05 00
FI
VE C D
L O
00
C M C M C M
C D
O
T t
C D
C M
t o
C O
O
O
C O
t o
C O
t o
h ~
t o
C O
t o
C O t f r C D C O 05 C O N T f C D N N C O
FO
UR C OC O t o" d " t oT l - t oN t o L OO N05 o T t
C M
C O
C D
T to
C M
0005 t oIs'.
TH
RE
E C M C O t O C O C O O t o t o t o C O i - O 00o O t oN C M 00 N ■M" C D 00Tf C O C MC M
05 C O t o T - T - C O O T f C O N o O O
TW
O C M C M Tl- N
C M
■^f
C M
NN 05r- C ON C DTT Tt t o
C O N I O 05 LO O t o C M 05 05 C O
O
NE C M
C D
C M
C ON C OC O C MN
O
C D
C O
t o C D
05N C DN 05 NN
TI
M
E fa
s
t
-0
.1
7 O
0.
5 C M C O T f LO C D N 00 05
XVII
Table III h Apo B-48(as a % of a standard)measured in CM-enriched
plasma samples following a fish oil test meal
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Table III i Total apo B measured in serum samples following a mixed oil
test meal
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Table III j Total apo B measured in serum samples following a fish oil
test meal
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Table III k Post-heparin LPL activity measured after a mixed oil and a 
fish oil test meal
Subject Mixed oil Fish oil
One
Two 221.1 220 .9
Three 123.5 186.3
Four 214.1
Five 212 .0 274.1
Six 164.6 215 .0
Seven 136.6 216 .5
Eight 145.9 265.1
Nine 161.1 222 .8
Ten 142.5 146.8
Eleven 148.8 273 .4
Mean 161.8 223 .5
SEM 11.1 12.6
SD 33.4 39 .8
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CELL-FREE SYNTHESIS OF GLYCOLIPID CANDIDATE PRECURSOR(S) FOR 
GLYCOSYL-PHOSPHATIDYLINOSITOL ANCHORS OF TOXOPLASMA GONDII 
SURFACE PROTEINS.
STANISLAS TOMAVO*, JEAN-FRANÇOIS DUBREMETZ# , and RALPH T. 
SCHWARZ*
(*) Med. Zentrum fiir Hygiene, Philipps-Universitât Marburg, D-3550 Marburg, Germany. 
(#) U.42 INSERM, 59650 Villeneuve d’Ascq, France.
The protozoan Toxoplasma gondii (T. gondii) is an intracellular parasite responsible for 
toxoplasmosis in humans and warm-blooded vertebrates. The pellicle of the tachyzoite 
(which is the invasive stage) has four major surface proteins of 43, 35, 30, and 22 kDa. We 
have previously shown that they are anchored to the membrane via glycosyl- 
phosphatidylinositols (GPIs) [1], Evidence for a GPI-anchor linked to the 30 kDa protein was 
also provided independently [2], In addition, we have recently identified a fifth surface 
protein (23 kDa) which is also GPI-anchored (Biochemistry Hoppe Seyler, in press). In this 
study, we report on the in vitro biosynthesis and analysis of glycolipid(s) of T. gondii which 
might be involved in the biosynthesis of the GPI membrane anchors.
T. gondii tachyzoites, isolated and purified from infected Vero cells were incubated in 
DMEM (Gibco) supplemented with 2% fetal calf scrum and 10 gg/ml tunicamycin 
(Calbiochem). After two hours at 37°C, parasites were hypotonically lysed using a 
modification of the method described by Masterson el al. [3], Tachyzoites (5.10 cells/ml) 
were resuspended in 0.1 mM TLCK, 1 yg/ml of leupcptin and sonification (Branson 3200,47 
kHz, 2 min) was followed by 50 strokes in a Douncc homogenizer. An equal volume of 100 
mM Na-Hepes (pH 7.4), 50 mM KCI, 10 mM MgCI ,^ 0.1 mM TLCK, 1 jrg/ml leupeptin, 20% 
glycerol was added to the parasite lysate. This lysate was used directly for radiolabelling 
experiments described below or was frozen at -70°C The frozen lysate was thawed and 
washed (three times) with 50 mM Na-Hepes (pH 7.4), 25 mM KCI, 5 mM MgCl^, 0.1 mM 
TLCK, 0.1 /tg/ml leupeptin. After centrifugation (Beckman J21; 10000 rpm, 30 min: 4°C), the 
pellet was resuspended in the incubation mixture: washing buffer supplemented with 5 mM 
MnCly 0.2 tig/ml tunicamycin, 1 mM ATP, 1 mM CoA, and 2 frCi nucleotide(3H)-!abelled 
nucleotide-sugars (UDP-(6-3H)G1cNAc (18.9 Ci/mmol, New England Nuclear) or GDP-(3,4- 
3H)Man (15.1 Ci/mmol, New England Nuclear). Assays were supplemented with 1 mM 
GDP-mannose for experiments involving UDP-(3H)G1cNAc or with 1 mM UDP-GlcNAc for 
experiments involving GDP-(3H)Man. Incubation was for 30 min or 2 hours at 37°C. 
Glycolipids were extracted twice with 1 ml chloroform/methanol (CM, 2:1) followed by 
chloroform/methanol/water (CMW, 10:10:3). The CM-extracted lipids were pooled and 
subjected to repeated Folch washing. The CMW-extracted lipids were dried and partitioned 
between water and water-saturated n-butanol. The Folch washed CM-extracts 
were analysed on silica 60 plates (Merck) using chloroform/methanol/acetic acid/water 
(25:15:4:2) and the n-butanol phase was spotted on silica 50 000 HPTLC (Merck) and 
developed with chloroform/methanol/0.2% KCI (10:10:3). The plates were scanned for 
radioactivity using a Berthold LB 2842 automatic scanner.
The CM-extracted two major glycolipid species designated glycolipids TV and V (R^ values 
0_5 and 056) labelled by UDP-vH)GlcNAc in the cell-free system were identified as GlcN- 
PI and GlcNAc-PI respectively. These glycolipids comigrated on TLC with authentic 
trypanosome GlcN-PI and GlcNAc-PI [3,6,7], Additional evidence that the glycolipid V was 
GlcN-PI is given by its sensitivity to nitrous acid whereas the glycolipid IV was nitrous acid 
resistant. The resulting product from acid hydrolysis (6N HQ, 100°C, 3,5 h) of TLC-purified 
GlcN-PI ( 1000 cpm) comigrates on "High Performance Anion Exchange Chromatography* 
(HPAEC, Dioncx Sunnyvale, CA, USA) with a glucosamine standard. Recovery of 
radioctivity after HPAEC was approximatively 95%. In addition, the sensitivity of the 
glycolipid V to PIPLC suggests that it might be the glycolipid intermediate for the 
biosynthesis of GPIs shown in Figure 1-G Three additional more polar glycolipids designated 
glycolipids I, II, and III with Rf values of 0.05, 0.13, and 0.30 were also found in the UDP- 
( H)GlcNAc labelled CM-extract. These glycolipids can also be labelled with GDP- 
(3H)Man. To etablish the GPI nature of these glycolipids, we have tested their susceptibility 
to PIPLC, PLD, PLA^, HN02 and NaOH. The results are summarized in Table l  a and 
indicate by using radiolabelled sugar nucleotides as substrates we can identify several CM- 
extractable GPI species which might be intermediates in the biosynthesis of the butanol 
extractable GPIs described in Fig. 1-C. In addition to the GPI species found in the CM- 
extract, this cell-free system synthesized do!ichol?P-Man (Fig.l-B, glycolipid VI, Rj. 0.84). 
Consistent with glycolipid VI being Dol?P-Man is the fact that mild acid hydrolysis (2M 
HQ/n-propanol, 1:1, v/v 50°C, 15 min) released 85% of the radioactivity as ( H)Man 
(identified by HPAEC and TLC cellulose. Glycolipid VI comigrate with authentic DolP-Man 
from trypanosomes.
Analysis of the butanol-phase showed four glycolipids with Rj. values of 0.45, 0.65, 0.75, and
0.85 synthesized by the T. gondii cell-free system (Fig.l-C). These cell-free glycolipids were 
labelled with both (3H)GlcNAc and (3H)Man. When the living parasites were labelled with 
(3H)G1cNH2 or (3H)PaImitic acid, four major glycolipids with Rj. values of 0.48, 0.65, 0.75, 
and 0.86, designated A, B, C, and D were identified (data not shown). Solely based on the Rj. 
values, the four major glycolipids produced in the cell-free system were therefore designated 
A’, B \ C , D \ Using chemical methods and enzymatic treatments as described above, they 
were shown to be GPIs (Table 1-b). The PLA2 treatment of the butanol-extractable 
glycolipids synthesized in vitro resulted in the disappearance of two glycolipids (B’ and D ) 
and in an increase in the radioactivity of the two other glycolipids (A’ and C ) suggesting 
them to be lyso-glycolipids. The occurence of lyso-species in the cell-free system not found in 
vivo might be due to the activation of non specific phospholipase. Alternatively, fatty acid
Table 1 C h a ra c te r is a tio n  o f  G y c o fp id s  syn th e s iz e d  In  th e
e) CU extract
Oycdîptdl
R M ™|U "
Extant o f lobdGng
(3 H  JCtcWe (3 H  )Uan
SenBlwiV lo3 
PFLC PIO P U j
t OJOS 1050 3436 - + ~
1 0.13 5750 17130 + * *
X 0 30 - 2800 - NT NT
m 0 30 1610 4850 - + -
IV 0 30 6640 - m NT NT
V 036 73380 - + NT NT
Y 039 - 3233 - NT NT
M (Ool TP-Uan) 034 ~ 15675
b) Bulonol extract
Oycoltpïd^ R r-vq lu u Extent o f labeCnfl 
( 3 h  )C lct*£n(3 H  )Uon
SenetinV 1° 
PFIC  PID Pl>2
A*. 0.45 789 2657 + * -
0JS5 715 2859 *
e OJS 807 4237
0* 0JBB 357 2937 * * *
SwecepUbZity la*
W O l NoCH
Suaceptibi&ty I» 
NaOH
Table 1:
1 and 2: Glycolipids were labelled with 2 p d  UDP-^HjGlcNAc or GDP-^HjMan in the 
cell-free system (5.10® Toxoplasma equivalents/assay); TLC radiochromatograms were 
shown in Fig. 1-A, B, and G
3 and 4: For enzymatic or chemical analysis the CM- or butanol-extractable glycolipids were 
dried and subjected to the treatments. Qeavage was assessed by scintillation counting and by 
TLC as described in the text. NT: not tested; ND: not determined.
remodelling which was described in the African trypanosome [8] might also be operating in 
T. gondii but does not go to completion in vitro resulting in the accumulation of lyso- 
intermediates. A similar observation was described by Masterson et aL [8] for the 
trypanosome GPI biosynthesis. We suggest that one of the four major glycolipids found in 
the butanol-phase is the GPI precursor of T. gondii surface proteins. We have also used the 
same extraction method previously described for the glycolipid precursor [3,7] of the VSG of 
African trypanosomes. However, the possibility exists that some or all of the glycolipids arc 
precursors of a low molecular weight antigen ("4.6 kDa") which we have recently identified as 
a glycolipid of the tachyzoite membrane anchored via GPI [9, StriepemB., Diploma thesis, 
Marburg 1991). The later "4.6 kDa* component of T. gondii could be related to the 
lipophosphoglycan and glycoinositol-phospholipids found in Leishmania [10].
B
j j-A -A
g
e
0
Fig 1: Thin layer radiochromatograms of 
UDP-^LQGlcNAc and GDP-^HjMan 
labelled glycolipids from T. gondii. 70 #tl 
(5x10® Toxoplasma equivalents) of lysates 
were incubated for 2 hours at 37°C with 2 #tCi 
of nucleotide sugars.
A and B: Analysis of CM extractable 
f^HjGlcNAc (A, 50 000 cpm) and ^HjM an 
(B, 120 000 cpm) labelled glycolipids.
G  Butanol extractable glycolipids labelled by 
(^G lc N A c (6600 cpm) or CH)Man (2 500 
cpm).
In conclusion, we describe a cell-free system from T. gondii tachyzoites capable of performing 
the biosynthesis of several glycolipids (GPIs) which might be candidate precursors) for the 
GPI membrane 'anchors of the tachyzoite surface proteins and/or for related membrane 
glycolipids. '
We thank D. Becker and M. Eppinger for technical assistance; M. Eppinger and M. 
Odenthal-Schnittler for help with the manuscript. The authors acknowledge support by DFG 
(SFB 286), Fonds der Qicmie, INSERM. S. Tomavo was a recipient of the Alexander von 
Humboldt Foundation.
1. Tomavo, S., Schwarz, R.T. & Dubremetz, J.F. (1989) Mol. Cell. Biol. 9,4576-4580.
2. Nagel, S. & Boothroyd, J. (1989) J. Biol. Chem. 264,5569-5574.
3. Masterson, W. J., Docring, T. L , Hart, G. W., & Englund, P. T. (1989) Cell 56,793-800.
4. Krakow, J. L , Hereld, D., Bangs, J. 0 ., Hart, G. W., & Englund, P. T. (1986) J. Biol. 
Chem. 261,12147-12153.
5. Mcnon, A. K , Mayor, S., Ferguson, M. A. J., Duszenko, M^ & Cross, G. A. M. (1988) J. 
Biol. Chem. 263,1970-1977.
6. Docring, T. L , Masterson, W. J., Englund, P. T., & Hart, G. W. (1989) J. Biol. Chem. 19, 
11168-11173.
7. Mcnon, A. K., Schwarz, R. TM Mayor, S. & Cross, G. A. M. (1990) J. Biol. Chem. 16,9033- 
9042.
8. Masterson, W. J„ Raper, J., Docring, T. L , Hart, G. W., & Englund, P. T. (1990) Cell 62, 
73-80.
9. Tomavo, S., Couvreur, G-, Lcrichc, MA., Sa dak. A., Achbarou, A-, Fortier, B-, & 
Dubremetz, JF. (manuscript in preparation)
10. McConville, M. J., & Basic, A. (1989) J. Biol. Chem. 2,757-766.
Biochemical Society Transactions ( 1992) 20 165S
A specfic antibody to apolipoprotein B-48: a 
novel approach.
Andrew S. Peel, Padma Komanduri, Christine M. 
Williams, Linda M. Morgan and Barry J. Gould.
Nutritional Metabolism Group, School of Biological 
Sciences, University of Surrey, Guildford. GU2 5XH. 
U.K.
Currently, there are no specfic, rapid assays that can 
distinguish the dietary and hepatic contribution to 
postprandial lipaemia. Apolipoprotein B-48 is uniquely 
associated with chylomicrons and their remnants of 
dietary origin [1], whereas apolipoprotein B-100 is 
associated with very low density lipoproteins and other 
lipoproteins of hepatic origin. Apo B-48 has an identical 
amino acid sequence to the N-terminal 48% of apo B-100. 
By exploiting the hydrophilic nature of the charged apo 
B-48 C-terminal, in a largely hydrophobic protein, an 
antibody has been raised which specifically recognises 
apo B-48. The corresponding sequence of amino acids in 
apo B-100 are in the middle of a peptide chain and less 
likely to be surface orientated.
Two heptapeptides were custom synthesised by the 
National Institute of Medical Research, Mill Hill, 
London. These corresponded to the two forms of apo B- 
48 (ie. 2152 amino acid residues with an isoleucine C- 
terminus and 2151 residues with a methionine C-terminus 
[2,3] and included an N-terminal cysteine residue for 
conjugation. Peptides were coupled to ovalbumin using 
N - s u c c i n i m i d y l - 6 - m a l e i m i d o c a p r o a t e ;  a 
heterobifunctional conjugating agent which cross-linked 
SH-groups on the peptides to NH^-groups on ovalbumin
[4]. An estimation of the number of peptides coupled to 
each ovalbumin molecule was made by measuring the 
reduction of 5,5’-dithiobis-(2-nitrobenzoic acid) at 
412nm. A ratio of eleven peptide molecules to each 
ovalbumin carrier molecule was produced. Antisera 
were raised to each peptide by emulsifying the conjugates 
(containing 200 |ig of peptide) in non-ulcerative 
Freund's incomplete adjuvant (Morris) and injecting into 
two New Zealand white rabbits. The rabbits were 
boosted six weeks later with 100 gg of peptide and blood 
collected.
Chylomicrons were prepared from human lymph by 
overlayéring with NaCl (d=1.006g/m l) and 
ultracentrifuging for 1.6x 108 g.min. [5]. Undiluted 
lymph and chylomicrons were run under denaturing 
conditions on an SDS-polyacrylamide linear gradient (5- 
20%) gel. The lymph sample gel was blotted onto a 
nitrocellulose membrane and incubated with anti-peptide 
antisera collected ten days after the boost. The Western 
blot was visualized using a streptavidin-biotin system, 
with a horseradish peroxidase label and 4-chloronapthol 
substrate.
A high molecular weight band, slightly greater than 
205 kDa and three lower molecular weight bands were 
observed in the chylomicron sample stained with 
Coomassie Blue (Fig 1). A single, sharp band was seen 
Abbreviations used: Apo, apolipoprotein; SDS, sodium 
dodecylsulphate.
1 2 3
Fig. 1. SDS-PAGE of chylomicrons stained for protein 
with Coomassie Blue R-250 and Western blot using Ile- 
2152 antisera
1. Molecular weight markers (Sigma) 2. Chylomicrons 
3. Western blot of lymph detected with Ile-2152 antisera. 
on the Western blot at about 205 kDa with serum raised 
against the Ile-2152 peptide. This is assumed to be apo B- 
48 since the apparent molecular weight of apo B-48 is 
264 kDa [6]. No band was observed with the Met-2151 
antisera. The potential of using apo B-48 as a marker for 
particles of intestinal origin has long been recognised [7], 
However, the similarity in structure between apo B-48 
and apo B-100 has made it difficult to produce specfic apo 
B-48 antibodies. This is the first report of an antibody 
specfic for apo B-48. We intend to use the antibody to 
develop an immunological-based assay that can be used 
for the routine detection of lipoproteins of dietary origin.
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Glucose dependent insulinotropic polypeptide and 
glucagon-like peptide-l(7-36)amide: effects on 
lipoprotein lipase activity.
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GIP (glucose dependent insulinotropic polypeptide) and GLP- 
l(7-36)amide (the major intestinal truncated form of glucagon­
like peptide-1) are important stimuli for insulin secretion in the 
post-prandial hyperglycaemic state [1]. Dietary triglycerides are 
a potent stimulus for GIP secretion [2]. In-vitro studies have 
shown that GIP can stimulate both de novo lipogenesis and fatty 
acid incorporation into rat epididymal adipose tissue [3,4] and 
increase LPL (lipoprotein lipase) activity in cultured 3T3-L1 
mouse pre-adipocytes [5]. GLP-l(7-36)amide is also modestly 
stimulated by fat [6] and can also stimulate de novo lipogenesis 
[3].
Here we present our preliminary findings on the in-vitro action 
of these two hormones GIP and GLP-l(7-36)amide on LPL 
activity in rats.
Adipose tissue explants (l-1.5mg) were prepared from the 
epididymal fat pads of rats (200-250g body weight). Explants 
were cultured in Medium 199, for 2h in the presence of insulin 
(0-4 nM); GDP (0-8 nM); insulin/GIP (0.5 and 4 nM 
respectively) or GLP-l(7-36)amide (0-4 nM). After 2h heparin 
was added to the incubation medium to give a final concentration 
of 2U/ ml, explants were further incubated for 45 min. 
Subsequently the medium was removed, assayed for LPL 
activity and the explants weighed. LPL activity was determined 
using triolein as substrate according to the method of Nilsson- 
Ehle & Schotz in the presence of high and low salt [7].
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Fig. 1. Stimulation of LPL activity in explants of rat epididymal 
adipose tissue cultures for 2h in the presence of insulin or GIP 
or Insulin and GIP.
Values are means ± SEM for n=7. Symbols (A,0,*) indicate values 
significantly different from the basal, insulin or GIP response 
respectively when assessed by oneway analysis of variance and 
Scheffe's range test, A=p<0.05, AA or 00 or **=p<0.01.________
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Fig. 2.
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Stimulation of LPL activity in explants of rat epididymal
adipose tissue cultures for 2 h in the presence of GLP-K7- 
36)amide.
Values are means ± SEM for n=7.
Heparin releasable LPL was measured in preference to tissue 
homogenate LPL as heparin release of LPL from tissue pieces is 
believed to extract the enzyme into the medium thus removing 
interfering lipase activity. The LPL-heparin complex is more 
stable and soluble than the enzyme alone and is catalytically 
active [8]. Salt resistant lipase activity was present in our 
system representing an average of 67% basal enzyme activity. 
This was unaffected by addition of hormones to the medium.
We assume this activity to be hormone sensitive lipase released 
from cells damaged during the preparation of explants. The 
stimulatory actions of insulin and GIP are via the increase in salt 
sensitive lipase i.e. LPL.
We confirm the observations of other workers that insulin 
stimulates heparin releasable LPL activity. GIP stimulated an 
increase in heparin releasable LPL in a dose dependent manner 
confirming the observations in pre-adipocytes [5]. GIP alone is, 
therefore, anabolic in adipose tissue stimulating both LPL 
activity and fatty acid synthesis (5). GLP-l(7-36)amide in 
contrast was without significant effect on heparin releasable LPL 
LPL activity over the range of concentrations investigated; 
although mean levels of lipase activity increased slightly 
following increasing concentrations of GLP-l(7-36)amide.
The action of GIP was not as potent as insulin over the 2 h 
incubation period. However, in the post-prandial state adipose 
tissue would be exposed to a variety of stimulatory hormones: 
for this reason we investigated the effect of incubating explants 
with insulin and GIP simultaneously. GIP and insulin were 
seen to be synergistic in their actions; the LPL activity stimulated 
being greater than the sum of the two hormones individually.
The mechanism of action of the individual hormones and the 
synergism between insulin and GIP remains to be elucidated!
Further work is necessary to extend this study especially with 
reference to the interaction between gastro-intestinal hormones 
and insulin on LPL activity. There are strong implications for 
these findings in man who routinely consumes a high fat diet 
and for whom LPL is an important regulator of fat deposition 
and adipose tissue metabolism. /.
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Chylomicrons and their remnants have been 
implicated as a possible cause of atherogenesis [1]. 
To date, the most widely used method of 
m onitoring chylom icrons and chylom icron- 
remnants is by HPLC measurement of ingested 
retinyl palmitate. However, the physiological basis 
of the method has been criticised by Krasinski et al. 
who found that within 9-10 hours of retinyl 
palmitate ingestion up to 40% was detectable in 
lipoprotein particles of non-dietary origin [2],
In humans, apo B-48 is uniquely associated with 
lipoprotein particles of dietary origin, that is 
chylomicrons and chylomicron-remnants, whereas 
apo B-100 is associated with Very Low Density 
Lipoproteins and Low Density Lipoproteins of 
hepatic origin. In principle, measurement of apo B- 
48 in human serum would offer an alternative and 
more specific method for detecting lipoproteins of 
intestinal origin. Development of an immunoassay 
for apo B-48 has been restricted by the inablility to 
raise a specific antibody to apo B-48. Apo B-48 is 
identical to 48% of the N-terminal half of apo B- 
100. Thus, if antibodies were raised to the whole 
apo B-48 molecule they would also cross-react with 
apo B-100. By exploiting the hydrophilic nature of 
the charged apo B-48 C-terminal, in a largely 
hydrophobic protein, we have raised an antibody 
which specifically recognises apo B-48 [3],
Following an overnight fast a 77 kg 24-year old 
male consumed a high fat breakfast containing 96g 
of fat and 1500 kCal of energy. 10 ml of blood was 
collected into heparinized tubes containing a 
preservative [4] before the meal and every hour 
postprandially for 5 hours. Plasma was separated 
following low speed centrifugation. Chylomicrons 
were prepared by overlayering plasma with sodium 
chloride (density = 1.006 g/ml) and centrifuging for 
1.73 x 108 g.mins. The chylomicrons were loaded 
onto an SDS-polyacrylamide linear gradient (5- 
20%) gel which was subsequently blotted onto a 
nitrocellulose membrane. The membrane was 
incubated with anti-apo B-48 antibody and 
visualized using a streptavidin-biotin system, with a 
horseradish peroxidase label and enhanced 
chemiluminescence with luminol substrate.
The resultant bands are shown in Fig 1. A high 
molecular weight faint band, presumed to be apo B- 
100 is just visible and a much darker, lower 
molecular weight apo B-48 band can be seen.
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Fig 2 shows the staining intensity of the apo B-48 
band was very low in the fasting sample, increased 
to a maximum at 2 hours and decreased steadily to 5 
hours.
Recently it was found that the apo B-48 to apo B- 
100 ratio, measured on gels stained for protein, was 
increased in patients with Coronary Artery Disease
[5], We will use the apo B-48 antibody to develop 
an immunological-based assay that can be used for 
the routine detection of lipoproteins of dietary 
origin.
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